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1 Summary 
Dendritic cells (DC) are unique players in the initiation and regulation of anti-tumor immune responses. 
Yet, the immunosuppressive tumor microenvironment may hamper the maturation stage and antigen-
processing capacity of tumor-residing DCs. Thus, in an optimal setting, anti-cancer drugs have the 
power to reduce tumor size and, at the same time, modulate DC function towards efficient priming of 
antigen-specific effector T cells. With this in mind, we screened a small library of classical 
chemotherapeutics with distinct pharmacological mechanisms for their DC-stimulatory potential. As a 
result we discovered a previously unrecognized immunostimulatory profile of microtubule-destabilizing 
agents (MDAs), including dolastatins and maytansines, which so far have been described exclusively for 
their tumor cell cytotoxicity. Intriguingly, distinct compounds of this class potently provoked 
phenotypic and functional maturation of murine as well as human dendritic cells, resulting in an 
enhanced capacity to prime naïve T cells. Local administration of MDAs triggered in situ maturation of 
skin Langerhans cells and efficiently promoted antigen uptake and migration of tumor-resident DCs to 
tumor-draining lymph nodes in murine tumor models.  
 
Underlining the requirement of an intact host immune system for the full therapeutic benefit of specific 
MDAs, the antitumor effect was far less pronounced in immunocompromised mice. Moreover, 
substantial therapeutic synergies were observed when combining MDAs with immunotherapy such as 
tumor-antigen-specific vaccination or blockade of the cytotoxic T-lymphocyte antigen 4 (CTLA-4) or 
programmed cell death ligand 1 (PD-L1) co-inhibitory pathways. Of note, combined T cell checkpoint 
inhibition and MDA treatment resulted in an increased intratumoral effector T cell to regulatory T cell 
ratio that is associated with beneficial prognosis in multiple tumor entities. Importantly, synthetic 
analogues of dolastatins and maytansines are currently used as cytotoxic payloads of the two recently 
approved antibody-drug conjugates (ADC) brentuximab vedotin and trastuzumab-emtansine (T-DM1), 
respectively. Treatment with ADCs coupled to microtubule-destabilizing agents induced DC homing in 
murine models and activated cellular antitumor immune responses in patients, thereby demonstrating 
the immune-modulating potential of these ADCs. 
 
Ultimately, these data shed light on the MDA-triggered molecular pathways that, when activated in 
DCs, result in inflammatory responses. We here propose that MDA-mediated microtubule disassembly 
triggers the release of the microtubule-associated nucleotide exchange factor GEF-H1 from its 
cytoskeletal anchor. Subsequent induction the small GTPase RhoA results in activation of mitogen-
activated protein kinases (MAPKs) including the c-Jun N terminal kinases (JNK). Phenotypic and 
functional DC maturation is then mediated by JNK-dependent phosphorylation of the transcription 
factor c-Jun, leading to activator protein -1 (AP-1) target gene expression.  
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Hence, by providing the molecular basis that links microtubule disruption with triggering of innate 
immune responses that translate into adaptive anti-tumor immunity, we reveal a novel mechanism of 
action for MDAs and provide a strong rationale for clinical treatment regimens combining MDA-based 
therapies with immune-based therapies. 
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2 Graphical Abstract 
 
 
Microtubule-depolymerizing agents potentiate anti-tumor immunity  
by stimulation of dendritic cells 
 
 
 
 
The cytotoxic compounds dolastatin 10 and ansamitocin P3 do not only induce tumor cell death and subsequent 
antigen release from dying cancer cells but are capable of directly promoting dendritic cell differentiation and 
maturation. Tumor-derived antigens are taken up by immature DCs at the tumor site that, upon MDA-induced 
maturation, up-regulate costimulatory molecules such as the B7 family members CD80 and CD86, as well as CD40 
and MHC molecules. Upon migration to the tumor-draining lymph nodes (LNs) these antigen-loaded DCs prime 
antigen-specific CD4+ and CD8+ T cells. Ultimately, expanded and activated T cells infiltrate the lesion where they 
recognize and attack antigen-expressing cancer cells. 
 
 
 
 
 
Abbreviations   
11 
3 Abbreviations 
A 
ADC  Antibody-Drug-Conjugate 
ADCC Antibody-dependent Cellular 
Cytotoxicity 
ADCP Antibody-dependent Cellular 
Phagocytosis  
AIDS Acquired Immune Deficiency 
Syndrome 
AIM2 Absent in Melanoma2 
ALCL Anaplastic Large Cell Lymphoma 
ALL Acute Lymphocytic Leukemia 
ALR AIM2-like Receptor 
AP-1  Activator Protein 1 
APC  Antigen-presenting Cells 
APC    Allophycocyanin 
ASC Apoptosis-associated Speck-like 
Protein Containing a CARD 
ASK1 Apoptosis Signal-regulating 
Kinase1 
ATP  Adenosin Triphosphat 
 
B  
BCA Bicinchoninic Acid  
BCG Bacillus Calmette–Guerin 
Bcl B-cell lymphoma/leukemia-10 
BDCA Blood Dendritic Cell Antigen 
BiTe Bi-specific T cell Engager 
BMDC Bone Marrow-derived Dendritic 
Cell 
BSA  Bovine Serum Albumin 
BTLA-4 B- and T-lymphocyte Attenuator 
4 
 
C   
CAR Chimeric Antigen Receptors 
CARD  Caspase Recruitment Domain 
CARDIAK CARD-containing ICE Associated 
Kinase 
CCR  C-C chemokine receptor    
CD  Cluster of Diffrentiation 
CDC Complement Dependent 
Cytotoxicity  
cIAP Cellular Inhibitor of Apoptosis 
Protein 
 
 
 
CHOP CCAAT/-enhancer-binding 
Protein Homologous protein 
CLA Cutaneous Lymphocyte-
associated Antigen 
CLL Chronic Lymphocytic Leukemia 
CLR C-type Lectin Receptor 
COX  Cyclooxigenase 
CpG DNA DNA containing unmethylated 
CpG motifs 
CR  Complement Receptor 
CRT  Calreticulin 
C/T Antigen Cancer/Testis Antigen 
CTL  Cytotoxic T-Lymphocyte 
CTLA-4 Cytotoxic T-lymphocyte Antigen 
4 
CTLD C-type Lectin Domain 
 
D 
DAMP Damage-associated Molecular 
Pattern Molecules 
DC  Dendritic Cell 
DMEM Dulbecco's Modified Eagle's 
Medium 
DMXAA 5,6-Dimethylxanthenone-4-
acetic Acid 
DNA Deoxyribonucleic Acid 
DSMO  Dimethylsulfoxid 
 
E 
EDTA Ethylendiamin-tetraacetatic 
Acid 
EGTA Ethyleneglycol-tetraacetic Acid 
ELISA Enzyme-linked Immunosorbent 
Assay 
EpCAM Ephitelial Cell Adhesion 
Molecule  
ER  Endoplasmatic Reticulum 
ERK Extracellular Signal-regulated 
Kinases 
ES  Embryonic Stem Cell 
 
F 
FACS Fluorescence Activated Cell 
Sorting 
FAP Fibroblast Activation Protein 
Fc Fragment, crystallizable 
FCM  Flow Cytometry  
FCS  Fetal Calf Serum 
FDA Food and Drug Administration 
FITC  Fluorescein-Isothiocyanat 
FoxP3  Forkhead box P3 
FSC  Forward Scatter  
5-FU  5-Fluorouracil 
 
G 
Gr-1  Gamma Response 1 
GTP   Guanosin Triphosphate 
Gp  Glycoprotein 
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GEF-H1 Guanine Nucleotide Exchange 
Factor H1 
GITR Glucocorticoid-induced TNFR 
Family Related Gene 
GM-CSF Granulocyte Macrophage 
Colony-stimulating Factor 
 
H 
H&E  Hematoxylin and Eosin  
HEPES 4-(2-Hydroxyethyl)-1-
piperazinethansulfonsäure 
HER2 Human Epidermal Growth 
Factor Receptor 2 
HeLa Henrietta Lacks (Tumor Cell 
Line; Donor) 
HL  Hodgkin Lymphoma 
HLA-DR Human Leukocyte Antigen 
(subunit combination DR) 
HMGB1 High-mobility Group Box1 
HS  Human Serum 
Hsp  Heat Shock Protein 
 
I 
ICD Immunogenic Cell Death 
IDO Indoleamine2,3-dioxygenase 
Ig  Immunoglobulin 
IF  Immunofluorescence 
IFN  Interferon 
IHC  Immunohistochemistry 
IKK  IκB Kinase 
IMDM Iscove’s Modified Dulbecco’s 
Medium 
i-NOS Inducible Nitric Oxide Synthase 
IL  Interleukin 
IPC Interferon Producing Cells 
IPS1 Interferon-β Promoter 
Stimulator 1 (MAVS) 
IRAK Interleukin-1 Receptor-
Associated Kinases 
IRF Interferon-regulatory Factor 
 
J 
JNK  c-Jun N-Terminal Kinases  
 
K 
kDA  Kilodalton 
Ko  Knockout 
 
L 
LAG-3 Lymphocyte-Activation Gene 3 
LC  Langerhans Cell 
L/D  Live/Dead (stain) 
3LL  Lewis Lung Carcinoma 
LN  Lymph Node 
LPS  Lipopolysaccharide 
LRR  Leucin-rich Repeat 
LT  Lymphoid Tissue 
Ly6C  lymphocyte Antigen 6C 
 
M 
mAB  Monoclonal Antibody 
MACS Magnetic-Activated Cell Sorting 
MAGE Human Melanoma Antigen 
Mal MyD88-adapter-like 
MALT-1 Mucosa-associated Lymphoid 
Tissue Lymphoma Translocation 
Protein-1 
MAM Mitochondrial-associated ER 
Membranes 
MAPK  Mitogen-activated Protein 
Kinase 
MAP2K Mitogen-activated Protein 
Kinase Kinases 
MAP3K Mitogen-activated Protein 
Kinase Kinase Kinases 
MART-1 Melanoma Antigen Recognized 
by T cells  
MAVS Mitochondrial Antiviral Signaling 
Protein (IPS-1) 
MCA  3-Methylcholanthrene 
MDA-5 Melanoma Differentiation- 
associated Gene-5 
M-CSF Macrophage colony-stimulating 
factor 
MDA Microtubule-depolymerizing 
agent 
MDSC Myeloid-derived suppressor cell 
MDP  Muramyl Dipeptide 
MFI Mean Fluorescence Intensity  
MHC  Major Histocompatibility 
Complex 
MICA/B MHC Class I Chain-related Genes  
MIIC MHC Class II-rich Compartments  
MIP Macrophage Inflammatory 
Protein 
MLK  Mixed-Lineage Kinase 
MMAE  Monomethylauristatin E 
moDC monocyte-derived dendritic cell 
MT Microtubule 
MTOC Microtubule-organizing Center 
MWCO  Molecular Weight Cut Off  
MyD88 Myeloid differentiation primary 
response 88 
 
N 
NACHT Neuronal Apoptosis Inhibitor 
Protein (NAIP) 
NaHCO3 Sodium Hydrogen Carbonate  
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NALP3 NACHT, LRR and PYD domains-
containing protein3 
NCI  National Cancer Institute 
NEMO NF-κB Essential Modulator 
NFAT Nuclear Factor of Activated T 
cells 
NF-κB Nuclear Factor κ-light-chain-
enhancer of activated B cells 
NHL  Non-Hodgkin Lymphoma 
NK cell  Natural Killer Cell  
NKG2D  Killer cell lectin-like receptor 
subfamily K, member 1 
NKT cell  Natural Killer T Cell 
NLR  NOD-like receptor 
NLT  Non-lymphoid Tissue 
NOD Nucleotide-binding 
Oligomerization Domain 
 
O 
OD  Optic Density 
OVA  Ovalbumin 
 
P 
PAMP Pathogen-associated Molecular 
Patterns 
PAP Prostatic Acid Phosphatase 
PBS  Phosphat Buffered Saline 
PBMC Peripheral Blood Mononuclear 
Cell 
PCR Polymerase Chain Reaction 
pDC Plasmacytoid Dendritic Cell 
PD-1  Programmed Cell Death 1 
PD-L1 Programmed Cell Death- Ligand 
1 
PDGF Platelet-derived Growth Factor  
PE  Phycoerythrin 
PET-CT Positron emission tomography–
computed tomography 
Pfu Plaque-forming unit 
PGE2  Prostaglandin E2 
PI  Propidiumiodid 
PMSF  Phenylmethanesulfonyl- 
Fluoride 
PMT Post-translational Modifications 
PolyI:C Polyinosinic:polycytidylic Acid 
PPR Pattern-recognition Receptors 
PYD  Pyrin Domain 
 
Q 
qPCR Quantitative Real Time PCR 
 
R 
RAE-1 Retinoic Acid Early Transcript-1 
RAG2 Recombination Activation Gene 
2 
RhoA Ras homolog gene family, 
member A 
RIG-I Retinoic Acid-inducible Gene 1 
RLR RIG-I-like Receptor 
RICK RIP-like Interacting CLARP 
Kinase 
RIP2 Receptor-interacting protein 2 
RIPA Radioimmunoprecipitation Assay 
RNA Ribonucleic Acid 
ROCK  RhoA-associated Kinase 
ROS Reactive Oxygen Species 
rpm  Revolutions per Minute  
RPMI Roswell Park Memorial Institute 
RT  Room Temperature 
 
S 
SAPK Stress-activated Protein Kinase 
scFv Single Chain Variable Fragments 
SDS  Sodium Dodecyl Sulfate 
Ser  Serine 
Siglec Sialic-Acid Binding 
Immunoglobulin-like Lectin 
SLC Secondary Lymphoid-Tissue 
Chemokine 
SMOC Supramolecular Organizing 
Centers 
SSC  Side Scatter  
STAT Signal Transducers and 
Activators of Transcription 
STING Stimulator of Interferon Genes 
 
T 
TAA Tumor-Associated Antigen 
Tab.  Table 
TAK1 Transforming Growth Factor β-
activated Kinase1 
TBK1  Tank-binding Kinase 1 
TCR  T Cell Receptor 
Teff  Effector T cell 
TGF Transforming Growth Factor 
TH  T Helper Cell 
Thy1.1  Thymocyte Antigen 1.1 
TIL Tumor-infiltrating Lymphocytes 
Tim-3 T cell Immunoglobulin Mucin-3 
TIRAP Toll-interleukin-1 receptor (TIR) 
domain containing adaptor 
protein 
TLR  Toll-like Receptor 
Tlp2  Tumor Progression Locus2 
TRAF TNF receptor Associated Factors 
TRAIL TNF-related Apoptosis-inducing 
Ligand 
TRAM TRIF-related adaptor molecule 
 Abbreviations 
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TRANCE TNF-related Activation-induced 
Cytokine 
 
Treg  Regulatory T cell 
TRIF TIR-domain-containing adapter-
inducing interferon-β 
TRIS Tris(hydroxymethyl)-
aminomethane 
TRUCK T cells Redirected for Universal 
Cytokine-mediated Killing 
TSA  Tumor-specific Antigen 
Tyr/Thr  Tyrosine/Threonine 
 
V 
VBL  Vinblastine 
VEGF Vascular Endothelial Growth 
Factor 
 
W 
WT  Wild Type 
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4 Introduction 
4.1 Cancer Immunology 
The immune system protects its host from pathogens by adequately differentiating between “self” and 
“non-self” antigenic structures. To this end, innate pattern recognition and genetic recombination of 
lymphocytic antigen receptors enable recognition of an immense diversity of foreign antigens, while 
appropriate regulation of immunity ensures tolerance to normal tissues. Cancer cells pose a challenge 
to the immune system by being pathogenic, but “self”. Nevertheless, genetic instability of cancer cells 
such as mutations, translocations, or other genetic abnormalities lead to expression of neo- or tumor-
associated antigens, which may be recognized as “altered self” and therefore initiate an anti-tumor 
immune response [1, 2]. An increasing understanding of naturally occurring anti-tumor immune 
responses as well as of the mechanisms employed by tumors to suppress immunity have led to the 
development of various successful immunotherapy approaches during the last decades [3]. Currently, 
the most commonly accepted view on the interaction of the immune system and tumors are described 
by the concepts of Cancer Immunosurveillance and Cancer Immunoediting [4]. 
 
4.1.1 Concept of Immunosurveillance & Immunoediting 
Cancer immunotherapy aims at using the body’s own protective mechanisms to actively fight emerging 
neoplastic cells. In 1909 Paul Ehrlich already stated that there must be mechanisms by which the 
immune system is able to protect the host against primary tumors, as if not, they would occur at much 
higher frequency. Therefore, tumors must express antigens that distinguish them from normal cells [5]. 
And indeed, with the first demonstration of tumor antigens, fifty years later the idea of the immune 
system controlling cancer outgrowth emerged again. Hence, in the 1960s Burnet and Thomas defined 
the concept of Immunosurveillance as the ability of the immune system to recognize and destroy tumor 
cells [6-8]. Meanwhile, various tumor antigens have been identified, with them often being products of 
mutated genes, aberrantly expressed normal genes, or genes encoding viral proteins. Human tumor 
antigens include differentiation antigens (e.g., melanocyte differentiation antigens MelanA/melanoma 
antigen recognized by T cells (MART)-1, tyrosinase and gp-100), mutational antigens (e.g., abnormal 
forms p53), overexpressed cellular antigens (e.g., survivin, telomerase, or human epidermal growth 
factor receptor 2 (HER2)/neu), viral antigens (e.g., human papillomavirus proteins), and cancer/testis 
(CT) antigens (e.g., Human Melanoma Antigen (MAGE) and NY-ESO1) [1, 9]. Further evidence for the 
hypothesis of Immunosurveillance appeared years later with the generation of the first molecularly 
defined immunodeficient mouse models. These models were generated, for example, by deletion of 
the recombination activation gene 2 (RAG2), which leads to a deficiency in peripheral αβ T cells, B cells, 
Natural Killer T (NKT) cells and γδ T cells [10, 11]. Using RAG2-/- mice, Shankaran and colleagues were 
able to demonstrate for the first time that tumors induced by the carcinogen 3-methylcholanthrene 
  Introduction 
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(MCA) occurred at higher frequency in immunodeficient mice when compared to strain-matched WT 
mice [10].  
 
The relationship between tumor and immune system, however, is considered to be much more 
complex as initially believed, which is why, over the last decades the concept has been extended. The 
so-called Immunoediting hypothesis takes into account that the immune system not only protects the 
host from developing tumors, but also shapes tumor immunogenicity. It describes a tumor-immune-
system-interaction that consists of three phases, namely Elimination, Equilibrium and Escape (Figure 4-
1) [4, 12].  
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Figure 4-1 The Cancer Immunoediting concept. In case of transformation of normal tissue cells and failure of 
intrinsic tumor suppressor mechanisms, a clinically detectable tumor may grow out. The immune system may 
either eliminate a developing tumor (Elimination phase) or, if elimination is incomplete, maintain it in a dormant or 
equilibrium state (Equilibrium phase). Constant immunosurveillance in combination with genetic instability of 
tumor cells, however, may promote tumor cell variants with low immunogenicity. These may elaborate additional 
immunosuppressive molecules and cells and ultimately escape from the extrinsic tumor suppressor actions of 
immunity (Escape phase). Adapted from Dunn GP. Interferons, immunity and cancer immunoediting. Reprinted 
with permission from Nature Publishing Group © 2006 [12]. 
 
4.1.1.1 Elimination  
During the initial elimination, or immunosurveillance phase the immune system is able to recognize and 
destroy an emerging tumor before it becomes clinically visible. CD4+ and CD8+ effector T cells activated 
and expanded by recognition of relevant tumor antigens are primarily required to mount an effective 
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immunosurveillance response [4, 10, 13]. But nevertheless, both innate and adaptive immunity act in 
concert to promote the elimination process and together with CD4+ and CD8+ T cells, NK and NKT cells 
as part of the innate response are major contributors to host antitumor defense mechanisms [14]. On a 
molecular level, cytokines such as interleukin (IL)-12 and IFN-γ as mediator of effector functions, as well 
as type I interferons (IFN-α/β), play major roles in antitumor immunity [12]. IFN-γ has been shown to be 
especially important for the establishment of host protection by acting on both the immune system-, as 
well as on the tumor cell-side [15, 16]. Type I IFNs may possibly activate antigen-presenting cells (APCs) 
and enhance cross-priming of tumor-associated antigens [17]. Damage-associated molecular pattern 
molecules (DAMPs) directly released by dying tumor cells or damaged tissue as a result of progressive 
tumor growth are considered as further APC-activating signals [18, 19]. In this line, a recent study 
determined tumor cell aneuploidy, in particular tetraploidization, as immunogenicity-increasing factor 
leading to enhanced immune elimination of tumor cells. Hyperploid cells displayed endoplasmic 
reticulum stress responses that induced increased surface expression of the danger signal calreticulin 
(CRT), which activated APCs at the tumor site [20]. Importantly, this study confirmed CD4+ and CD8+ T 
cells, IFN-γ and the IFN-γ receptor as major determinants of the elimination process. Also, stress 
ligands such as the human MHC class I chain-related genes MICA/B (mouse Retinoic acid early 
transcript; RAE-1 and MHC class I-related glycoprotein H60) are frequently expressed on tumors. These 
bind to activating receptors (e.g., Killer cell lectin-like receptor subfamily K, member 1; NKG2D 
receptor) on innate cells, thereby inducing release of pro-inflammatory and immunomodulatory 
cytokines that establish a favorable microenvironment for adaptive antitumor mechanisms [21]. 
Furthermore, studies have shown that mice lacking the cytotoxic T and NK cell effector molecule 
perforin develop carcinogen-induced and spontaneous tumors at a higher incidence as their wild type 
counterparts [22]. In summary, a balanced action of various cell types, signaling, and effector molecules 
of both innate and adaptive immunity is necessary for the elimination of transformed cells; a process 
that may not always be achieved in a complete fashion. 
 
4.1.1.2 Equilibrium 
The equilibrium phase has been characterized as a state of tumor cell dormancy that is induced, at least 
to some extent, by constant immunosurveillance. Few tumor cells may survive the elimination phase, 
but are usually not able to grow out to form recurrent primary tumors or metastases. In this case, the 
adaptive immune system maintains residual cancer cells in a state of dormancy, thus, specifically 
controls and limits cancer progression [21]. Hence, both tumor and immune cells enter the state of 
equilibrium, which may possibly last for decades. The mechanisms underlying the equilibrium process 
are still largely unknown due to the difficulty in isolating dormant tumor cells from patients. Evidence 
for this state comes mainly from clinical observations of breast cancer, melanoma and renal carcinoma, 
indicating that tumor growth is not continuous but may undergo long periods of subclinical dormancy 
[20]. Experimental evidence is provided by studies using mouse models of spontaneous tumor 
development. In this line, immune-competent mice treated with low-dose MCA remained apparently 
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tumor free, but at all times harbored transformed cells as upon depletion of adaptive immunity such as 
CD4+ and CD8+ T cells and/or blocking of IFN-γ and IL-12p40 by administration of antibodies, tumors 
rapidly grew out at the site of original MCA injection in 50% of the mice [23]. Interestingly, depletion of 
NK cells, their cell recognition (anti-NKG2D) or their effector functions (anti-TNF-related apoptosis-
inducing ligand; TRAIL) did not induce tumor outgrowth, implicating that the adaptive immune system 
exclusively maintains the equilibrium phase and thus, contrasts to the need of an interplay of both 
innate and adaptive immune system to protect hosts in the elimination phase. Also, the recognition of 
the type and frequency of tumor-infiltrating lymphocytes (TILs) as prognostic factor for different types 
of cancer has been steadily increasing over the last decade [24]. Consistent with this, Wu et al. 
discovered enhanced infiltration of CD3+ T cells as well as an increased ratio of CD8+ T cells to 
regulatory T cells (Treg) in the tumor microenvironment of dormant sarcomas when compared to 
progressively growing tumors. The authors further describe that a high proportion of intratumoral 
effector cells such as cytotoxic T Lymphocytes (CTLs), NK cells, and γδ T cells together with a low 
proportion of regulatory cells such as MDSCs and Tregs maintains dormancy, hence favors the state of 
equilibrium and ultimately, the overall-survival [25]. In contrast to the previous study, which indicated 
no role for innate effectors such as NK cells in inhibiting tumor outgrowth [23], this study demonstrates 
that NK cells make up an important proportion of TILs in equilibrium phase tumors, which indicates a 
more prominent role for NK cells than previously appreciated [25]. The role of IL-12p40 as TH1 cytokine 
in supporting the process of elimination has been previously described extensively by Koebel and 
colleagues [23]. In a following study, the same group demonstrated that the IL-12 cytokine family 
member IL-23 may counteract the function of IL-12p40 by promoting tumor cell resistance [26]. It is 
becoming increasingly evident that the balance of pro-and anti-tumoral immune effectors plays an 
important role in maintaining tumors in the equilibrium phase. Apart from inducing tumor cell 
dormancy, adaptive immunity has furthermore been ascribed responsible for the process of 
immunoediting [10, 27]. Selective pressure exerted by immunological defense mechanisms may help to 
shape tumor cells that are less immunogenic and therefore, may evade recognition until some of these 
cells eventually enter the escape phase. The concept of immunoediting has emerged in 2001, when 
Shankaran and colleagues observed that tumors formed in immunodeficient mice were in general more 
immunogenic than those formed in immunocompetent mice [10].  
 
4.1.1.3 Escape 
Cancer cells entering the escape phase mean failure of the immune system to eliminate or control 
transformed cells and therefore, allowing them to grow in an unrestricted manner. These tumor cells 
are highly instable and rapidly undergo genetic and epigenetic modifications to bypass immunological 
defenses. The immune system contributes to a Darwinian selection process by killing of antigen-
positive tumor cells and hence, by leaving behind only the more aggressive and less immunogenic 
cancer cell variants [4, 28]. There is a long list of mechanisms, which tumors may evolve in order to 
avoid immunological destruction. Apart from the ability to induce central or peripheral T cell tolerance, 
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tumors may acquire defects in antigen-processing or -presenting pathways by means of MHC class I 
down-regulation or the development of IFN-γ or IFN-α/β insensitivity, which prevents T cell-mediated 
elimination. Tumor cells with impaired IFN-γ signaling are not able to produce the intracellular 
machinery needed for antigen-presentation [15]. The before mentioned genetic instability of tumor 
cells may lead to complete loss of tumor-specific antigens (TSAs), and in a similar way, cancer cells may 
lose ligands for recognition by innate immune cells (such as NKG2D-ligands). Even if effector T cells 
recognize tumor cells, they may still evade destruction by the expression of impaired death receptors, 
such as mutated, inactive forms of TRAIL [29]. A rather active way to circumvent immunological 
defenses is the expression of immune-inhibitory ligands, such as PD-L1, on the surface of transformed 
cells [30]. A tumor may generate an immunosuppressive tumor-microenvironment by the secretion of 
factors that directly inhibit cells of both the adaptive and the innate immune system, or by inducing 
regulatory immune cells [4, 31]. 
 
Furthermore, dendritic cell function is crucial for the priming of T cells and initiation of immunity. 
Tumors may secrete sterol metabolites to suppress the expression of the C-C chemokine receptor type 
7 (CCR7) on DCs, thereby impeding their migration capacity [32]. In addition, many cancers express 
vascular endothelial growth factor (VEGF), which supports one of the characteristic mechanisms of 
tumors, angiogenesis, and also may prevent endogenous DC function [32]. A study from Gabrilovich in 
1999 demonstrated that monoclonal antibodies targeting VEGF can increase DC function in vivo, and 
therefore improve overall success of tumor immunotherapy [33]. Furthermore, the release of immune-
suppressive cytokines such as transforming growth factor (TGF)-β inhibits DC activation as well as T 
and NK cell function [34-36]. The role of IL-10 is not yet clear, as it has been found to suppress DC 
function and to affect T cell responses, but also may enhance immunological destruction of tumor cells 
[37]. Ultimately, cancer cells protect themselves by the expression of enzymes that metabolize amino 
acids in the tumor microenvironment. Indoleamine 2,3-dioxygenase (IDO), for example, metabolizes 
tryptophan, which leads to inhibition of T cell proliferation by starvation or through toxic metabolites 
[38]. 
 
Additionally, tumors may recruit regulatory immune cells such as CD4+CD25+FoxP3+ regulatory T cells 
(Tregs) or myeloid-derived suppressor cells (MDSC). Tregs are known to suppress CTL function by 
various mechanisms, including a) expression of suppressive cytokines such as TGF-β, IL-35 or IL-10, b) 
direct killing of effector T cells via granzymeA/B (cytolysis), c) by consumption of IL-2, which is required 
for effector T cell homeostasis, as well as expansion and d) by interfering with APC activation leading to 
insufficient T cell costimulation [39, 40]. MDSCs expand and accumulate in tumors due to expression of 
granulocyte macrophage colony-stimulating factor (GM-CSF), IL-1β, VEGF or prostaglandin E2 (PGE2). 
Cells of this heterogeneous group of myeloid progenitors and immature myeloid cells produce 
immunosuppressive cytokines, [41, 42]. An immunosuppressive microenvironment further attracts M2 
macrophages into the tumor mass. These cells, in contrast to M1-polarized macrophages, are able to 
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inhibit T cell function via the expression of TGF-β and IL-10 or promote stromal development and 
angiogenesis via the expression of platelet-derived growth factor (PDGF) [43]. All together, the 
complex mixture of an immunosuppressive milieu that directly inhibits effector cells or recruits 
regulatory immune cells in combination with the high genetic variation of cancer cells enables them to 
hide from immunological recognition and makes it difficult for an organism to fight cancer. 
 
4.1.1.4 Immunoediting in human cancer 
Indication for immunosurveillance in human patients is reported in studies associating the occurrence 
of tumor-infiltrating lymphocytes (as in quantity, quality, and localization) with the survival of the 
corresponding patients [44]. Presence of CD4+ T helper (TH) cells and CD8
+ CTLs within tumors, in 
addition to cytokines such as tumor necrosis factor (TNF)-α or IFN-γ that promote tumor control, has 
been shown to improve the prognosis of patients with various cancers such as ovarian and colorectal 
cancers, non-small cell lung cancer or breast cancer [21, 44]. In this line, spontaneous antibody and T 
cell responses against tumor-associated antigens (TAAs) have been detected in cancer patients, 
demonstrating active immunosurveillance mechanisms. Further data supporting the concept of 
immunosurveillance in human cancers arises from immunodeficient individuals, such as acquired 
immune-deficiency syndrome (AIDS) patients or transplant recipients, which demonstrate an increased 
risk to develop cancers [45-48]. These cancers are mainly of viral origin, but some clinical studies show 
an increased incidence of colon, lung, pancreas, kidney, head, and neck as well as non-melanoma skin 
cancers [21]. In a special case of organ transplantation, both recipients of kidneys from the same donor 
developed malignant melanoma, which originated in the donor’s tissue. Sixteen years before 
transplantation, the donor was successfully treated against melanoma [15]. Hence, the donor’s immune 
system was able to keep the tumor cells in a dormant state (as supposed to be found in the equilibrium 
phase), while the immunosuppressed recipients were not able to control tumor outgrowth. Together, 
these observations support the hypothesis that new malignancies only arise in the permissive 
environment of a compromised immune system, which cannot sustain an elimination or equilibrium 
phase [44].  
 
4.2 Therapeutic options in cancer 
4.2.1 Immunotherapy  
4.2.1.1 Cancer vaccines 
Active immunotherapy includes cancer vaccines designed to prime and expand a pool of tumor reactive 
T cells by delivering a specific antigen in a surrounding supportive for T cell activation. Thus, 
vaccination relies on APCs and, in most cases, on concomitant administration of adjuvants, such as 
Freund`s adjuvant, Bacillus Calmette–Guerin (BCG), montanide, alum, or Toll-like receptor (TLR) 
agonists such as CpG-DNA for their optimal stimulation [49]. Possible preparations of tumor antigen-
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dependent cancer vaccines include a) recombinant short peptides that directly bind MHC molecules on 
the surface of APCs or full-length proteins, which rely on the uptake and processing by APCs, b) TAA-
containing whole tumor cells or lysates, alone or complexed with chaperones, c) TAA-encoding nucleic 
acids in the form of naked DNA or RNA or delivered by viral entities (adeno-, or lentivirus) and d) DC-
based vaccines [3]. The latter include autologous DCs loaded with TAAs ex vivo as well as fusion 
proteins and TAA-linked antibodies directed against a DC surface receptor, such as DEC205, which 
both allow selective delivery of TAAs to DCs in vivo [50, 51]. Apart from the two multivalent 
prophylactic vaccines Cervarix® and Gardasil®, that have been approved against HPV-infection-related 
cervical cancer, only one therapeutic vaccine has been approved recently; the cell-based vaccine 
sipuleucel-T (Provenge®). It is made of autologous peripheral blood mononuclear cells (PBMCs) loaded 
ex vivo with a fusion protein containing the TAA prostatic acid phosphatase (PAP) and the APC-
stimulating cytokine GM-CSF, and has been clinically approved for the treatment of patients with 
metastatic hormone-refractory prostate cancer in 2010 [3, 52]. Multiple peptide- or protein-based 
cancer vaccines are currently under evaluation in phase I-III clinical trials [3]. Yet, further approvals are 
still rare as most cancer vaccines struggle to demonstrate improved survival or quality of life. Poor 
antigenicity or heterogeneous expression of the tumor antigen, ineffective adjuvants, and the 
immunosuppressive nature of the tumor microenvironment include reasons for constant failure or low 
efficacy of therapeutic vaccines. Thus, extensive research is ongoing to overcome these limitations. 
Importantly, vaccines targeting DCs in vivo with TAA-encoding mRNA, as well as ex vivo modification of 
DCs are considered save and have been demonstrated to induce potent CD4 and CD8 T cell responses 
[53, 54]. To improve CD4 help and memory formation, DCs may be targeted by viruses that encode for 
co-stimulatory molecules or TH1 polarizing cytokines in addition to the TAA. Ex vivo modified 
autologous DC-based vaccines may further be improved in regard to the DC subset used [55], optimal 
ex vivo or in vivo DC activation including concomitant administration of immunostimulatory 
chemotherapeutics or radiotherapy [56], pre-conditioning of the vaccine site with recall antigens [57], 
or appropriate routes of DC re-infusion [3]. Finally, tumor cells can be targeted with oncolytic viruses 
that selectively infect and kill tumor cells and additionally may be modified to express immune-
attracting cytokines such as GM-CSF [58]. 
 
4.2.1.2 Adoptive cell therapy: TILs, CARs & TRUCKs 
Further approaches engaging the hosts' immune system include adoptive transfer of ex vivo expanded 
tumor-infiltrating lymphocytes (TILs) or chimeric antigen receptor-bearing autologous T cells (CAR-
engineered T cells). Although expansion of autologous TILs with IL-2 produced remarkable responses in 
metastatic melanoma, the protocols for ex vivo T cell activation and expansion are constantly being 
improved [59, 60]. T cells engineered to express a TCR of defined antigen-specificity or chimeric 
antigen receptors (CARs) overcome the hurdles that pose the isolation of sufficient TILs from patients 
and the unknown specificity of those T cells. A CAR is composed of one polypeptide chain with an 
extracellular antigen-binding domain derived from an antibody and an intracellular signaling chain, 
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which is frequently the TCR-derived CD3ζ chain. Importantly, the antibody domain recognizes a 
specific ligand independent of MHC molecules, while signals are transduced by TCR-associated 
downstream kinases [61]. Second and third generation CARs additionally incorporate one or two co-
stimulatory signaling domains into the cytoplasmic CAR tail in order to prolong and fine-tune T cell 
responses [62]. Indeed, second-generation CARs directed against CD19 are evaluated in clinical trials 
for treatment of chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL,) and non-
Hodgkin lymphomas (NHL) with encouraging results [63-65], similar to TCR engineered T cells in 
melanoma [66], and CD4+ TIL infusions in metastatic epithelial cancer [67]. CAR efficacy may further be 
enhanced by introduction of chemokine- or cytokine-encoding sequences, resulting in “T cells 
redirected for universal cytokine-mediated killing” (TRUCKs). The additional cytokine expression in the 
tumor microenvironment is believed to enhance anti-tumor immunity to those tumor cells that are not 
recognized by a specific CAR [61]. Drawbacks of T cells transduced with modified TCRs, CARs, or 
TRUCKs are autoimmune side effects due to limited control of T cell activation. Hence, attempts have 
been made to include inducible molecular “safety switches” in order to remove inappropriately 
activated CAR T cells in case of severe autoimmune symptoms [68].  
 
4.2.1.3 Monoclonal antibodies, bispecifics and BiTes 
Monoclonal antibodies (mAb) are widely used for cancer therapy. These may either directly trigger 
adaptive immunity, or target tumor cells for both immune-mediated or -independent triggering of 
tumor cell death by a) blockade of receptors involved in tumor cell growth and survival (i.e., anti-HER2; 
trastuzumab), b) depletion of tumor-associated stroma and vasculature to support disruption of the 
microenvironment (i.e., anti-fibroblast activation protein (FAP) and anti-tenascin or anti-VEGF; 
bevacizumab), or c) the selective delivery of cytokines into the tumor in form of immunoconjugates. 
Tumor-targeted mAbs often additionally activate innate immune cells via their Fc (fragment, 
crystallizable) portion by complement-dependent cytotoxicity (CDC), antibody-dependent cellular 
cytotoxicity (ADCC), or antibody-dependent cellular phagocytosis (ADCP), thereby increasing tumor 
cell killing (i.e., anti-CD20; rituximab, as well as trastuzumab) [69]. Bispecific antibody constructs are 
engineered to recognize a specific tumor-associated or stromal antigen with one arm and CD3 with the 
other. T cells are thereby brought into close proximity of tumor cells, while triggering of CD3 results in T 
cell activation, degranulation and tumor cell killing independent of TCR specificity, MHC expression and 
peptide presentation [70]. The so-called TriomAb catumaxomab was designed to target the tumor 
antigen epithelial cell adhesion molecule (EpCAM) as well as CD3 on T cells, while additionally engaging 
Fc receptors on innate cells [71]. Its approval for the treatment of malignant ascites by the European 
Commission in 2009 was granted due to efficient triggering of tumor cell death as well as protective 
immunity. Bi-specific T cell engager (BiTe) molecules recognizing CD19 [72], CD33 or EpCAM are 
currently tested in several phase I/II trials for treatment of non-Hodgkin lymphomas (NHL), acute 
myeloid leukemia (AML) and metastatic colorectal, gastric or lung cancer, respectively [72, 73]. BiTes 
function similar to bispecific mAbs, but instead of assembling a complete antibody, these molecules 
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directly combine two single chain variable fragments (scFv) recognizing a tumor- or stromal antigen 
and CD3. Interestingly, BiTes seem, at least in cell culture experiments, to better overcome mutations 
in signaling pathways that classically lead to tumor cell resistance [74]. In essence, multiple forms 
(diabodies, minibodies, complete IgG) and fragments (scFvs) of antibodies are engineered in order to 
improve antigen-binding, tumor-targeting, and T cell activating properties of the constructs [69]. 
 
4.2.1.4 T cell checkpoint blockade 
In contrast to the above-described tumor antigen-dependent approaches, monoclonal antibodies 
targeting activating receptors or immune-regulatory checkpoints on T cells aim at non-specific 
prolongation of endogenous T cell responses. Agonistic antibodies have been developed against the 
TNF-receptor family related activating receptors CD137 (4-1BB), OX40, glucocorticoid-induced TNFR 
family related gene (GITR), and CD27 on T cells or against CD40 on APCs [75]. Inhibitory T cell receptors 
such as the checkpoint receptors CTLA-4, programmed cell death 1 (PD-1), T cell immunoglobulin 
mucin-3 (Tim-3), lymphocyte-activation gene 3 (LAG-3), or B- and T-lymphocyte attenuator 4 (BTLA-4) 
are expressed either constitutively or upon activation and function to dampen T cell responses in order 
to prevent autoimmunity in healthy individuals. Tumors, however, adopt these mechanisms in order to 
promote their growth and survival by circumventing immunosurveillance. Blockade of inhibitory 
receptors results in enhanced T cell proliferation and effector activity, although specific mechanisms 
may differ amongst distinct receptor-ligand pairs. The CTLA-4 blocking antibody ipilimumab was the 
first of its class to be approved for metastatic melanoma in 2011 and has since demonstrated 
impressive clinical success including long-term protective immunity in responding patients [52, 76]. 
Mechanistically, CTLA-4 outcompetes the activating T cell receptor CD28 for its ligands on APCs, i.e., 
CD80 (B7-1) and CD86 (B7-2), with a 10-100 fold higher affinity, which is one way to suppress T cell 
function. Furthermore, CTLA-4 transduces negative signals in effector T cells through phosphatases 
and directly controls activation of CD4+ Tregs, which constitutively express CTLA-4 [77]. Known ligands 
for PD-1 include PD-L1 (B7-H1) and PD-L2 (B7-DC), which are expressed on APCs, but also on non-
hematopoietic cells including stromal cells at the tumor site and tumor cells themselves, and of which 
at least PD-L1 is inducible by IFN-γ [78]. While CTLA-4 acts to diminish T cell responses during the 
process of priming, PD-1 signaling is thought to be crucial for limiting effector T cell responses in 
tissues, hence at the tumor site. Thus, combinatorial blockade of distinct checkpoints has 
demonstrated to be synergistic and is thoroughly evaluated in pre-clinical as well as clinical trials [77]. In 
fact, about 70% of currently (January 2015) registered clinical trials for melanomas evaluate safety 
and/or efficacy of ipilimumab in combination with radiotherapy, surgery, or other monoclonal 
antibodies [52]. Also, T cell checkpoint blockade has become attractive for treatment of multiple other 
solid tumor entities. The PD-1 blocking mAb nivolumab received FDA approval in March 2015 for 
squamous non–small cell lung cancer, but also demonstrated potent clinical activity in renal cell 
carcinoma, colon carcinoma, and melanoma and is evaluated in a number of additional entities in phase 
I-III clinical trials [77]. Of note, blockade of the IFN-γ inducible PD-L1, has shown equally promising 
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therapeutic activity [77]. Interestingly, patients that had progressed under anti-CTLA-4 treatment 
responded to anti-PD-1 treatment, thus demonstrating their distinct modes of action [79]. Despite of 
all successes, a major limitation of checkpoint inhibition is the low response rate, while the factors 
determining responsiveness remain unknown. Seven recent articles, however, refine our understanding 
of a) potential cancer types that respond to those therapies [80], b) biomarkers that can predict the 
success of checkpoint inhibition, such as high numbers of pre-existing CD8+, PD1+ and PD-L1+ T cells in 
the tumor microenvironment [81-83], and c) the effect of the number, as well as the nature of 
additional somatic mutations on the response rates [84-86]. As an example, patients responding best 
to inhibition of CTLA-4 had mutations leading to neoantigens similar to viral or bacterial antigens [86]. 
Also, Minn and colleagues recently demonstrated synergy of CTLA-4 blockade and radiotherapy in 
melanoma patients, although 64% of patients were resistant to treatment [87]. Using the B16 mouse 
model of melanoma, the group subsequently highlighted the failure to increase the intratumoral ratio 
of CD8+CD44+ effector T cells to Treg cells (CD8/Treg ratio) as predictor of immunological resistance. 
Importantly, resistance correlated with PD-L1 expression on insensitive melanoma cells and was 
overcome with additional blockade of the PD-1/PD-L1 signaling axis [87]. These data highlight the need 
for additional biomarkers that predict the outcome of T cell checkpoint blockade. In the same line, 
further investigations will ultimately help determining effective combinations with additional 
checkpoint blocking antibodies, agonistic antibodies, such as anti-CD40 or anti-41BB (CD137), or even 
with immune-modulatory chemo- and radiotherapy approaches.  
 
4.2.2 Immunostimulatory chemotherapeutics 
In light of the recent success of novel immunotherapy approaches, future therapeutic efforts will 
ultimately focus on the development of effective combination strategies that exert complementary 
pressure on tumors via immune activation and additional direct toxicity. Of note, accumulating 
evidence reveals previously unrecognized immune-modulatory features of chemo- and radiotherapy 
[88, 89]. In addition to reducing the primary tumor burden, and thereby, at least in part, reverting the 
immunosuppressive microenvironment, specific compound classes can also induce DC maturation, 
enhance antigen cross-presentation, selectively eliminate immunosuppressive cells, or induce 
immunogenic tumor cell death (ICD) [90, 91]. Chemotherapeutics may additionally increase tumor cell 
immunogenicity by triggering upregulation of tumor antigen and MHC expression, enhanced co-
stimulation via B7-1, or decreased expression of co-inhibitory molecules, such as PD-L1 [91, 92]. Further 
agents render tumor cells more sensitive to T cell–mediated lysis through fas-, perforin-, and granzyme 
B–dependent mechanisms [93]. Anthracyclines [94], oxaliplatin [95], and cyclophosphamide [96], as 
well as irradiation [94] have been reported to induce ICD, which, in distinction to non-immunogenic 
apoptosis, is characterized by the induction of endoplasmatic reticulum (ER) stress and autophagy [97, 
98]. Hallmarks of ICD include the pre-apoptotic exposure of calreticulin (CRT) on the cell surface, the 
secretion of adenosine triphosphate (ATP), and the post-apoptotic release of the chromatin-binding 
protein high-mobility group box 1 (HMGB1). Importantly, the suppression of each of these APC-
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activating signals abolishes the immunogenicity of cell death, demonstrating the non-redundancy of 
each of these pathways [79, 94, 99]. Several cytotoxic agents are able to target suppressive subsets, 
such as Tregs or MDSCs and thereby promote adaptive anti-tumor immunity. One of the first drugs 
reported to interfere with Tregs was cyclophosphamide, which at low doses depletes Tregs and inhibits 
their effector functions as well as homeostatic proliferation [100-103]. Similar, doxorubicin, 5-
azacytidine, 5-fluorouracil (5-FU), and gemcitabine substantially reduce the numbers of MDSCs by 
induction of apoptosis [104-107]. In contrast, low, non-cytotoxic doses of paclitaxel stimulate the 
differentiation of MDSCs into functional DCs expressing MHCII and costimulatory molecules [108, 109]. 
These functional DCs have lost their suppressive capacity and contribute to the induction of T cell 
responses. Similarly, docetaxel treatment polarizes MDSCs towards an M1 phenotype with loss of 
suppressive effects, higher levels of MHCII and CD80 expression, and a shift from IL-10 to IL-12 
secretion [110]. Triggering of direct DC maturation by chemotherapeutics has been reported for 
topoisomerase I inhibitors, although with conflicting results [111-113], for camptothecin, lenalidomide, 
and docetaxel [113], as well as for paclitaxel and other compounds at low, non-cytotoxic concentrations 
[114-117]. Along the same line, microtubule-destabilizing agents (MDAs), such as the vinca-alkaloids 
have been demonstrated to directly affect DC maturation at clinically relevant doses [118, 119]. Early 
studies indicated that microtubule disruption by colchicine, vinblastine, and vincristine induced marked 
expression of IL-1 in monocytes [120]. Yet, the mechanisms for the induction of DC maturation remain 
elusive. 
 
Thus, a detailed characterization of the immunostimulatory effects of currently used chemotherapeutic 
agents may guide the way for rational combinations with immunotherapeutic approaches.  
 
4.3 Dendritic cell biology 
DCs were first described by Steinman and Cohn in 1973 as large stellate cells with distinct properties 
from the formerly known cell types, such as mononuclear macrophages, granulocytes, or lymphocytes 
[121]. They function as sentinel cells seeking out foreign invaders throughout the body, whether these 
are bacteria, viruses, or toxins. Upon encounter with endogenous or exogenous antigens, DCs capture 
and process these antigens for the subsequent presentation to T cells, thereby initiating an adaptive 
immune response. DCs possess highly specialized mechanisms for antigen uptake and processing, the 
capacity to migrate to defined sites in lymphoid organs, such as the T cell areas, and most important, 
the capacity to provide costimulation necessary for activation of effector cells. DCs rapidly differentiate 
or mature in response to a variety of stimuli ranging from pathogen-associated molecular patterns 
(PAMPs) to many other non-microbial factors, such as DAMPs, cytokines, innate lymphocytes or 
immune complexes. But other than the exclusive display of antigens, DCs may also alert other immune 
cells to the presence of injury or infection at a specific site. With these functions, DCs play a major role 
in the connection of innate and adaptive immunity [122, 123].  
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4.3.1 Dendritic cell subsets  
One striking feature of dendritic cells is their short life cycle and rapid turnover. Although originally 
isolated from lymphoid tissues, it is known today that all lymphoid and most non-lymphoid tissues 
possess their own DC populations [124]. The heterogeneity in body localization, developmental stages, 
and functional properties makes a clear definition of sub populations rather difficult. Generally, DCs 
may belong to lymphoid tissue (LT)-resident DCs or non-lymphoid tissue (NLT) migratory DCs that 
migrate to lymph nodes (LNs) via the lymphatics. To date DCs are categorized in four main subsets: 
conventional DCs (cDCs), plasmacytoid DCs (pDCs), Langerhans Cells (LCs), and inflammatory DCs 
(iDCs) (Figure 4-2) [125]. 
 
In mice, CD11c expressing conventional DCs in lymphoid tissues can be divided in two subgroups with 
largely complementary functions based on expression of CD4 or CD8α. CD8α+ DCs are generally 
recognized for their highly efficient cross-presentation of exogenous antigens via MHCI molecules to 
CD8+ T cells, whereas CD4+ DCs are specialized in priming CD4+ T cells by presentation of MHCII-
restricted antigens. Counterparts of CD8α+ DCs in peripheral non-lymphoid tissues have been described 
to express CD103, whereas peripheral equivalents to lymphoid tissue CD4+ DCs express high amounts 
of CD11b [126, 127]. 
 
 
Figure 4-2 Development, migration and tissue residency of distinct DC subsets. “cDCs, pDCs and monocytes 
(Mono) derive from bone marrow progenitors. Pre-cDCs, pDCs and monocytes transit through the blood and seed 
peripheral organs, where pre-cDCs complete their differentiation into CD8+ (or CD103+) cDCs or CD4+ (or CD11b+) 
cDCs. Monocytes can migrate into tissues and differentiate into macrophages. In the intestine, cDCs and 
macrophages populate the villi; cDCs are also present in intestinal lymphoid follicles (ILF). In the skin, dermal DCs 
consist of both CD11b+ and CD103+ cDC subsets. LCs populate the epidermis and self-renew locally. Macrophages, 
pDCs and both cDC subsets reside in the lung. A hallmark characteristic of cDCs is their ability to migrate from 
tissues to draining lymph nodes after encountering antigen, to prime T cell responses. In contrast, macrophages 
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mostly remain at the site of differentiation”. Adapted from Satpathy AT. Re(de)fining the dendritic cell lineage. 
Reprinted with permission from Macmillan Publishers Limited. Copyright © 2012 [125]. 
 
In humans three major types of conventional DCs are found and classified based on the expression of 
CD141 (blood dendritic cell antigen; BDCA-3), CD1c (BDCA-1) and CD14. CD141+ DCs may be both 
migratory and resident, are found in human blood, tonsils and LNs as well as in some NLTs and 
resemble mouse CD8+/CD103+ DCs in their capacity to cross-present antigens to CD8+ T cells [128]. 
CD1c+ DCs are mainly found in blood, LNs, spleen and NLTs such as the skin, express CD11c and CD11b 
and display a phenotype comparable to that of mouse CD11b+ DCs. Their major function is thought to 
include the modulation of mucosal T cell responses and initiation of immunity towards extracellular 
antigens [129]. CD14+ DCs are unique to the human system as murine counterparts are still unknown. 
This subset has been shown to potently induce follicular helper T cells (TFH) and antibody-secreting B 
cells and phenotypically resemble monocytes as well as macrophages [128].  
 
Plasmacytoid DCs, skin resident LCs, and inflammatory DCs have been described both in humans and 
mice. It has been proposed that LCs and dermal (interstitial) DCs originate from a myeloid precursor, 
whereas plasmacytoid DCs may develop from a lymphoid precursor. However, this hypothesis is still 
under discussion [130]. Conventional DCs (here: other than pDCs) predominantly express the leukocyte 
integrin CD11c/CD18 (CD11c) or complement receptor 4 (CR4). pDCs only weakly express CD11c and 
have been identified by expression of BDCA-2 in humans and sialic-acid binding immunoglobulin-like 
lectin H (Siglec-H) in mice. In contrast, macrophages and monocytes express mainly CD11b/CD18 
(CD11b) [131]. LCs and interstitial DCs share the ability to both activate CD4+ and CD8+ naïve T cells and 
secrete IL-12. However, only interstitial DCs are capable of inducing naïve B cells to differentiate into 
immunoglobulin (Ig)-secreting plasma cells. Plasmacytoid DCs (also: interferon-producing cells; IPC) 
were named after their resemblance to Ig-producing plasma cells and are unique in their ability to 
produce large amounts of type I IFNs upon viral stimulation. pDCs express the toll-like receptors TLR7 
and TLR9, which provide sensitivity to single-stranded RNA viruses as well as to the non-methylated 
CpG-residues associated with many DNA viruses. It has been shown that type I IFNs stimulate a rapid 
antiviral response in uninfected somatic cells, while also influencing the development and maturation 
of DCs from blood monocytes [131, 132]. However, pDCs are less efficient in antigen capture and 
presentation as they express fewer MHCII and costimulatory molecules as conventional DCs do. 
Nevertheless, they may support a sustained production of IL-12 by conventional DCs via CD40 
signaling, as TLR9 stimulation induces CD40ligand (CD40L) expression on pDCs. Epidermal LCs display 
a typical immature phenotype, are highly phagocytic and contain large granules called Birbeck 
granules. In contrast to other DC subsets, LCs develop from embryonic precursors, mainly fetal liver 
monocytes. LCs promote peripheral tolerance by constantly migrating to skin-draining LNs to present 
dermal and epidermal antigens to CD4+ T cells, which induces anergy due to their immature phenotype. 
In some cases of viral infections, however, LCs in the skin may capture antigens and travel to the lymph 
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nodes to transfer them to resident CD8+ DCs via cross-presentation, which seem to be responsible to 
prime naïve CD8+ T cells [129]. 
 
Tissue inflammation, e.g., upon infection, may induce DCs of monocytic origin expressing CD11b and 
CD11c across species as well as CD64, FcγRε, and lymphocyte antigen 6C (Ly6C) in mice and CD1a, 
CD206, CD1c as well as CD14 in humans. So-called inflammatory DCs or TipDCs (due to expression of 
TNFα and i-NOS) migrate to tissue-draining LNs while expressing IL-12 and IL-23 to induce TH1 or TH17 
responses, depending on the type of activation stimulus [133, 134]. Further known DC populations are 
splenic marginal DCs, interdigitating DCs in T cell-rich zones in secondary lymphoid tissues, germinal 
center (follicular) DCs, thymic DCs, liver DCs, and peripheral blood DCs [135]. Efforts are done to define 
an alignment of human and murine DC subsets and their respective functions (Figure 4-3). In this line, 
analysis of transcription factors seems to define lineages more accurately as compared to cell surface 
antigens [129].  
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Figure 4-3 Different DC subsets shape different immune responses. Transcription factors that define DC lines are 
highlighted (mouse: red, human: blue). Adapted from Schlitzer A, Ginhoux F. Organization of the mouse and 
human DC network. Reprinted with permission from Elsevier Ltd. Copyright © 2014 [129]. 
4.3.1.1 DC subsets and cell lines used in this study 
Human monocyte-derived DCs. Generation of large amounts of immature dendritic cells in vitro by 
culture of CD14+ blood monocytes in presence of GM-CSF and IL-4 have first been described by 
Lanzavecchia and colleagues in 1994 [136]. Monocyte-derived DCs (moDCs) display efficient antigen-
presentation capacity accompanied by the ability to induce activation of naïve T cells. Meanwhile, 
many studies have been performed using monocyte-derived DCs and thereby evaluated the use of this 
in vitro culture system for the assessment of DC biology [137]. 
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Murine bone marrow-derived DCs and SP37A3 DC-cell line. For the study of murine DC activation, both 
bone marrow-derived DCs (BMDCs), generated by differentiation of bone marrow cells in the presence 
of GM-CSF (first described in) [138], and the DC cell line SP37A3 were used. SP37A3 DCs were 
established by growth-factor dependent long-term culture of splenic DCs as described by Winzler et al. 
[139]. SP37A3 DCs express CD11b and CD11c, low levels of CD205, but no CD8α. Properties of this DC 
cell line have been described extensively by Bros et al. [140].  
 
4.3.2 Dendritic cell activation & initiation of T cell immunity 
In most tissues DCs are present in an immature state. They possess low capacity to stimulate naïve T 
cells but are very well equipped for antigen capture and processing. Pathways for antigen (Ag) capture 
include macropinocytosis, receptor-mediated endocytosis via C-type lectin receptors (mannose 
receptor, DEC205), or Fcγ receptor types I (CD64) and II (CD32) as well as phagocytosis of particles, 
fragments from apoptotic and necrotic cells, viruses or bacteria [141]. Furthermore, DCs are able to 
internalize peptide-loaded heat shock proteins glycoprotein 96 (gp96) and heat shock protein 70 
(Hsp70) [123]. Capture of an antigen itself may provide a first signal for activation of the DC, whereas 
signaling through the receptors CD40, TNF-R, and IL-1R may furthermore trigger activation of DCs 
[141]. Additionally, the danger model suggests that signals indicating inflammation or tissue damage 
such as cytokines, heat shock proteins, HMGB1, uric acid, or extracellular ATP may be necessary for the 
activation of Ag-bearing DCs to induce their full maturation [18, 19, 142]. After activation, DCs change 
phenotypically as well as functionally from Ag-capturing cells to antigen presenting cells. They rapidly 
lose their Ag-capturing capacities, as at this stage the processing of antigens as well as the assembly of 
peptide-MHC class II complexes is of most importance. The antigen enters the cell and is directed to 
MHC class II-rich compartments (MIIC), which are abundant in immature DCs. Within these 
compartments, peptide binding to MHCII molecules is edited and enhanced. During maturation, MIICs 
convert to vesicles that release their MHC-peptide complexes at the cell surface where they remain 
stable for days (Figure 4-4) [123]. 
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Figure 4-4 Antigen presentation pathways in dendritic cells. Phagocytosis, macropinocytosis, and endocytosis 
mediate uptake of exogenous particles, proteins or pathogens into the cell. Antigens are then processed in 
endocytic vesicles (phagosomes, endosomes, lysosomes and/or endolysosomes) and loaded onto MHCII molecules 
in a lysosome or MHCII compartment (MIIC) before antigen-MHC complexes are moved to the cell surface. MHCII 
loading of endogenous antigen provided by autophagy may occur in stress situations. Antigens are loaded onto 
MHCI either through the classical pathway or by cross-presentation. Endogenous or viral proteins in the cytosol are 
processed through the proteasome, transported into the endoplasmic reticulum, passed through the Golgi and 
finally transported to the cell surface via the classical pathway. In addition, exogenous antigens that have been 
phagocytosed, macropinocytosed or endocytosed can be cross-presented on MHCI molecules by specific DC 
subsets. Here, antigen is loaded in endocytic compartments or may escape endosomes and arrive in the cytosol, 
where it is processed through the proteasome as usual, loaded onto MHC class I molecules and transported to the 
surface. Adapted from Hubbell YA. Materials engineering for immunomodulation. Reprinted with permission from 
Macmillan Publishers Limited. Copyright © 2015 [143]. 
 
For generation of CTLs, DCs present antigenic peptides in the context of MHCI molecules. Peptides 
from self and intracellular pathogens are loaded via the endogenous pathway, whereas peptides 
originating from extracellular Ags or immune complexes captured by FcγR are processed via the 
exogenous pathway. Endogenous, cytosolic proteins are degraded and loaded onto newly synthesized 
MHCI molecules in the ER. Extracellular antigens that are taken up with phagocytosed particles, 
exosomes or dead (dying) cells may escape the endocytic pathway and enter the ER to be loaded onto 
MHCI molecules for presentation to CD8+ CTLs [130]. The later has been termed cross-presentation and 
is an important process in the generation of immunity against tumors or viruses that do not infect the 
APC itself. Cross priming denotes the activation of CTLs via this pathway. In case specific self-antigens 
(auto-antigens) are presented to CD8+ T cells, the process leads to elimination of auto-reactive T cells 
and has been termed cross-tolerance. Furthermore, the family of MHC-related CD1 molecules has been 
identified as non-classical Ag-presentation molecules that present microbial lipids and glycolipid-
containing antigens [123]. 
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DC maturation is a continuous process that is initiated with Ag-capture and DC activation in the 
periphery and is not completed until the mature DC interacts with T cells in secondary lymphoid organs 
(Figure 4-5). Hence, migration of DCs occurs simultaneously to the maturation process. Various 
molecules such as Lipopolysaccharide (LPS) from bacterial cell walls, bacterial DNA, and double-
stranded RNA, as well as T cell-derived signals are known to influence maturation. In addition, the 
balance between pro- and anti-inflammatory signals in the local microenvironment plays an important 
role. Apart from the loss of receptors for phagocytosis or endocytosis and the change in MIICs, the up-
regulation of co-stimulatory molecules such as CD40, CD58, CD80 (B7.1), and CD86 (B7.2) as well as 
morphological changes, such as a loss of adhesive structures, and cytoskeleton reorganization are 
accompanying and enabling maturation and migration [123]. DCs migrate from the periphery to T cell 
areas in lymphoid organs via afferent lymph, which is triggered by chemokines as well as cytokines 
such as IL-1. During maturation, DCs up-regulate CCR7, which binds to and is activated by macrophage 
inflammatory protein-3 beta (MIP-3β) and secondary lymphoid-tissue chemokine (SLC, also known as 
6Ckine) from which the latter is expressed on lymphatic vessels. Mature DCs enter draining lymph 
nodes and migrate to the T cell area in response to MIP-3β and/or 6Ckine. DCs themselves may be able 
to produce these chemokines to enhance and stabilize the signal. Expression of both MIP-3β and 
6Ckine is necessary to attract naïve T and B cells and therefore, these chemokines may support the 
encounter of mature Ag-bearing DCs with antigen-specific lymphocytes [144]. Once DCs are 
interacting with T cells via the TCR, they receive additional maturation signals from the T cell, such as 
CD40L or TNF-related activation-induced cytokine (TRANCE). To sum up, in lymph nodes DCs 
complete maturation, attract T and B cells by the release of chemokines and maintain the viability of 
re-circulating T cells [141]. 
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Figure 4-5 The DC maturation process. “Hematopoietic stem cells (HSCs) differentiate into immature dendritic 
cells (iDCs) that are recruited to peripheral tissues, where they continuously internalize and process antigens. After 
antigen capture and depending on the nature of the antigen, DCs migrate to the draining lymphoid tissue and 
mature phenotypically, which results in upregulation of CD40, CD80, CD86, MHCII and CCR7. In the draining 
lymphoid tissue, they present peptide–MHC complexes, interact with antigen-specific lymphocytes and mature 
functionally. Mature DCs activate T cells, B cells and NK cells and produce pro-inflammatory cytokines, such as IL-
12 and TNF”. Adapted from Hackstein H, Thomson W. Dendritic cells: emerging pharmacological targets of 
immunosuppressive drugs. Reprinted with permission from Macmillan Publishers Limited. Copyright © 2015 [145]. 
 
4.3.2.1  Dendritic cell signaling pathways & PRR 
As key initiators and regulators of adaptive immunity, dendritic cells respond to a broad variety of 
conserved molecular patterns derived from infectious pathogens (i.e., PAMPs), as well as host-derived 
molecules from damaged or transformed self-tissues (i.e., DAMPs). Endogenous DAMPs may be 
identified as dangerous in case of aberrant localization or as part of abnormal (immune-) complexes 
that arise as a consequence of infection, inflammation or other types of cellular stress [146]. For 
recognition of either alarm signal, a broad variety of cells including DCs, macrophages, monocytes, B 
cells, neutrophils, or epithelial cells express the germ-line encoded pattern recognition receptors 
(PRRs). By differential triggering of a plethora of extra- and intracellular PRRs, not only the type, but 
also the duration and timing of encountered stimuli define the outcome of any immune activation. 
Hence, fine-tuning of innate signaling by PRRs determines tailor-made immune responses to distinct 
molecular patterns by directing T helper cell differentiation via DC-mediated cytokine secretion and 
expression of costimulatory molecules [147]. 
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PRRs can be classified in five sub families: Toll-like receptors (TLRs), C-type lectin receptors (CLRs), 
nucleotide-binding domain, leucine-rich repeat (LRR)-containing (or NOD-like) receptors (NLRs), RIG-I-
like receptors (RLRs), and AIM2-like receptors (ALRs) [148]. Of those, TLRs and CLRs are membrane-
bound receptors located either on the cell surface or in endocytic compartments for recognition of 
extracellular or endosomal antigens, respectively. NLRs, RLRs and ALRs are located in the cytoplasm 
and recognize intracellular antigens. Upon activation, PPRs oligomerize and, by recruiting specific 
adaptor proteins and kinases, form multi-subunit complexes that transduce signals for initiation of both 
transcriptional and non-transcriptional responses. Major transcriptional response is the induction of 
leukocyte-recruiting chemokines, as well as pro-inflammatory cytokines and type I IFNs for initiation of 
innate as well as adaptive immune responses. Non-transcriptional responses include autophagy, 
phagocytosis and the processing of cytokines. Also, signaling via the IL-1 and IL-18 receptors is closely 
related to TLR signaling due the shared Toll/interleukin-1 receptor (TIR) homology domain, which 
mediates interaction with adaptor proteins. Importantly, IL-1 and TNF-α play outstanding roles in 
pathogen clearance by amplifying inflammatory responses induced by PAMPs or DAMPs [149]. 
 
TLRs. To date 13 TLRs have been described, from which TLR1-9 are conserved between humans and 
mice, while TLR10 is expressed in humans and TLR11-13 are expressed in mice. TLRs are type I 
transmembrane receptors that recognize PAMPs via leucine-rich repeats (LRRs), while their 
cytoplasmic TIR domain interacts with a set of adaptor proteins that is composed of TIR-containing 
adaptor protein (TIRAP), myeloid differentiation primary response 88 (MyD88), TIR domain–containing 
adaptor-inducing IFN-β (TRIF), and TRIF-related adaptor molecule (TRAM). Adaptor proteins 
transducing signals from PPRs play a crucial role in simultaneous detection of divers ligands as they 
integrate signals from more than one receptor. Signal transduction from the receptors to the adaptors 
depends on the cytoplasmic TIR domain that serves as the docking site for the TIR-containing 
cytoplasmic adaptor proteins [149]. All TLRs except for the endosomal TLR3 engage MyD88 either 
directly or in combination with the adaptor TIRAP/Mal, whereas TLR4 uniquely engages either MyD88 
or TRIF for downstream activation of signaling cascades. TLR4 can either undergo trafficking to 
specialized sites on the cell membrane to induce MyD88-dependent pro-inflammatory cytokine 
production, or it is endocytosed and mediates production of IFNs via TRIF-dependent endosomal 
signaling [150]. Recruitment of adaptors subsequently initiates formation of larger signaling complexes 
composed of serine/threonine kinases (such as interleukin-1 receptor-associated kinases (IRAK)-1,-2,-
4), ubiquitin E3 ligases (such as TNF receptor associated factors (TRAF)-3,-6 and cellular inhibitor of 
apoptosis proteins (cIAP)-1,-2), as well as the regulatory subunit of the IκB kinase (IKK) complex, NF-κB 
essential modulator (NEMO; also called IKKγ). They induce activation of mitogen-activated kinases 
(MAPKs) and the transcription factor families nuclear factor κ-light-chain-enhancer of activated B cells 
(NF-κB), activator protein 1 (AP-1), or interferon regulating factors (IRFs) for production of pro-
inflammatory cytokines and type I IFNs (Figure 4-6) [151].  
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Figure 4-6 Multiple levels of intracellular signaling pathways downstream of pattern-recognition receptors. 
“Signaling is initiated by cell surface or intracellular receptors and transduced via adaptor proteins and kinases that 
mediate activation of transcription factors followed by subsequent transcription of effector molecules. Adapted 
from Eunshil Jeong and Yoo Young Lee. Intrinsic and Extrinsic Regulation of Innate Immune Receptors.” Reprinted 
with permission from Creative Commons Attribution (CC BY) license (open access article) [151]. 
 
RLRs. The group of antiviral RLRs includes retinoic acid-inducible gene I (RIG-I), melanoma 
differentiation-associated gene-5 (MDA-5), and laboratory of genetics and physiology 2 (LGP2), which 
use the mitochondrial antiviral signaling protein (MAVS, also known as IPS-1, Cardif or VISA) as 
common adaptor protein. RLRs recognize intracellular viral and bacterial nucleic acids based on 
differences in structure and localization. Upon RLR triggering, MAVS forms a complex with caspase 
recruitment domain 9 (CARD9) and B-cell lymphoma/leukemia-10 (Bcl-10) to induce pro-inflammatory 
cytokines via activation of MAPKs and NF-κB transcriptional activation, whereas induction of type I 
IFNs requires TRAF3 and the kinases TBK1 and IKKε that activate IRF3 and IRF7 [149]. Similar to the 
MyD88-TIRAP-IRAKs-cluster, which has been termed “myddosome”, MAVS forms so-called 
“supramolecular organizing centers (SMOC)” with RIG-I or MDA-5 in combination with TRAFs in order 
to facilitate enzymatic activation of signaling components and to provide spatial specificity [152]. Also, 
subcellular localization of receptors and adaptors is an important determinant of innate recognition of, 
and responses to PAMPs and DAMPs. As an example, viruses require cytoplasmic organelle-like 
replication complexes in order to transcribe their genome. These complexes contain host-derived 
membranes originating from the ER, the Golgi apparatus, mitochondria, or lysosomes, and indeed, 
MAVS is situated at mitochondria, peroxisomes, and mitochondrial-associated ER membranes (MAM). 
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Interestingly, MAVS situated on mitochondria and MAVS situated on peroxisomes induce different 
types of IFNs [153].  
 
While RLRs recognize viral RNA species, sensing of pathogenic DNA is accomplished either by TLR9 in 
case of unmethylated CpG-DNA, or via the stimulator of interferon genes (STING) pathway. STING is 
localized at the ER from where, upon activation, it moves to the Golgi, leaves the Golgi and associates 
with TBK1 on still not well defined “IFN-inducing vesicles” to induce IRF3 and NF-κB-mediated cytokine 
expression. To date the only viral DNA receptor that has been shown to activate STING is called cGas 
and recognizes B-type cytoplasmic DNA [154, 155]. 
 
CLRs. CLRs form a heterogeneous group of hundreds of receptors that all contain the so-called C-type 
lectin domain (CTLD) and have meanwhile been divided in 17 subgroups based on their structure. Most 
CLRs function as opsonins that lack the ability to directly induce pro-inflammatory responses. Specific 
subgroups such as the dectins, however, can induce the NF-κB signaling cascade via a complex 
composed of CARD9, Bcl-10, and mucosa-associated lymphoid tissue lymphoma translocation protein-
1 (MALT-1). Furthermore, Dectin-1 signaling initiates phagocytosis of microbes upon binding to 
particulate ligands [148]. 
 
NLRs. The family of intracellular NOD-like receptors is divided into four subfamilies based on different 
N-terminal effector domains. Similar to other PRR-associated proteins, NLRs nucleate large signaling 
complexes (SMOCs), which either form the caspase-1 dependent “inflammasomes”, activate MAPK 
and NF-κB pathways in caspase-1 independent fashion, or act in the nucleus as transcriptional 
regulators [156]. Within the NLRC (formerly known as NOD) subfamily, NOD1 and NOD2 are best 
described. They recognize different components of bacterial peptidoglycan [NOD1: D-γ-glutamyl-
meso-DAP dipeptide (iE-DAP); NOD2: muramyl dipeptide (MDP)], and upon activation undergo 
oligomerization, which enables interaction with the kinase receptor-interacting protein 2 (RIP2; also 
known as CARDIAK or RICK). Further recruitment of a kinases as well as ubiquitin ligases and NEMO 
mediate activation of NF-κB and MAPKs. Both NOD1 and NOD2 may also recognize ssRNA and it has 
been shown that NOD2 signaling after RNA stimulation is RIP2 independent but engages MAVS to 
induce type I IFNs via IRF3. ssRNA triggering of NOD2 furthermore synergizes with previous MDP 
stimulation in production of pro-inflammatory cytokines [157].  
 
Inflammasomes. Caspase-1 dependent signaling complexes termed inflammasomes perform the 
crucial task to produce the mature form of the pro-inflammatory cytokines IL-1β and IL-18 in response 
to a variety of pathogenic, but also endogenous danger-associated stimuli, such as ATP and uric acid, or 
crystalline structures, such as alum and silica [158]. Importantly, inflammasome activation requires two 
signals. Prior triggering of TLRs as first signal is necessary to induce production of pro-IL-1β, which is 
then processed by the inflammasome upon its activation by a second signal [159]. They are generally 
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composed of a sensor protein belonging to the absent in melanoma (AIM)2-like receptor (ALR)-, RLR- 
or NLR families, the adaptor protein apoptosis-associated speck-like protein containing a CARD (ASC) 
and the inactive zymogen procaspase-1. Formation of the inflammasome is enabled only after 
triggering of the sensing receptor, which enables sensor oligomerization and recruitment of ASC and 
procaspase-1. The close proximity of zymogens within the inflammasome is believed to facilitate their 
autocatalytic cleavage into the enzymatically active protease caspase-1, which then cleaves its 
substrates pro-IL-1β and pro-IL-18 into their active forms [158]. Triggering of the inflammasome 
furthermore provokes an extremely rapid, inflammatory form of cell death termed “pyroptosis”. After 
this explosion-like cell death, prion-like ASC structures may serve as messengers to promote cell-to-cell 
communication in at least two ways: first, ASC oligomers continue to produce IL-1β in the extracellular 
space and second, ASC prions act as danger signals themselves, as their uptake by macrophages 
induces further production of IL-1β. Consequently, an initial triggering of only few sensor molecules 
may induce an immune response that is extensively amplified via polymerization of ASC-caspase-1 
prions, which then expand the inflammasome response to other innate cells [158].  
 
Multiple NLRPs (NALPs), NLRCs (NODs), and AIM2-like proteins serve as inflammasome- nucleating 
proteins. Of these, the best-described initiator is NLRP3, which was shown to be activated in canonical 
or non-canonical manner, depending on the activating stimuli. The canonical pathway is induced by 
certain Gram-positive bacteria, viruses such as influenza virus, pore-forming toxins, as well as by a row 
of endogenous ligands, such as ATP and crystalline substances such as alum or silica. Rather than 
recognizing such a divers set of ligands, it is now accepted that NLRP3 responds to stress-induced 
signaling pathways including potassium efflux, the generation of mitochondrial reactive oxygen species 
(ROS), cathepsin release as a result of phagolysosomal membrane destabilization, release of 
mitochondrial DNA, or translocation of NLRP3 to mitochondria through the adaptor molecule MAVS 
[158]. Non-canonical activation has been proposed to occur by direct recognition of cytoplasmic LPS by 
caspase-11. Direct activation of caspase-11, however, seems to be against former paradigms, as it has 
never been shown that caspases bind PAMPs directly and it was believed that the scaffolding by a 
multiprotein complex is crucial for caspase activation. Therefore, caspase-11 seems to be an exception 
to the rule, as triggering by cytoplasmic LPS leads to self-oligomerization inducing subsequent 
caspase-1 maturation downstream of the NLRP3 inflammasome well as cell death by pyroptosis, 
although the underlying mechanisms remain unknown. Since caspase-11 is only expressed in mice, it is 
believed that the caspases 4 and 5 are the respective homologues that perform non-canonical 
inflammasome activation in humans [160]. All together, the field of innate pattern-recognition, and 
especially regarding the induction of inflammasomes and other novel SMOCs, is constantly moving. It 
is to expect that various paradigms will have to be re-considered upon new insights.  
 
Signaling effectors: MAPKs, NF-κB, IRFs and AP-1. MAPKs are ubiquitously expressed and respond to 
a variety of stimuli including growth factors, hormones, cytokines, agents that signal through G 
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protein-coupled receptors, or are related to TGF-β, and environmental stresses [161]. Thus, multiple 
cellular processes involve activation of MAPKs, which is not limited to innate immunity. Hence, MAPKs 
may promote tumor cell apoptosis in response to cytotoxic agents and at the same time, activate 
innate immunity as a result of inflammation or PRR-triggering. A complex network of distinct 
intermediate signaling components thus regulates specific responses. MAPK initiation in innate 
immunity involves simultaneous or subsequent induction of the NF-κB, AP-1 or IRF transcription 
factors. Importantly, while NF-κB and AP-1 mediate induction of proinflammatory responses, IRFs are 
essential for production of IFNs (Figure 4-7). 
 
 
Figure 4-7 Innate signaling pathways: induction of MAPKs, NF-κB, AP-1 and IRFs. “TLRs located in plasma 
membrane (TLR1, 2, 4, 5, 6, 11) activate the NF-κB and MAPK (JNK, ERK, p38) signaling pathways via MyD88. 
Nucleic acid recognition by endosomal TLRs (TLR3, 7, 8, 9) induces production of type I interferon and 
proinflammatory cytokines via TRIF-IRF3 and MyD88-NF-κB signaling pathways, respectively (left). NOD1 and 
NOD2 recognize i.e.-DAP and MDP from bacterial cell wall components, respectively, while NOD-induced 
proinflammatory responses require MAPK and NF-κB activation through the recruitment of adaptor molecule 
CARD9 and RICK/RIP2. Members of NLRs participate in the activation of inflammasome complex consisting of 
NLRs, procaspase-1 and ASC in the cytosol”. Adapted from Hyo Sun Jin, Jeong-Kyu Park and Eun-Kyeong Jo. Toll-
like Receptors and NOD-like Receptors in Innate Immune Defense during Pathogenic Infection. Reprinted with 
permission from Creative Commons Attribution (CC BY) license (open access article) [162].  
 
MAPKs themselves are activated by phosphorylation within a three-tiered signaling cascade in which 
upstream kinases phosphorylate downstream kinases. Hence, MAPKs are initiated via 
tyrosine/threonine (Tyr/Thr) phosphorylation by dual-specificity MAPK kinases (MAP2Ks, also called 
MEKs or MKKs). These MAP2Ks are activated by serine-threonine (Ser/Thr) phosphorylation mediated 
by upstream MAPK kinase kinases (MAP3Ks), while MAP3Ks are typically activated by interactions with 
a small GTPase and/or phosphorylation by protein kinases downstream from cell surface receptors 
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[163]. 14 MAPKs are known in mammalian cells, including the classical MAPKs extracellular signal-
regulated kinase 1 (ERK1) and ERK2, the p38 MAPK family, which comprises four isoforms (p38α, p38β, 
p38γ and p38δ), and the Jun N-terminal kinase (JNK) family, consisting of three isoforms (the 
constitutively expressed JNK1 and JNK2, as well as the tissue-specific JNK3, which is mainly expressed 
in the brain). ERK1/2 are activated by the MAP2Ks MKK1 or MKK2 and p38 is activated by the MKK3 
and MKK6, while JNKs are phosphorylated preferentially by MKK4 and MKK7. MAP3Ks for the JNK 
module include MEKK1 and MEKK4, MLK2 and MLK3, ASK1, TAK1, and Tpl2. MAPKs can either induce 
activation of downstream kinases or transcription factors such as CCAAT/-enhancer-binding protein 
homologous protein (CHOP), nuclear factor of activated T cells (NFAT) or AP-1 [161].  
 
4.4 Microtubule function 
The eukaryotic cytoskeleton is composed of three types of filamentous structures: i.e., intermediate 
filaments, actin filaments and microtubules, of which all are linked with each other. The long and 
tubular-structured microtubules (MTs) are formed by polymerization of α- and β-tubulin subunits that 
associate to heterodimers. MTs orchestrate numerous cellular activities such as organizing cytoplasmic 
organelles, directing intracellular transport, supporting cell proliferation, inducing cellular motility as 
well as maintaining cell shape and polarization [164-166]. Polymerization of MTs occurs via the 
nucleation-elongation mechanism, in which a short microtubule nucleus is formed prior to rapid 
elongation at the ends of the MTs by non-covalent addition of tubulin dimers. Polymerization and 
depolymerization processes are highly dynamic as microtubules switch stochastically between states of 
consecutive growing and shortening, a process that is crucial to the cellular functions of MTs and that is 
called “dynamic instability”. Transitions during this process are called “catastrophes” (from growth to 
shrinkage) and “rescues” (change to assembly of MTs) [167]. As these dynamics are not only 
equilibrium-driven, energy is provided by the hydrolysis of GTP at the time that tubulin with bound GTP 
adds to the microtubule ends (Figure 4-8). MTs are polar structures having a fast growing (+) end 
exposing β-tubulin subunits and a slow growing (-) end exposing α-tubulin subunits. This polarity is an 
important factor for directing movement along MTs. Secondly, microtubules undergo “treadmilling”, a 
dynamic behavior in which tubulin molecules bound to GDP dissociate from one end and are replaced 
by the addition of tubulin molecules bound to GTP at the opposite end of the same MT [168, 169].  
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Figure 4-8 Microtubule structure. (A) α- and β-tubulin molecules combine to form heterodimers. 13 of these 
vertically-stacked tubulin heterodimers form the protofilaments, which are arranged side-by-side to form a hollow, 
cylindrical microtubule. (B) The minus end final subunits are α-tubulin (blue), whereas the plus end final subunits 
are β-tubulin (purple). The red dashed line along the length of the microtubule indicates the seam formed by two 
adjacent protofilaments. MTs are usually nucleated by a complex containing γ-tubulin as well capping proteins at 
the minus end (not shown). (C) GTP bound to tubulin subunits (lighter color) at the plus end loose one phosphate 
with time, resulting in GDP-bound tubulin subunits within the MT. Adapted from Anna Akhmanova and Michel O. 
Steinmetz. Tracking the ends: a dynamic protein network controls the fate of microtubule tips. Reprinted with 
permission from Nature Publishing Group © 2015 [170]. 
 
MTs in most cells grow out from a microtubule-organizing center (MTOC), in which the minus ends of 
microtubules are anchored. In eukaryotic cells the centrosome takes over the role of the MTOC and is 
located near the nucleus in non-dividing interphase cells. Importantly, during mitosis duplicated 
centrosomes are the starting point for outward growing MTs to form the mitotic spindle [167]. 
 
4.4.1 Microtubule-binding anti-cancer agents 
Due to their major contribution to important cellular processes such as the precise segregation of 
chromosomes during cell division, the transport of cellular cargos, or the positioning and movement of 
intracellular organelles, MTs have been extensively explored as target for anti-cancer therapeutics [165, 
169, 171]. Inhibition of microtubule function leads to cell cycle arrest at G2/M phase and subsequent cell 
death. Microtubule-targeted drugs at relatively high concentrations either inhibit microtubule 
polymerization, destabilize microtubules and decrease microtubule polymer mass, or promote 
microtubule polymerization, stabilize microtubules and increase the polymer mass. By suppressing the 
dynamic instability of microtubules, these compounds induce mitotic arrest leading to subsequent 
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inhibition of cell proliferation and induction of apoptosis. Most microtubule-targeted antimitotic drugs 
have originally been isolated from a large range of plants (i.e., algae) and animals (i.e., sea hares), with 
the earliest discovery being the vinca-alkaloids that have been isolated over 40 years ago and are 
meanwhile widely used for treatment of mainly hematologic, but also solid cancers [169, 172]. Based on 
their effect on MTs, these compounds are usually classified into two main groups (Table 4-1): 
 
Microtubule-destabilizing agents stimulate depolymerization of microtubules at high doses. Compounds 
of this class include the vinca-alkaloids (vinblastine, vincristine, vinorelbine, vindesine and vinflunine), 
nocodazol, colchicine, dolastatins, maytansines (mertansines), combretastatins and others 
(cryptophycins, halichondrins, estramustine, noscapine, rhizoxin, spongistatins, podophyllotoxin, 
steganacins and curacins). 
 
Microtubule-stabilizing agents stimulate microtubule polymerization and include taxol (paclitaxel), 
docetaxel (taxotere), the epothilones, discodermolide, the eleutherobins, sarcodictyins, laulimalide, 
rhazinalam, and certain steroids and polyisoprenyl benzophenones.  
 
Of note, both classes, although increasing or decreasing microtubule polymerization at high 
concentrations (e.g., 10-100 nM for vinblastine in HeLa cells), powerfully suppress microtubule 
dynamics at 10–100-fold lower concentrations and, therefore, kinetically stabilize microtubules without 
changing the microtubule-polymer mass. In other words, the effects of the drugs on dynamics are often 
more pronounced than their effects on polymer mass [169].  
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Table 4-1 Microtubule-binding agents currently in clinical practice or in development in clinical trials. 
Abbreviations: ADC, antibody–drug conjugate; ALL, acute lymphoblastic leukemia; NSCLC, non-small-cell lung 
cancer; GBM, glioblastoma multiforme; nab, nanoparticle albumin-bound; T-DM1, trastuzumab emtansine. 
Adapted from Herbert H Loong, Winnie Yeo. Microtubule-targeting agents in oncology and therapeutic potential 
in hepatocellular carcinoma. Reprinted with permission from Dove Medical Press © 2015 [173]. 
 
 
4.4.1.1 Dolastatins 
Dolastatin 10, described as one of the most potent antineoplastic agents, was originally isolated from 
the Indian Ocean sea hare Dolabella auricularia by George Pettit (Figure 4-9) [174]. The five-subunit 
penta-peptide potently inhibits microtubule assembly by interacting with tubulin at the "peptide sub-
site" of tubulin's "vinca domain" (Table 4-1). The binding site is in close physical proximity to 
vinblastine, with dolastatins acting as non-competitive inhibitors of vinblastine binding to tubulin [175]. 
Dolastatin 15 has very similar properties and although only slightly differing in structure, it is nine times 
less potent than dolastatin 10, but both are more potent than vinblastine [176]. Meanwhile, a range of 
synthetic analogues, the auristatins, have been synthesized and although dolastatin 10 failed in a phase 
II clinical trial with advanced breast cancer patients due to high toxicity when administered systemically 
[177], further auristatins have been developed for use in antibody-drug conjugates (ADC) [178]. In terms 
of hydrophobicity, stability and potency, monomethylauristatin E (MMAE) was the most successful 
compound and is now used as cytotoxic payload of the ADC brentuximab vedotin, developed by Seattle 
Genetics and approved for treatment of relapsed Hodgkin lymphomas (HL) and systemic anaplastic 
large cell lymphomas (ALCL) [179].  
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Figure 4-9 Chemical structures of dolastatin 10 and MMAE. Image courtesy of Robert Lyon, Seattle Genetics. 
 
4.4.1.2 Maytansinoids  
Maytansine, a natural product originally derived from the bark of the African shrub Maytenus ovatus, 
has been known to exert its antimitotic activity by inhibiting the assembly of microtubules and blocking 
the cells at mitosis. Its structural analogue ansamitocin P3 binds to tubulin in a competitive manner 
with vinblastine and rhizoxin suggesting that it partially overlaps the vinblastine binding site (Figure 4-
10; Table 4-1) [180-182]. Treatment of MCF-7 breast cancer cells with ansamitocin P3 resulted in severe 
disruption of interphase and mitotic microtubules. The affected cells were blocked in mitosis and 
accumulated p53 and its downstream partner p21 in the nucleus, which activated apoptotic cell death in 
these cells [183]. Similar to dolastatin 10, systemic administration of free maytansinoids has 
demonstrated substantial toxicity. The extraordinary cell-killing potency, though, has led to the 
exploration of maytansine derivatives as cytotoxic payloads of antibody-drug conjugates [184]. In 
addition, synthetic derivatives of maytansine have been developed that possess a 100- to 1000-fold 
higher cytotoxic potency than clinically used anticancer drugs, such as the vinca alkaloids [185]. 
Amongst those, DM1 has been developed for conjugation to the α-HER2 antibody trastuzumab 
(Herceptin®), which has been approved for treatment of HER2-overexpressing metastatic breast cancer 
in 1998 [186]. The resulting trastuzumab-emtansine (T-DM1) has recently been approved in HER2-
positive breast cancer while further maytansinoid-conjugated antibodies, such as BT062 (α-CD138-
DM4), SAR3419 (α-CD19-DM4), BAY94-9343 (α-mesothelin-DM4), and IMGN529 (α-CD37-DM1) are 
currently under clinical evaluation in phase I/II protocols [187]. 
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Figure 4-10 Chemical structures of maytansine and its analogue ansamitocin P3. Adapted from Venghateri JB. 
Ansamitocin P3 depolymerizes microtubules and induces apoptosis by binding to tubulin at the vinblastine site. 
Reprinted with permission from Creative Commons Attribution (CC BY) license (open access article) [183]. 
 
4.4.2 Regulation and sensing of MT structure 
The functional heterogeneity of MTs is largely mediated by a variety of microtubule-associated 
proteins (MAPs), such as motor-proteins or microtubule plus end-tracking proteins (+ Tips), by 
expression of different tubulin isotypes, or by post-translational modifications (PTMs) [188, 189]. 
Similarly, small Rho-GTPases, which belong to the Ras superfamily of GTPases, have been described as 
major regulators of cytoskeleton function [190]. The Ras homolog gene (Rho) family of small GTPases 
compromises at least 20 members, from which Rac, RhoA/B/C, and Cdc42 have been best 
characterized. The so-called “molecular switches” constantly cycle between their active, GTP-bound 
and inactive, GDP-bound state and have been implicated in controlling MAPK signaling pathways as 
well as cell cycle-associated processes [191]. They are themselves carefully regulated by a large amount 
of activators and inhibitors. A large variety of guanine nucleotide exchange factors (GEF) mediate 
activation by catalyzing GDP exchange with GTP, whereas the group of GTPase-activating proteins 
(GAPs) induce deactivation via GTP hydrolysis [190]. Finally, RhoGTPases are regulated by guanine 
nucleotide exchange inhibitors (GDIs) that extract inactive Rho proteins from membranes and 
sequester them in the cytosol [192]. Functionally, Rho is known to be responsible for the assembly of 
contractile actin and myosin filaments (stress fibers), Rac mediates the assembly of actin-rich surface 
protrusions (lamellipodia), and Cdc42 was shown to promote the formation of actin-rich, finger-like 
membrane extensions (filopodia) [190]. 
 
4.4.3 Linking microtubule-disruption with DC maturation 
In the context of signal transmission in response to microtubule destabilization, GEF-H1, a guanine 
nucleotide exchange factor for Rho (first characterized by Ren and colleagues) [193], is particularly 
interesting. Only two GEFs are currently known to co-localize with MTs, namely p190Rho-GEF and 
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GEF-H1 (as well as its murine homologue lfc). However, of those only GEF-H1 may sense MT 
depolymerization [194]. Moreover, Krendel et al. provide experimental evidence that GEF-H1 is 
responsible for regulating Rho activity in response to microtubule depolymerization and that 
microtubule disassembly results in the activation of RhoA (Figure 4-11) [195-197]. Also, it has been 
shown that GEF-H1 preferentially activates RhoA when compared to Rac1 or Cdc42 [195]. Importantly, 
MT depolymerization in response to the MDA nocodazol disrupted the phosphorylated, hence inhibited 
GEF-H1 complex, resulting in potent activation of GEF-H1 [198]. Interestingly RhoA activation by the 
MDA vinblastine has previously been shown for tumor cells as well as for DCs [199, 200]. Due to the 
localization of GEF-H1 on MTs and its specificity for RhoA, it seems that during MT depolymerization, 
RhoA might be an important molecular mediator of downstream signaling. Importantly RhoGTPases 
have been shown to induce MAPK signaling cascades via interaction with MAP3K family proteins or 
Rho-associated kinase (ROCK) [201, 202]. Both MAP3Ks as well as ROCK have been known to induce 
activation of the stress-activated protein kinases JNK and p38, which in turn induce AP-1 and NF-κB 
dependent gene transcription [202, 203]. Therefore, Rho-mediated MAP kinase activation might 
possibly be involved in linking microtubule disassembly with activation of pro-inflammatory molecules 
in innate immune cells.  
 
 
Figure 4-11 A model for the regulation of GEF-H1 activity by microtubules. "Inactive GEF-H1 is bound to MTs and 
released upon disruption of those. Release induces activation of GEF-H1, which in turn catalyzes GTP binding to 
RhoA. Active RhoA may then induce formation of actin stress fibers, increase myosin II contractibility or induce 
serum-responsive element (SRE)-dependent gene expression”. Adapted from Krendel M. Nucleotide exchange 
factor GEF-H1 mediates cross-talk between microtubules and the actin cytoskeleton. Reprinted with permission 
from Nature Publishing Group © 2015 [198].  
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5 Aim of the thesis 
Efficient therapeutic options for patients suffering from cancer are still limited. Cytotoxic or targeted 
therapies display high toxicity, and although these therapies are often initially successful, most tumors 
ultimately relapse. On the other hand, recent advances in understanding the anti-tumor immune 
response have led to major improvements in the field of cancer immunotherapy [204]. In particular, 
blocking immune checkpoints with monoclonal antibodies such as anti-CTLA-4 and anti-PD-1 has 
emerged as promising strategy that mediates clinically significant responses in a broad variety of 
cancer types [205, 206]. Nevertheless, only a fraction of patients respond and many responders 
eventually relapse. Possible explanations include immune effector cell exhaustion at the tumor site 
mediated by the immunosuppressive tumor microenvironment [207]. In this line, the physical reduction 
of the primary tumor burden by ionizing radiation, targeted therapies or chemotherapy may relieve the 
suppressive pressure exerted on the immune system and at the same time, release tumor-associated 
antigens for priming of de novo T cell responses. Furthermore, it has recently become evident that 
specific chemotherapeutic agents and molecular targeted therapies display formerly unrecognized 
immunomodulatory features, and thus mediate therapeutic effects by promoting anti-tumor immune 
responses [88, 89, 208]. Therefore, the combination of selected chemotherapy partners with 
immunotherapies has great clinical potential, but requires a deeper understanding of the immune-
promoting nature of these agents. 
 
In order to provide the basis for rational development of chemo-immunotherapy regimens, we 
formulated the following aims to be addressed in this thesis: 
 
I. To screen classical chemotherapeutic agents with distinct pharmacological mechanisms for their 
capacity to trigger DC maturation. 
 
II. To provide a detailed description of the nature of the anti-tumor immune response initiated by 
DC-stimulatory compounds. 
 
III. To characterize the interplay of immune effector cells with those agents and to define the impact 
of host immunity on the compounds’ anti-tumor efficacy.  
IV. To characterize potentially synergistic treatment regimens that combine immunostimulatory 
chemotherapeutics with immunotherapy, including a description of the immunological basis of 
synergistic regimens. 
 
V. To translate important findings into the human setting and to put observations in a clinically 
relevant perspective. 
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VI. To identify the molecular pathways that mediate activation of dendritic cells upon drug-
treatment. 
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6 Methods 
For a listing of materials and mammalian cell lines, please refer to chapter 10 (Attachments). 
6.1 Cell culture methods 
All work concerning mammalian cell culture was done under sterile conditions. Cells, buffers, media 
and reagents were handled under a laminar flow bench that guarantees a particle-free environment 
inside the hood by constantly passing the air though filters with a size of 0.2 µm. All fluids were either 
purchased sterile, autoclaved or passed though filters with 0.2 µm pore size. Incubation of cells took 
place in respective incubators with 37 °C in saturated steam atmosphere and 5-10% CO2. The media 
was exchanged every 3-4 days. In case cells of one flask reached confluency, they were detached with 
PBS + 2 mM EDTA, centrifuged and resuspended in fresh medium to be expanded onto two or more 
culture flasks.  
 
SP37A3 DCs were grown in SP-culture medium (IMDM + 10% FCS, 1 mM Na-pyruvat, 10 mM non-
essential amino acids, 100 U penicillin / 0.1 mg/ml streptomycin, 50 μM β-mercaptoethanol and 2 mM 
glutamin) supplemented with 20 ng/mL murine GM-CSF and 20 ng/mL M-CSF. DC stimulation with was 
performed in IMDM complete supplemented with 20 ng/mL GM-CSF only.  
 
Murine and human tumor cell lines were grown in DMEM complete medium (DMEM + 10% FCS, 1 mM 
Na-pyruvat, 10 mM non-essential amino acids, 100 U penicillin / 0.1 mg/ml streptomycin, 50 μM β-
mercaptoethanol and 2 mM glutamin). 
 
Cell counting 
The cell number was determined using a Neubauer hemocytometer. 10 μL of a homogeneous cell 
suspension were mixed with trypan blue solution 1:1 and pipetted under the microscope slide of the 
hemocytometer. Viable cells, i.e., cells that were not stained by the blue dye, present in 16 small 
squares were counted 4 times (upper left, upper right, lower right and lower left quadrant). The number 
of cells per mL was then calculated as follows: average number of cells in 16 small squares x 2 x 104. 
 
Cryoconservation and defreezing of cells 
For long-term storage in liquid nitrogen, cells were frozen in FCS + 10% DMSO (freezing medium) in 
cryovials. To this end, cells were detached, counted and resuspended in freezing medium at a density 
of 1x106 - 5x106 cells/mL, with 1 mL per vial. The vials were then transferred into a cryo freezing 
container and stored at -70 °C for at least two days before transferring the vials into a liquid nitrogen 
tank. 
 
For a quick defreezing of cells, the vials were thawed in the water bath at 37 °C until only a small 
amount of frozen material was left. By carefully pipetting up and down, the cell suspension was thawed 
  Methods 
50 
completely, added to 10 mL pre-warmed culture medium and centrifuged at 300xg for 5 minutes. 
Finally, cells were resuspended in 5-10 mL culture medium and transferred into an appropriate cell 
culture flask. 
 
6.1.1 Generation of murine bone marrow-derived DCs  
Bone marrow cells from C57Bl/6 WT, TRIF-/-, TLR4-/-, MyD88-/, RIP2-/- and NALP3-/- mice were prepared 
as previously described [209]. Briefly, bone marrow cells were flushed from femurs and tibias with pre-
warmed culture medium, washed, depleted of red blood cells and washed again. 2x106 cells in 10 mL 
RPMI1640 complete medium supplemented with 20 ng/mL GM-CSF were plated per 10 cm cell culture 
dish. 10 mL culture medium containing GM-CSF was added on day 3 and 10 mL medium was 
exchanged on day 6. DCs were activated on day 7 either on 10 cm culture dishes or on 96-well plates 
(7x104 cells/well). After 24h stimulation, the phenotype was assessed by flow cytometry or DCs were 
used in co-culture assays. 
 
6.1.2 Generation of human DCs from CD14+ monocytes  
PBMCs were isolated from buffycoats from healthy blood donors (Blood Transfusion Center, University 
Hospital Basel) by density gradient centrifugation using Histopaque®-1077. CD14+ monocytes were 
isolated from PBMCs by either positive selection using MACS CD14-microbeads (Miltenyi Biotec) or by 
plastic adherence as described previously [210]. The CD14- PBMC fraction was kept for subsequent 
isolation of T lymphocytes (see below). CD14+ monocytes were counted and cryo-preserved in freezing 
medium or cultured in RPMI1640 supplemented with 10% FCS, 50 ng/mL recombinant human GM-CSF 
and 250 U/mL recombinant human IL-4 on 6-well plates [137]. After 5 days of culture the surface 
expression of CD11b, CD11c, CD40, CD86 and HLA-DR was analyzed by flow cytometry and cells were 
used for subsequent assays.  
 
6.1.3 Purification of human T cells  
CD4+ T cells and CD8+ T cells were purified from the CD14- PBMC fraction by positive selection using 
anti-CD4 or anti-CD8 Microbeads (Miltenyi Biotec), respectively, according to the manufacturer's 
instructions. The purity of positively selected CD4+ and CD8+ T cells was analyzed by direct staining for 
membrane expression of CD4 and CD8 by flow cytometry. A portion of both CD4+ and CD8+ T cells was 
cryopreserved for later use in T-cell priming experiments. 
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6.2 In vitro and ex vivo cell-based assays & flow cytometry 
6.2.1 Flow cytometry  
Staining of cell surface or intracellular proteins was generally conducted in 96-well round bottom 
plates. All washing steps were performed with 200 μL buffer per well followed by centrifugation at 
300xg at 4 °C, buffer was discarded by inverting the plate quickly. Cells were harvested and washed in 
cold PBS prior to incubation with an Fc receptor-blocking antibody to reduce non-specific binding of 
the staining antibodies (50 μL/well; 1:100 in PBS) together with a fixable live/dead stain (LD-IR; 1:400) 
for 20 minutes on ice. The cells were washed twice with cold FACS buffer before addition of a mix of 
fluorescently labeled monoclonal antibodies for staining of cell surface proteins. The cells were then 
incubated for another 30 minutes on ice and in the dark, followed by three more washing steps. In case 
of intracellular staining (e.g., for detection of cytokines), the cells were fixed in IC fixation buffer 
(eBioscience) for 20 minutes after surface staining. Staining of intracellular proteins was performed in 
permeabilization buffer (Biolegend) for 45 minutes at room temperature (RT) in the dark after 3 
washing steps in permeabilization buffer. Finally the cells were washed twice and resuspended in FACS 
buffer prior to analysis.  
 
6.2.2 Drug screen for DC maturation  
24 chemotherapeutic compounds were tested for their ability to induce DC maturation at varying doses 
(for a list of cytotoxic compounds please refer to the Materials section; chapter 10.1). To this end, 
murine SP37A3 DCs or human monocyte-derived DCs (moDCs) were tested for their maturation status 
prior to the experiment. Non-treated and LPS-treated (500 ng/mL) cells were stained for anti-mouse 
CD86-APC, anti-mouse CD40-PE and anti-mouse MHCII (I-A/I-E)-Pacific Blue or anti-human CD86-PE, 
anti-human CD40-APC and anti-human MHCII (HLA-DR)-Pacific Blue, respectively. Dead cell exclusion 
occurred in both cases by prior Live/Dead-IR staining.  
 
Experiments determining the optimal assay plate, cell number and assay medium were performed 
previously. Murine SP37A3 cells were plated at 8x104 cells/well in 180 μL medium supplemented with 20 
ng/mL mGM-CSF in 96-well flat bottom plates. The cells were allowed to adhere overnight before the 
chemotherapeutic compounds were added 10-fold concentrated in 20 μL to yield final concentrations 
between 0.01 μM – 10 μM. Controls contained 3 wells of a) untreated cells, b) LPS-treated cells (500 
ng/mL) and d) vinblastine-treated cells (0.1 μM). For determination of optimal assay conditions when 
performing the drug screen with human DCs, various protocols were tested. As human monocyte-
derived DCs are highly sensitive to mechanical stress, CD14+ monocytes were seeded onto 24-well 
plates (5x104 cells/well in 500 µL RPMI1640 + 10% FCS + 50 ng/mL hGM-CSF) immediately after 
purification and were left untouched for 5 days. On day 5 chemotherapeutics or LPS were added to the 
cells. Both human and murine cells were incubated with drugs or controls for 24 h, detached, washed 
and subsequently stained for flow cytometric analysis as described above. All assays were performed in 
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duplicates. Supernatants were kept and immediately frozen at -70 °C for later analysis of cytokine 
release by ELISA. 
 
6.2.3 In-vitro stimulation of murine OVA-specific OT-I and OT-II T cells  
To assess priming of antigen-specific T cells, SP37A3 DCs or day 7 BMDCs were pulsed for one hour with 
OVA full-length protein (0.1 mg/ml) prior to exposure to dolastatin 10 (0.1 μM) or LPS (500 ng/mL) for 
24 hours. In case DCs were pulsed with the respective peptides, i.e., OVA257-264 peptide (T4; SIITFEKL; 
low-affinity variant of SIINFEKL) or OVA323-339 peptide (both 500 ng/mL), these were added after DC 
activation by dolastatin 10 or LPS for one hour. In both cases, activated and pulsed DCs were washed 
twice and counted. Meanwhile, CD8+/ CD4+ T cells were purified from LNs and spleen of naïve OT-I/ OT-
II transgenic mice expressing a TCR specific for ovalbumin. T cells were separated from other 
splenocytes by negative selection using the Pan T cell Isolation Kit (Stemcell Technology) and were 
loaded with the proliferation dye eFluor670 (eBioscience) before seeding onto a 96-well round bottom 
plate at a density of 2x105 cells/well. Activated DCs were added in varying cell densities to yield DC: T 
cell ratios ranging between 1:5 and 1:50. Proliferation of T cells was assessed after 3 days by flow 
cytometry.  
 
6.2.4 Human mixed lymphocyte reaction  
Human moDCs were activated with cytotoxic compounds [MMAE (1 nM), dolastatin 10 (1 nM)] or LPS 
(500 ng/mL) for 24h, washed twice in culture medium, counted and used for functional analysis. To this 
end, allogeneic CD8+ T cells from healthy blood donors loaded with the proliferation dye eFluor670 
were plated in sterile 96-well flat-bottom plates (105 cells/well) in RPMI complete medium containing 
10% human serum (AB) instead of FBS. Activated DCs were added at various cell densities to yield DC 
to T cell ratios of 1:5 to 1:50. T cell proliferation was assessed after 4 days by flow cytometry.  
 
6.2.5 Culture of human tumor explants 
Tumor resections obtained from patients (based on signed informed consent) with different tumor 
entities, including non-small cell lung-, breast-, kidney- and stomach cancer, were cut into pieces of 
approximately 1-2 mm diameter and cultured in presence of cytotoxic compounds (0.1 μM) or LPS as 
positive control (500 ng/mL) for 24 h in 24-well plates. Analysis was performed using flow cytometry. 
For this purpose, tumor pieces were dissociated mechanically and digested enzymatically with 
accutase, collagenase IV, hyaluronidase, and DNAse typeIV (see recipe digestion mix). To this end, cut 
tumor pieces were transferred to 50 mL centrifuge tubes, 4 mL of digestion mix were added and the 
tubes were incubated for 1 - 1.5 h at 37 °C while shaking smoothly at 150 rpm. Cell suspensions were 
passed through a 70 μm nylon mesh to remove remaining tissue. Single-cell suspensions were washed 
once with culture medium and once with cold PBS before proceeding to the FACS staining.  As 
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described above, cells were incubated with a FcR-blocking antibody together with the fixable near-IR 
Live/Dead stain in PBS and subsequently stained with anti-CD45, anti-CD11c, anti-CD11b, anti- HLA-
DR, and anti-CD86 fluorescently labeled antibodies in FACS buffer.  
 
6.2.6 Human lymphoma-DC co-culture  
The CD30+ lymphoma cell lines Karpas-299 and L-540 as well as the CD30- cell line Ramos were plated 
in 96-well plates (5x104 cells/well) in the presence of the antibody-drug conjugate brentuximab vedotin 
at concentrations between 0 and 10 μg/mL, or the control cytotoxic agents cisplatin, etoposide and 
mafosfamide at 100 μM for 3 days. On day 3, immature day 5 monocyte-derived dendritic cells (moDCs, 
see above) were added (5x104 cells/well) and co-cultured for another 24 h. Control DCs were left 
untreated or incubated with the free agent MMAE at 0.1 μM for 24 h. For analysis of moDC maturation 
by flow cytometry, the cells were stained for CD11c, HLA-DR and CD86. Dead cells were excluded by 
Live/Dead-IR staining. 
 
6.2.7 Phenotypic characterization of patient PBMCs  
PBMCs from six patients were collected before and after brentuximab vedotin administration. The 
patients received brentuximab vedotin 1.8 mg/kg per day every 21 days as monotherapy. The blood 
collection was performed before the first brentuximab infusion and just before the second application 
(except one patient, no. 2, from whom the follow-up blood sample was drawn after two 
administrations of brentuximab). PBMCs were isolated from heparinized blood samples by density 
gradient centrifugation using Histopaque®-1077. Multicolor flow cytometry analysis was performed to 
assess the frequency and activation status of T and B cells, as well as DC populations. For detection of 
FoxP3+ regulatory T cells, intracellular staining using the FoxP3-Fix/Perm-Kit (Biolegend) was 
performed following the manufacturer's instructions. Dead cells were stained with Live/Dead near IR 
fixable dead cell stain. 
 
6.3 Immunohistochemistry  
Tumor biopsies were collected at the German Hodgkin Center, Köln (Prof. M. von Bergwelt-Baildon) 
from two patients with a CD30+ cutaneous T cell and a CD30+ Hodgkin lymphoma, respectively. The 
biopsies were taken before and after one and two cycles of brentuximab vedotin, respectively. 
Stainings were performed at the Institute of Pathology, University of Basel (Dr. S. Savic). The biopsies 
were fixed in 4% neutral-buffered formaldehyde and embedded in paraffin wax. All 
immunohistochemical stainings were performed using primary antibodies against CD30, CD4 and CD8 
(all Roche/Ventana Medical Systems) on a Benchmark XT autostainer (Roche/Ventana Medical 
Systems) according to the manufacturer's protocol. The biopsies were examined by 2 independent 
investigators. Lymphocytes expressing the above mentioned markers were quantified in an area of 10 
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high power fields (400x). Total numbers of lymphocytes (as determined by H&E staining), CD30+ 
lymphoma cells, as well as CD4+ and CD8+ T cells were determined for pre- and post-therapy biopsies.  
 
6.4 Cytokine detection 
IL-1β, IL-6, and IL-12p40 in supernatants of murine DC cultures were detected by standard sandwich 
enzyme-linked immunosorbant assay (ELISA) procedures using commercially available kits, following 
manufacture's instructions. Furthermore, cytokine production of SP37A3 DCs or BMDCs was 
characterized by flow cytometric analysis. For this purpose, cells were cultured in presence of dolastatin 
10, ansamitocin P3 (both 0.01 μM) or LPS (500 ng/ml) for 20 h (IL-12p40), 15 h (IL-6) or 6 h (IL-1β). 
Brefeldin A was added for the whole incubation time (IL-1β and IL-6) or for the last 6 h of culture (IL-
12p40). Cell surface staining of MHCII and CD11c was performed prior to fixation, permeabilization and 
intracellular cytokine staining. 
 
6.5 Animal experiments 
6.5.1 In-vivo activation of skin Langerhans cells 
Dolastatin 10 (10 μg/animal), dolastatin 15 (10 μg/animal), vinblastine (17,6 μg/animal) or vehicle alone 
was injected intradermally (i.d.) into the ears of C57Bl/6 mice. Analysis was performed after 24 h using 
flow cytometry and immunofluorescence (immunofluorescence protocol described in paragraph 6.7). 
For flow cytometric analysis, epidermal sheets were dissociated mechanically and digested 
enzymatically by incubation with digestion mix for 1 h at 37 °C while shaking. Single-cell suspensions 
were prepared and stained with anti-CD45, anti-CD11c, anti-MHCII, and anti-CD86 antibodies. Dead 
cells were excluded using SytoxBlue® nucleic acid stain. 
 
6.5.2 Analysis of DC homing to tumor-draining LNs  
For detection of DC homing upon injection of free dolastatin, C57Bl/6 mice bearing subcutaneous (s.c.) 
E.G7 tumors were injected intratumorally (i.t.) with FITC-conjugated dextran (FITC-Dx; 100 μg/mouse) 
together with dolastatin 10 (10 μg/mouse) or PBS. For analysis of DC homing upon systemic 
administration of the anti-Thy1.1-MMAE ADC, mice bearing subcutaneous RMA-Thy1.1 tumors were 
injected intravenously with the anti-Thy1.1-MMAE ADC (30 mg/kg) or PBS 24 h prior to intratumoral 
injection of FITC-Dx (100 μg/mouse). Single cell suspensions from tumor-draining and non-draining LNs 
were prepared 48 h after injection of dolastatin 10 or ADC, stained for CD45, CD11c, MHCII and CD86 
and analyzed by flow cytometry, while excluding dead cells from the analysis.  
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6.5.3 In-vivo stimulation of OT-I and OT-II T cells 
LN and spleen cells from naïve OT-I and OT-II transgenic mice (congenic marker Ly5.2) were labeled 
with eFluor670 and adoptively transferred into C57Bl/6-Ly5.1 mice bearing s.c. MC38 tumors. After 24 
h, mice were immunized via tail-base injection with peptides alone [25 μg/mouse OVA257-264 peptide 
(T4) and 5 μg/mouse OVA323-339 peptide], or together with dolastatin 10 (1 μg/mouse) or LPS (25 
μg/mouse). Tumor-draining and non-draining inguinal LNs were dissected and single cell suspensions 
were prepared. Cells were stained for CD4 and CD8 and proliferation of OT-I CD8+ T cells as well as OT-
II CD4+ T cells was assessed 4 days after adoptive transfer by flow cytometry. 
 
6.6 Tumor challenge and therapeutic protocols 
7-10 week-old C57Bl/6 mice were injected s.c. with 2.5 - 5x105 tumor cells (i.e. E.G7, 3LL, MC38 or RMA-
Thy1.1) in 100 μl DMEM without phenol red into the right flank. Tumors were allowed to grow until they 
reached a size of approximately 100 mm3 before initiation of treatment or analysis of infiltrates. Tumor 
growth, determined as a function of tumor size over time, was measured every second day. Tumor 
volume was calculated according to the formula: D/2*d2 with D and d being the longest and shortest 
diameter of the tumor in mm, respectively. According to animal regulations mice were euthanized 
when tumors reached a size of 1500 mm3. 
 
6.6.1 Vaccination in combination with dolastatin 10 
For the dolastatin 10/vaccination treatment combination, a single dose of dolastatin 10 (0.4 mg/kg) was 
administered i.v. 15 days after tumor cell (3LL-OVA) injection. On days 17 and 24, mice were immunized 
intra muscular (i.m.) with 5x107 plaque-forming units (pfu) of replication-deficient adenovirus type 5 
encoding for chicken OVA (Ad-OVA).  
 
6.6.2 Checkpoint blockade in combination with dolastatin 10 
For the dolastatin 10/antibody treatment combination, two doses of dolastatin 10 (0.3 mg/kg) were 
administered i.v. on day 16 and 19 after tumor challenge (MC38). Treatment with four doses (250 μg 
per mouse and dose) of anti-CTLA-4 and anti-PD-1 [intra-peritoneal (i.p.) administration] was initiated 
at day 16 (without dolastatin treatment) or on day 21 (in combination with dolastatin treatment).  
 
6.6.3 Treatment upon T cell-depletion/ IFN-γ neutralization  
For T cell depletion mice were injected with anti-CD4 (clone: GK1.5) or anti-CD8 (clone: 53-
6.72) antibodies at 10 mg/kg on day 14, 15, 19, 23 and 27 after tumor cell implantation. Dolastatin 10 (a 
single dose of 0.4 mg/kg) treatment was initiated on day 16. For IFN-γ neutralization mice were injected 
with anti-IFN-γ (clone: XMG1.2) at 25 mg/kg on day 14, 15, 19, 23 and 27 after tumor cell implantation.  
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6.6.4 Treatment in CD11c DTR/GFP mice, Rag2-/- mice or IFN-γ R-/- mice 
WT C57Bl/6, Rag2−/−, and IFN-γR−/− mice bearing s.c. E.G7 (or 3LL-OVA) tumors received intratumoral 
injections of dolastatin 10 (0.4 mg/kg) or vehicle (PBS) on day 10.  WT and CD11c-DTR/GFP mice 
bearing s.c. MC38 tumors were treated i.v. with dolastatin 10 (0.4 mg/kg) on day 16. Diphteria toxin 
(DT; 4 ng/g body weight) or PBS (control) was injected i.p. on day 15. 
 
6.6.5 Analysis of tumor infiltrating lymphocytes  
7-10 week-old mice were injected s.c. with 5x105 MC38 tumor cells in 100 μl DMEM without phenol red 
into the right flank. On day 16 and 18 after tumor challenge mice were treated with dolastatin 10 (both 
0.3 mg/kg) i.v., followed by three doses of anti-CTLA-4/ anti-PD-1 (250 μg each, i.p.) on day 20, 22 and 
24. Mice receiving anti-CTLA-4/PD-1 only were treated on day 16, 18 and 20. On day 26 tumors were 
dissociated mechanically and digested using digestion mix. Cell suspensions were further enriched for 
immune cells by density gradient centrifugation using Histopaque®-1119 solution. After washing, single 
cell suspensions were stained for the indicated markers for flow cytometric analysis. For detection of 
IFN-γ-producing cells, single cell preparations were cultured over night in the presence of anti-
CD3/CD28 (2/4 μg/mL) antibodies and monensin (2 μM).  
 
6.7 Immunofluorescence  
Skin Langerhans cells_CD86 and MHCII 
Mice were treated as outlined in chapter 6.5.1 (In-vivo activation of skin Langerhans cells). 24 h after 
injection of cytotoxic compounds or control substances, ears were harvested and epidermal sheets 
were separated. Epidermal sheets were prepared as previously described [211]. Epidermal sheets were 
stained overnight with anti-MHCII-PE (1:100) and anti-CD86-FITC (1:100) antibodies in 50 μl staining 
buffer (PBS + 5% FBS) at 4 °C, washed two times for 10 min with PBS + 5% FBS and mounted onto glass 
slides. Analysis was done using an Olympus BX61 fluorescence microscope. 
 
SP37A3_α-Tubulin and GEF-H1 
SP37A3 dendritic cells were serum-starved (IMDM w/o FCS) overnight. Two hours before treatment 
with ansamitocin P3 (0.1 μM) for 5 or 15 minutes, 2x105 cells were plated on polylysine-coated cover 
slips in 24-well plates in serum-free medium. After treatment, cells were washed twice with cold PBS (5 
min each) on ice, fixed with IC fixation buffer for 20 min at RT, washed three times in PBS (5 min each) 
and permeabilized using 1x perm-buffer for 5 min. The coverslips were blocked with 10% FCS in perm-
buffer for 30 minutes at RT to block nonspecific protein-binding sites. Primary antibodies (sheep anti-
lfc/GEF-H1, 1:15 and rabbit anti-α-tubulin, 1:150) were added in 150 μL blocking buffer and coverslips 
were incubated for 1 h at RT prior to washing in perm-buffer (3x 10 min). Fluorochrom-labeled 
secondary antibodies (anti-sheep Alexa488, 1:200 and anti-rabbit Alexa647, 1:200) were added to the 
slides in 150 μL blocking buffer. After 1 h incubation at RT, coverslips were washed three times for 10 
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min in PBS and subsequently mounted using antifade reagent (ProLong®, Life Technologies) containing 
DAPI to stain nuclei. Slides were analyzed by confocal microscopy using the LSM 710 Rocky microscope 
(Zeiss) and Zen software (Zeiss).  
  
6.8 Molecular biology methods 
6.8.1 RNA isolation and quantitative real-time PCR (qPCR) 
Total RNA was isolated from 1x106 - 5x106 cells using TRIzol-Reagent (Invitrogen Life Technologies) and 
Direct-zol™ RNA MiniPrep columns (Zymo Research) according to the manufacturer's instructions. 
RNA concentration and purity was determined using a Nanodrop spectrophotometer. Single-stranded 
cDNA was synthesized from total RNA (pretreated with DNaseI amplification grade) with the use of 
oligo(dT) as primer and RevertAid™ H Minus M-MuLV Reverse Transcriptase (Life Technologies) 
according to manufacturer’s instructions.  
 
Sequences of qPCR primers are depicted in Table 6-1. Primers were synthesized by Microsynth AG and 
were used for qPCR at 10 μM. 
 
 
 
Table 6-1 Oligonucleotides used for qPCR. Primer sequences are either based on previous reports or have been 
designed using the web-based primer design tool from Roche (Universal ProbeLibrary Assay Centre; 
https://lifescience.roche.com).  
Gene Sequence       (5’ – 3’) Source of sequence 
CD80 GAAGCCGAATCAGCCTAGC 
CAGCGTTACTATCCCGCTCT 
Roche Universal Probe 
Library 
CD86 TCGTCTTTCACAAGTGTCTTCAG 
TTGCCAGTAGATTCGGTCTTC 
Roche Universal Probe 
Library 
IL-1β CATGGAATCCGTGTCTTCCT 
GAGCTGTCTGCTCATTCACG 
[212] 
IL-6 AGTTGCCTTCTTGGGACTGA 
TCCACGATTTCCCAGAGAAC 
[213] 
IL-12p35 TGGCTACTAGAGAGACTTCTTCCACAA 
GCACAGGGTCATCATCAAAGAC 
[214] 
IL-12p40 CAGCTCGCAGCAAAGCAA 
GACGCCATTCCACATGTCACT 
[215] 
IL-23p19 TGCTGGATTGCAGAGCAGTAA 
GCATG CAGAGATTCCGAGAGA 
[215] 
IFN-α1 CCTGAGAA/GAGAAGAAACACAGCC 
GGCTCTCCAGAC/TTTCTGCTCTG 
Roche Universal Probe 
Library 
IFN-β GCTCCTGGAGCAGCTGAAT 
CGTCATCTCCATAGGGATCTTGA 
Roche Universal Probe 
Library 
TNF-α CTGTAGCCCACGTCGTAGC 
TTGAGATCCATGCCGTTG 
Roche Universal Probe 
Library 
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S18RNA AGTCAGTTCATCCGGCCTTA 
ATCTTCACGCACTCCTCGAT 
Roche Universal Probe 
Library 
 
 
Quantitative real-time PCR 
qPCR was performed on the Applied Biosystems® Vii A7 Real-Time PCR System using the SYBR Green-
based GoTaq® qPCR Master Mix (Promega). PCR reactions were performed in 40 cycles of 15 seconds 
at 95°C and 60 seconds at 60°C. Product was not generated in control reactions in which reverse 
transcriptase was omitted during cDNA synthesis. Gene expression values relative to S18RNA gene 
expression (internal control), and fold expression in treated samples normalized to expression in 
untreated DC samples was calculated by a comparative CT method according to the following formula 
[216]: 
 
2-ΔΔCT = [(CT gene of interest - CT internal control) treated sample 
- [(CT gene of interest - CT internal control) control sample)] 
6.8.2 Western Blot 
Cells (2x106 - 4x106) were washed twice in ice-cold TBS prior to lysis in 100 μl ice-cold RIPA lysis buffer 
(10 mM Tris-Cl (pH 8.0), 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% 
SDS, 140 mM NaCl, 1mM PMSF) containing a commercially available protease and phosphatase 
inhibitor cocktail (Thermo Scientific). Samples were cleared by centrifugation at 4 °C (10 min, 10.000xg) 
and a small aliquot was used for determination of protein concentration using the colorimetric Thermo 
Scientific Pierce BCA Protein Assay Kit according to manufacturer's instructions. Samples were mixed 
with 2x Laemmli buffer and reduced and denatured at 95 °C for 5 minutes. 10-30 μg total protein was 
separated by SDS polyacrylamide gel electrophoresis using 4-20% gradient gels (Mini-PROTEAN® 
TGX™ Precast Gels, Bio-Rad) and transferred onto PVDF (Immun-Blot®, 0.2 μm, Bio-Rad) or 
nitrocellulose (0.45 μm, Bio-Rad) membranes using a semi-dry transfer cell apparatus (Bio-Rad). The 
running gel, the membrane and Whatman filter papers were soaked in transfer buffer and a transfer 
sandwich was realized (anode - filter paper – membrane – gel - filter paper - cathode). The transfer was 
performed during 36 min at 25 V and 0.17 A per gel. Membranes were stained with Ponceau S solution 
to verify the quality of the protein transferred.  
 
Next, membranes were blocked in ROTI-block (Roth; both total and phosphorylated proteins), 5% non-
fat dry milk (total proteins) or 5% BSA (phosphorylated proteins) in TBS-T (0.1% Tween-20 in TBS) for 
two hours at RT before overnight incubation with primary antibodies in ROTI block, 1% non-fat dry milk 
or 1% BSA at 4 °C. All incubation and washing steps were performed with slight agitation on a rocking 
table. After washing in TBS-T (5 x 5 min), membranes were incubated with secondary HRP-conjugated 
antibodies for 1 hour at RT. The membranes were washed in TBS-T (4 x 5 min) and TBS (2 x 5 min) and 
subsequently incubated with ECL solution during 1 min. Excess substrate reagent was drained out 
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before the membranes were transferred into an autoradiography cassette and exposed to ECL films 
(Kodak). 
 
Membrane stripping for reprobing 
For reprobing, the membranes were washed twice with TBS-T for 10 minutes each to remove the 
remaining ECL solution prior to incubation with stripping buffer (Thermo Scientific) for 15 min at RT. 
After washing (TBS-T; 3 x 5 min), membranes were blocked again and immunodetection was repeated 
as previously described. 
 
6.8.3 RhoA activation (G-LISA) 
2x106 SP37A3 DCs were plated onto 6 cm cell culture dishes (BD Falcon) in 2 mL SP culture medium 
(IMDM complete + 20 ng/mL mGM-CSF and 20 ng/mL mM-CSF) and were allowed to adhere for two 
hours. Next, culture medium was exchanged with serum-free medium (IMDM + 20 ng/mL mGM-CSF) 
and cells were serum-starved overnight in order to reduce baseline RhoA activation. After overnight 
culture, DCs were stimulated with 0.1 μM ansamitocin P3 for 5, 10, 15, 30 and 60 minutes and collected 
on ice using cell scrapers. Cells were washed once with ice-cold PBS and lysed in 90 μL cell lysis buffer 
provided by the kit (RhoA G-LISA; Cytoskeleton Inc.; cat: BK124). 15 μL of each cell lysate were set 
aside for measurement of protein concentrations using the provided Precision Red™ Advanced Protein 
Assay Reagent, while remaining lysates were snap-frozen in liquid nitrogen. Samples were thawed prior 
to analysis and volumes were adjusted to yield equal concentrations of total protein in each sample 
(0.5-2 mg/mL). Samples and constitutively active RhoA protein (control) were added onto the G-LISA 
plate in duplicates (GTP-bound RhoA from samples is bound by the immobilized Rho-GTP-binding 
protein) and the plate was processed according to manufacturer's instructions. Similar to the procedure 
of an ELISA, active RhoA bound to the plate is detected by an HRP-conjugated secondary anti-RhoA 
antibody. Finally, active RhoA is quantified by absorbance measurement at 490 nm.  
 
6.9 Statistics 
Statistical values were calculated using a 2-tailed paired Student’s t test, if not indicated otherwise; p< 
0.05*; p< 0.01**, p< 0.001***, p< 0.0001****. Kaplan Meier survival plots were analyzed using a log 
rank test (Mantel-Cox). P < 0.05 was considered significant for all biological tests. 
 
6.10 Study approval 
Tumor biopsies and blood drawing from cancer patients who received brentuximab vedotin were 
performed upon signing a consent form in accordance with the local institutional review board. Animals 
were maintained and treated in compliance with the guidelines of the Swiss Federal and the Cantonal 
Veterinary Office Basel-Stadt. 
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7 Results 
7.1 Microtubule-depolymerizing agents (MDAs) promote DC maturation 
7.1.1 Screening for DC-promoting anti-cancer-agents 
Owing to their highly sophisticated antigen-presenting machinery DCs are central to the initiation 
and regulation of anti-cancer immunity [217]. Tumors may, however, hamper the maturation and 
antigen-processing capacity of tumor-residing DCs [218-220]. In contrast to mature DCs that 
efficiently launch immune responses, immature or dysfunctional DCs are rather immune suppressive 
[217, 221, 222]. Therapeutic approaches that activate DCs, and thereby promote priming of tumor 
antigen-specific T cells, may induce durable immunity against cancer. Recent work has identified 
several cytotoxic agents, including the mitotic spindle inhibitor vinblastine, as potent activators of 
DC maturation [223-225]. On the other hand, some anti-tumor therapeutics do block DC maturation 
and therefore antagonize anti-tumor immunity. Hence, it is of great importance to investigate the 
impact of chemotherapeutic compounds of different classes on the maturational state of DCs.  
 
In order to analyze the effects of cytotoxic agents on DC maturation, a previously established 
primary murine DC line (SP37A3), which resembles immature DCs [140], as well as human monocyte-
derived DCs (moDCs) were used to screen a library of 22 chemotherapeutics. These included 
microtubule-stabilizing (paclitaxel, patupilone A/B, docetaxel), and -destabilizing agents (vinca-
alkaloids, combretastatin-A4-phosphate, ansamitocin P3, dolastatin 10), a tubulin polymerization 
inhibitor (D-64131), cyclooxygenase (COX)-inhibitors (naproxen, celecoxib), the angiokinase inhibitor 
BIBF1120, the angiotensin-converting-enzyme inhibitor enalapril, the nitric-oxide-synthase inhibitor 
I-NMMA, the DNA replication blocker gemcitabine, the alkylating agent mafosfamide, the receptor 
tyrosine kinase inhibitor sunitinib and the histone deacetylase inhibitor SAHA. To delineate which of 
these compounds could induce DC maturation, murine SP37A3 splenic DCs and human moDCs were 
incubated with these drugs at concentrations ranging from 1 to 0.001 μM. Cell viability and 
expression of CD86 were assessed by flow cytometry after 24h as shown for a drug concentration of 
0.1 μM in Figure 7-1, A-B. Ansamitocin P3 (red circle) and dolastatin 10 (red triangle) were by far the 
most potent inducers of CD86 on murine and human DCs (Figure 7-1, C). Cell viability was only 
modestly affected at this drug concentration. Of note, all microtubule-destabilizing agents including 
the vinca-alkaloids (blue), dolastatin 10 and ansamitocin P3 (red), displayed a pronounced capacity to 
upregulate CD86 on murine as well as human DCs, in contrast to microtubule-stabilizing agents such 
as the taxanes (green) and compounds of other classes. 
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Figure 7-1 Identification of ansamitocin P3 and dolastatin 10 as potent inducers of DC maturation in vitro. (A-
C) SP37A3 murine DCs and human moDCs were incubated with the indicated chemotherapeutic compounds (0.1 
μM) for 24h. (A+B) Expression of CD86 on murine SP37A3 DCs and human moDCs after exposure to 
chemotherapeutic agents was correlated with viability (left and middle panel). (C) Mean fluorescence intensity 
(MFI) fold change in murine SP37A3 DCs vs. MFI fold change in human moDCs is shown in the right panel. MFI 
was assessed by flow cytometry; graphs show fold change of MFI compared to untreated cells, which were set 
as 1. Data are representative of two independent experiments with similar results. 
 
7.1.2 MDA-triggered phenotypic and functional DC maturation  
The next aim was to determine whether the observed DC maturation reflected a class-effect. This 
would imply that different compounds of the class of microtubule-depolymerizing agents (MDAs) 
demonstrate equal capacities to induce DC maturation, independent of their varying binding sites on 
microtubules (Table 4-1). Vinblastine (VBL) was included into the experimental set-up as 
representative member of the vinca-alkaloid family based on previously published data showing its 
capacity to mature murine DCs [224, 225]. Dolastatin 15, dolastatin 10 and its synthetic analogue 
MMAE represent the family of dolastatins, whereas ansamitocin P3 and its analogue DM1 belong to 
the family of maytansines. All of these compounds are used as chemotherapeutics due to their 
capacity to block mitosis as a result of suppression of microtubule dynamics at low (pM) 
concentrations in tumor cells. At higher concentrations, i.e. 10-100 nM, they induce active 
depolymerization of MTs [169]. LPS was included in all following experiments as positive control due 
to its well-known capacity to induce the full spectrum of DC maturation via TLR4 triggering.  
 
The capacity of above-mentioned MDAs to induce upregulation of further costimulatory receptors 
and maturation markers on DCs was assessed by flow cytometry. To this end, SP37A3 DCs were 
exposed to distinct MDAs for 24 h prior to analysis of CD80, CD86, CD40 and MHCII expression. Dead 
cells were detected using a commercial live/dead stain (L/D Near-IR, Invitrogen) and were excluded 
from further analysis. DC viability was slightly decreased after incubation at nanomolar 
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concentrations, but stayed stable up to a concentration of approximately 10 μM (Figure 7-2, D-F). 
Compared with untreated controls, all MDAs significantly increased expression of DC maturation 
markers in a dose-dependent manner (Figure 7-2). Of note, dolastatin 10 and ansamitocin P3 
displayed the highest DC maturing potency, which correlated with their increased tumor cell 
cytotoxicity when compared to dolastatin 15, VBL, MMAE or DM1 (see Introduction chapter 4.4.1). 
Also, these results were confirmed using dolastatin 10 and ansamitocin P3 on mouse bone marrow-
derived DCs (BMDCs; Figure 7-4, A).  
 
 
Figure 7-2 MDA-induced phenotypic DC maturation in vitro. (A-C) Representative histograms (n=3) for the 
expression of MHCII and costimulatory molecules CD80, CD86, and CD40 by SP37A3 murine DCs exposed to (A) 
dolastatin 15 (0.1 μM), dolastatin 10 (0.1 μM), vinblastine (0.1 μM), (B) ansamitocin P3 (0.1 μM), DM1 (0.1 μM) or 
(C) MMAE (0.1 μM). LPS (500 ng/mL) was used as positive control in all experiments. (D-F) MFI was assessed by 
flow cytometry; graphs show fold change of MFI compared with untreated cells, which were set as 1. Viability 
was determined by L/D staining and is depicted as percentage of viable cells (viability of untreated cells was set 
as 100%). All data are representative of at least three independent experiments with similar results. Mean ± SD 
of one representative experiment is shown. 
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In order to assess functional activation of DCs, supernatants from DC cultures described in Figure 7-2, 
D-F were analyzed for pro-inflammatory cytokines that have been demonstrated to play critical roles 
in regulating T cell function and anti-tumor immune responses [226]. Dolastatin 10, ansamitocin P3, 
MMAE and, to a lesser extent, DM1 and vinblastine triggered production of IL-1β, IL-6, and IL-12p40 
(Figure 7-3). Intracellular cytokine staining utilizing SP37A3 DCs (Figure 7-3, A-B) and BMDCs (Figure 
7-4, B-C) confirmed the pattern of cytokine expression, whereas cytokine production in BMDCs was 
generally less pronounced. Importantly, expression of the costimulatory molecules CD80 and CD86 
as well as production of all three cytokines was induced to a similar degree by all MDAs and LPS on 
SP37A3 DCs (Figure 7-3). 
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Figure 7-3 MDA-induced expression of pro-inflammatory cytokines by SP37A3 DCs. (A-D) Bar graphs depict 
secretion of IL-1β, IL-6, and IL-12p40 assessed in supernatants from cultures described in Figure 7-2, D-F using 
ELISA. MMAE was used at 0.1μM, LPS at 500 ng/mL. Dot plots illustrate cytokine expression by (A) dolastatin 10 
(0.01 μM) or LPS (500 ng/mL) and (B) ansamitocin P3 (0.01 μM) or LPS (500 ng/mL) pretreated DCs, assessed by 
intracellular staining and flow cytometric analysis. Controls indicate untreated DCs. Three experiments in 
triplicates were performed with similar results. Bar graphs depict mean ± SD of one representative experiment. 
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Figure 7-4 Phenotypic and functional BMDC maturation by MDAs. (A) Representative histograms (n=3) for the 
expression of MHCII and costimulatory molecules CD80, CD86, and CD40 by C57Bl/6 BMDC cultures exposed to 
dolastatin 10 (0.01 μM; upper panel) or ansamitocin P3 (0.01 μM; lower panel). LPS (500 ng/mL) was used as 
positive control. (B+C) Cytokine expression by (B) dolastatin 10 (0.01 μM) or LPS (500 ng/mL) and (C) 
ansamitocin P3 (0.01 μM) or LPS (500 ng/mL) treated BMDCs was assessed by ELISA (bar graphs) as well as by 
intracellular staining and flow cytometric analysis. Controls indicate untreated DCs. Three experiments in 
triplicates were performed with similar results. 
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Given that all investigated MDAs displayed similar capacities to induce phenotypic as well as 
functional maturation of murine DCs, it appears that the observed effects on DCs could be attributed 
to a general class effect of MDAs. During the initial screen of different classes of chemotherapeutics 
it has become evident that the second class of microtubule-binding compounds, i.e., the class of 
microtubule-stabilizing agents (MSAs), including the taxanes as its most prominent members, 
displayed no direct immune-stimulatory effects on DCs in our setting. To further support this 
hypothesis, induction of maturation markers and pro-inflammatory cytokines has been tested upon 
incubation of SP37A3 DCs with the microtubule-stabilizing compound paclitaxel. This compound 
binds to a distinct site on β-tubulin when compared to MDAs, such as the vinca-alkaloids, 
maytansines or colchicine [227]. Paclitaxel was compared to ansamitocin P3 as MDA, and etoposide, 
which represents a cytotoxic agent of a non-relevant class (topoisomerase inhibitor). As expected, 
paclitaxel and etoposide failed to induce expression of maturation markers (Figure 7-5, A) or the pro-
inflammatory cytokines IL-1β, IL-6, and IL-12p40 in SP37A3 DCs (Figure 7-5, B). Consistent with 
previous data, a moderate upregulation of MHCII was detected in paclitaxel treated samples [116, 
228].  
 
 
Figure 7-5 DC maturation in response to MDAs but not MSAs. (A) Upregulation of maturation markers CD40, 
CD80, CD86 and MHCII on SP37A3 DCs upon culture with ansamitocin P3, paclitaxel or etoposide in the 
indicated concentrations. MFI was assessed by flow cytometry as described in Figure 7-2. (B) Secretion of IL-1β, 
IL-6, and IL-12p40 was assessed in supernatants from cultures described in (A) using ELISA. All data are 
representative of at least three independent experiments with similar results. Mean ± SD of one representative 
experiment is shown. 
Consequently, it seems that microtubule-destabilization in contrast to -stabilization, is a prerequisite 
for the observed immune-stimulatory capacity of MDAs. This issue will be addressed in the third 
chapter of the results section (see chapter 7.3 Molecular mechanism of MDA-induced DC 
maturation). Importantly, as all tested MDAs displayed similar DC-maturing capacity and due to the 
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limited frame of this work, only dolastatin 10 and ansamitocin P3 will be used for further 
investigations. Both compounds demonstrated to be representative of their drug class and are most 
potent in inducing DC maturation. 
 
The following experiments were divided in two further chapters. Chapter 7.2 illustrates the in-depth 
description of MDA-induced anti-tumor immune responses. To this end, 1.) DC maturation and 
migration, 2.) subsequent T cell priming and expansion and 3.) the therapeutic efficacy of dolastatin 
10 alone, or in combination with immunotherapy, was assessed in murine in vitro and in vivo models. 
Importantly, these results could be translated into the human setting and were extended by the 
analysis of immune cell activation after exposure to therapeutic antibody-drug conjugates that use 
the dolastatin analogue MMAE as cytotoxic payload. Hence, dolastatin 10 and MMAE were used as 
representative MDAs during chapter 7.2. Experiments described in chapter 7.3 focus on the molecular 
events in DCs that ultimately translate into potent activation of host innate immune responses and 
therefore possibly trigger the effects observed in chapters 7.1 and 7.2. Ansamitocin P3 as MDA, as 
well as paclitaxel as MSA were chosen to compare DC signaling cascades induced in response to 
microtubule-disruption and -stabilization, respectively.  
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7.2 MDAs potentiate anti-tumor immunity  
7.2.1 In vivo maturation of skin Langerhans cells and tumor-resident DCs  
Infiltration of DCs into primary tumor lesions has been associated with significantly prolonged 
patient survival and a reduced incident of metastatic disease in patients with distinct cancers such as 
head and neck tumors, lung, bladder or gastric carcinomas [229]. Furthermore, Langerhans cell (LC) 
infiltration has been associated with regression of primary cutaneous melanomas [230, 231]. In 
contrast to other DC subsets, skin-resident LCs promote peripheral tolerance by constantly 
migrating to skin-draining LNs to present dermal and epidermal antigens to CD4+ T cells, which 
induces anergy due to their immature phenotype [129]. In order to elucidate whether dolastatins are 
capable of reverting their immature state, dolastatin 10 or 15 were injected into the ears of C57Bl/6 
mice. Consistent with previous in vitro observations, dolastatin 10 and, to a lesser extent, dolastatin 
15 induced the expression of CD86 and MHCII on LCs (Figure 7-6, A-B). Compatible with in situ 
maturation of LCs, immunofluorescence staining revealed an enlarged cell size, profound 
morphological changes, such as dendrite hyper-elongation, a strong upregulation of the 
costimulatory molecule CD86, and a marked decrease in LC density, which may reflect migration of 
LCs to the draining lymph nodes (LN) (Figure 7-6, C). Hence, the migratory behavior of dolastatin 10 
activated DCs was investigated using FITC-dextran (FITC-Dx), a carbohydrate with a high molecular 
mass, which is readily taken up by DCs during early activation [232]. FITC-Dx was injected 
intratumorally either together with dolastatin 10 or with PBS into C57Bl/6 mice bearing 
subcutaneous E.G7 tumors. In mice treated with vehicle alone, DCs from tumor-draining LNs showed 
almost no increased FITC signal. In stark contrast, FITC-Dx-bearing DCs could be robustly detected 
and correlated with high CD86 expression in tumor-draining LNs of mice treated with dolastatin 10 
(Figure 7-6, D-E). FITC-dextran bearing DCs could not be detected in non-tumor-draining LN in both 
cases, providing evidence for local, tumor-selective DC-stimulatory effects of dolastatin 10 
treatment. 
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Figure 7-6 In situ maturation of skin LCs and DC homing to tumor-draining LNs triggered by dolastatin 10. (A-
C) Dolastatin 10 (10 μg/animal), dolastatin 15 (10 μg/animal), vinblastine (17.6 μg/animal) or vehicle alone was 
injected intradermally into the ears of C57Bl/6 mice (four mice per group, two ears per point; mock treated = 
ears of PBS/carrier injected mice). Ear skin specimens were collected 24h later and epidermal sheets were 
digested. Cells were stained for CD45, CD11c, MHCII, and CD86 and subsequently analyzed by flow cytometry. 
Data show the mean (n=2) of % CD86high cells and MFI of CD86 within the CD45+MHCII+CD11c+ population per 
data point (B). One representative contour plot per group from three independent experiments is shown (A). (C) 
Mice were treated as in (A+B); epidermal sheets were fixed in acetone, stained for MHCII (red) and CD86 (green) 
and analyzed by immunofluorescence. (D+E) Mice bearing subcutaneous E.G7 tumors were injected 
intratumorally with FITC-conjugated dextran suspended in vehicle alone (PBS/DMSO) or in vehicle containing 
dolastatin 10 (10 μg per mouse). 48 hours later, tumor-draining LNs were examined for the presence of FITC-
dextran-bearing DCs (CD45+MHCII+CD11c+) by flow cytometry. (D) Representative plots depict FITC+ DCs 
detected in tumor-draining LNs after PBS/DMSO (left) or dolastatin 10 (right) injection. (E) Graphs summarize 
percent of FITC+ DCs from one experiment; representative results from one of three experiments are shown. 
Results   
71 
7.2.2 Activation of antigen-specific T cells 
To assess the capacity of MDA-treated DCs to activate naïve, antigen-specific T cells in vitro, OVA-
specific, TCR transgenic OT-I and OT-II mice were used. Thus, SP37A3 DCs or BMDCs were exposed 
to dolastatin 10 or LPS for 16 h prior to loading with OVA257-264 or OVA323-339 peptide. Meanwhile, T 
cells were isolated from LNs and spleen of OT-I (CD8+) and OT-II (CD4+) mice, labeled with the 
proliferation dye eFluor670 and co-cultured with DCs for three days. Notably, dolastatin 10-
pretreated, peptide-pulsed DCs induced robust expansion of both OT-I and OT-II T cells (Figure 7-7, 
A). In a next step, DCs were loaded with recombinant OVA full-length protein prior to incubation 
with dolastatin 10 or LPS and subsequent co-culture with OT-I or OT-II T cells. Both SP37A3 and 
BMDCs were capable to induce significant proliferation of both OT-I and OT-II antigen-specific T cells 
(Figure 7-7, B). Thus, dolastatin treatment of DCs allowed efficient antigen uptake and processing for 
both MHC class II and class I antigen-presentation, the latter pathway being commonly referred to as 
cross-presentation [233]. Of note, DCs exposed to dolastatin 10 supported T-cell proliferation to 
levels comparable to that of LPS-stimulated DCs.  
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Figure 7-7 Activation of antigen-specific T cells in vitro. (A+B) SP37A3 DCs or BMDCs were treated with 
dolastatin 10 (0.1 μM) or LPS (500 ng/mL) for 16 h before or after loading with peptide or protein, respectively. 
Controls indicate untreated, antigen-pulsed DCs. DCs were pulsed with OVA257-264 or OVA323-339 peptide (A) or 
loaded with OVA protein (B) and added to micro-cultures of transgenic CD8+ OT-I (upper panels) or CD4+ OT-II T 
cells (lower panels). DC:T cell ratios are indicated. Proliferation of OT-I/OT-II T cells was assessed by flow 
cytometry. Data show representative histograms from one of at least three independent studies. 
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We furthermore assessed whether dolastatins promoted expansion of antigen-specific T cells in vivo. 
Naïve CD8+ and CD4+ T cells from OT-I and OT-II transgenic mice (Ly5.2) were adoptively transferred 
into congenic C57Bl/6 (Ly5.1) recipient mice bearing established subcutaneous MC38 tumors. T-cell 
responses were measured following tail-base immunization with a weak agonist peptide derived 
from the original OVA257-264 peptide SIINFEKL (T4= SIITFEKL) [234] and the OVA323-339 peptide, 
respectively. A much stronger proliferation of both OT-I and OT-II T cells was observed in mice 
receiving peptide plus dolastatin 10 compared with dolastatin 10 or peptide alone (Figure 7-8). 
Therefore, under in vivo conditions, dolastatin 10 is capable of inducing efficient antigen 
presentation, thereby augmenting antigen-specific T-cell responses. Most importantly, T cell 
proliferation was observed to the same degree in tumor draining as well as non-draining lymph 
nodes. 
 
 
 
Figure 7-8 Activation of antigen-specific T cells in vivo. T cells from spleen and LNs of naïve OT-I or OT-II 
transgenic mice (Ly5.2) were adoptively transferred into congenic C57Bl/6-Ly5.1 recipient mice bearing 
subcutaneous MC38 tumors. After 24h, mice were immunized using 25 μg OVA257-264 T4 (SIITFEKL) and 5 μg 
OVA323-339 peptide in the absence (PBS/DMSO) or presence of dolastatin 10 (1 μg per mouse) or LPS (25 μg per 
mouse). Proliferation of donor-derived transgenic CD8+ OT-I T cells or CD4+ OT-II T cells was assessed 4 days 
after adoptive transfer by flow cytometry. Histograms show data from one representative experiment. The 
experiment was performed independently three times. 
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7.2.3 Contribution of host immunity to the therapeutic efficacy of dolastatins 
Next, the requirement of T cells and/or IFN-γ for the efficacy of dolastatin 10-based treatments was 
assessed using E.G7 T cell lymphoma, Lewis Lung carcinoma (3LL-OVA) or MC38 adenocarcinoma 
subcutaneous tumors (Figure 7-9). In immunocompetent syngeneic wild type (WT) mice, systemic 
treatment with dolastatin 10 was sufficient to suppress growth of all three tumors. Depletion of CD8+ 
cells or neutralization of IFN-γ with monoclonal antibodies (mAbs) administered prior to dolastatin 
10 treatment severely abrogated the antitumor effect of the drug in an established tumor setting, as 
evidenced by significant loss of tumor growth suppression (Figure 7-9, A). Abrogation of dolastatin 
10 efficacy was not observed in mice depleted of CD4+ cells. To investigate the specific role of CD11c+ 
DCs in dolastatin 10 mediated tumor rejection, CD11c-DTR transgenic mice were used [235]. 
Injection of diphtheria toxin (DT) led to transient systemic depletion of CD11c+ cells in these mice 
(data not shown). Consequently, CD11c-DTR mice with established MC38 tumors were treated with 
diphtheria toxin before treatment with dolastatin 10 or vehicle. Interestingly, depletion of CD11c+ 
cells was sufficient to abrogate the antitumor effect of dolastatin 10 (Figure 7-9, B). In addition, 
RAG2-/- and IFN-γR1-/- mice have been used to investigate tumor growth kinetics in E.G7 and 3LL-
OVA tumors upon treatment with dolastatin 10. In immunocompetent syngeneic WT mice, 
treatment with dolastatin 10 was sufficient to induce persistent regression of transplanted tumors. In 
both RAG2-/- and IFN-γR1-/- mice, the therapeutic effect of dolastatin 10 treatment was significantly 
reduced (Figure 7-9, C-D). These data underline the importance of CD11c+ DCs and, subsequently, T 
cells and IFN-γ as critical determinants of the anti-tumor effects of dolastatins, irrespective of the 
tumor model.  
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Figure 7-9 Requirement of intact host immunity for full therapeutic efficacy of dolastatins. (A+B) Growth of 
MC38 tumors during treatment with dolastatin 10 (0.4 mg/kg) in tumor bearing (A) C57Bl/6 WT control mice and 
upon depletion of CD4 or CD8 T cells or neutralization of IFN-γ with monoclonal antibodies and (B) CD11c-DTR 
mice (depleted of CD11c DCs) bearing 16-day established subcutaneous MC38 tumors. (C+D) Tumor growth 
during treatment with dolastatin 10 (0.4 mg/kg) in C57Bl/6 WT, Rag2-/- or INFγR1-/- mice bearing 10-day 
established subcutaneous (C) E.G7 tumors or 15-day established subcutaneous D) 3LL-OVA tumors. Control, 
tumor-bearing, mock-treated mice. All data are expressed as mean ± SEM (n=11-12). Two independent 
experiments were performed; pooled data are shown. 
 
7.2.4 Therapeutic synergy of dolastatins and immune-based therapies 
Given its capacity to augment anti-tumor immunity, dolastatin was thought to synergize with and 
enhance the efficacy of immunomodulatory agents. In order to test this hypothesis, mice with 
established ovalbumin-expressing 3LL tumors (3LL-OVA) were treated by systemic administration of 
dolastatin 10 and subsequent vaccination using a recombinant adenovirus expressing ovalbumin 
(Adeno-OVA). Indeed, the overall survival of mice treated with 5x107 pfu Adeno-OVA plus dolastatin 
10 was significantly longer than that of mice given dolastatin 10 or vaccination alone (Figure 7-10). 
Thus, dolastatin 10 improved the efficacy of antigen-specific vaccination in a setting with established 
tumors. 
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Figure 7-10 Synergy of dolastatin 10 treatment and tumor-antigen-specific vaccination. (A) WT mice bearing 
15-day established subcutaneous 3LL-OVA tumors were treated with vaccination alone, comprising 5x107 pfu of 
Ad-OVA (intra muscular), dolastatin 10 alone (0.4 mg/kg) or the combination of both. All data are expressed as 
mean ± SEM (n=12-14). Two independent experiments were performed and pooled results are shown as 
individual tumor-growth curves or cumulative tumor volume over time (B) and in a Kaplan-Meier survival plot; 
Log-rank (Mantel-Cox) Test, P value <0.0001 (C). 
 
Impressive clinical success has been achieved by novel cancer immunotherapies that target immune-
regulatory checkpoints on T cells [76, 236, 237]. Only recently and in accordance with preclinical data 
from a murine B16 melanoma model [238], unprecedented clinical benefits with rapid and deep 
responses have been reported with concurrent CTLA-4/PD-1 blockade [239]. Hence, therapeutic 
synergies between dolastatin 10 treatment and immune checkpoint inhibition were delineated. Mice 
with established MC38 tumors were treated using a combination of anti-CTLA-4/PD-1 antibodies and 
systemically administered dolastatin 10. Slower tumor outgrowth was observed with monotherapy 
using either dolastatin 10 or anti-CTLA-4/PD-1 compared with the control group. In the dolastatin 10 
group, 1 out of 12 mice experienced complete tumor regression compared with 3 out of 12 mice in 
the anti-CTLA-4/PD-1 group. In contrast, concomitant treatment with dolastatin 10 and anti-CTLA-
4/PD-1 achieved complete tumor rejection in 7 out of 12 mice and significantly delayed outgrowth in 
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the rest of the mice (Figure 7-11). These results demonstrate therapeutic synergy between dolastatin 
10 and immunotherapy treatment approaches, leading to potent induction of anti-tumor immunity 
and finally tumor rejection. 
 
 
Figure 7-11 Treatment synergy of dolastatin 10 combined with antibody-mediated blockade of T-cell 
inhibitory receptors PD-1 and CTLA-4. (A+B) Tumor growth during treatment with dolastatin 10 (0.4 mg/kg), 
anti-PD-1/CTLA-4 (each 250 μg/mouse) or the combination in C57Bl/6 WT mice bearing 16-day established 
subcutaneous MC38 tumors. Control, tumor-bearing mice received matched isotype control Abs. All data are 
expressed as mean ± SEM (n=11-12). Two independent experiments were performed, and the pooled data are 
shown. Results are depicted as individual tumor-growth curves (A), cumulative tumor volume over time (B), and 
as a Kaplan-Meier survival plot (C); the x-axis depicts post-tumor implantation (days).  
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7.2.5 Increased intratumoral effector T cell to Treg ratio upon combination therapy 
To define the immunological mechanism of action of a treatment approach combining dolastatins 
and anti-CTLA-4/PD-1 antibodies, tumor-infiltrating lymphocytes were analyzed 10 days after 
treatment onset. To this end, the impact of the indicated treatments on the frequency of Tregs and 
IFN-γ-producing intratumoral CD8+ effector T cells (Teff) was determined. A significantly lower 
frequency of intratumoral Tregs was observed in dolastatin and anti-CTLA-4/PD-1 treated tumors, 
which was even more pronounced in tumors exposed to the combination treatment (Figure 7-12, 
A+C). Similarly, the number of IFN-γ producing CD8+ T cells in dolastatin treated tumors was found 
to be increased, in particular in combination with anti-CTLA-4/PD-1 blocking antibodies (Figure 7-12, 
B+C). Previous work has demonstrated a correlation between the therapeutic efficacy of 
immunotherapies and a shift in the intratumoral Teff to Treg ratio [240]. Accordingly, a significant 
increase in the CD3+IFN-γ+ and CD8+IFN-γ+ Teff to Treg ratio could be documented in the 
combination group compared with non-treated, dolastatin only or anti-CTLA-4/PD-1 only treated 
tumors (Figure 7-12, C). Absolute cell numbers of the respective cell populations are provided in 
Figure 7-12, D. Overall, the therapeutic efficacy of the combined treatment with dolastatin and 
CTLA-4/PD-1 blockade correlated with a shift in the intratumoral balance between Teff cells and 
Tregs towards a more anti-tumorigenic profile. 
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Figure 7-12 Combined effects of dolastatin 10 and anti-CTLA-4/PD-1 treatment on tumor infiltrating 
lymphocyte subsets. Established MC38 tumors were treated as indicated in Materials and Methods and 
analyzed for (A) Tregs or (B) IFN-γ producing CD8+ effector cells. For IFN-γ analysis whole tumor digests were 
incubated for 16 hours with soluble anti-CD3/28 (2/4 μg/ml) and monensin. CD8+IFN-γ+/FoxP3+ and 
CD3+IFNγ+/FoxP3+ ratios are depicted in (C). In addition total CD4 and CD8 as well as CD4+FoxP3+ and CD8+IFN-γ+ 
cell counts are shown in (D). Results represent pooled data from two independent experiments (Mean ± SEM); p 
< 0.05 *, p < 0.01 **, p< 0.001 ***, p< 0.0001 ****. 
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7.2.6 Enhanced T cell-stimulatory capacity of MDA-treated human DCs 
To determine whether human DCs respond comparably to their murine counterparts, the maturation 
stage of monocyte-derived DCs (moDCs) from healthy blood donors was analyzed during exposure 
to dolastatin 10 and MMAE. The dolastatin analogue MMAE is currently successfully used in clinics as 
cytotoxic component of the antibody-drug conjugate (ADC) brentuximab vedotin for treatment of 
relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphomas (ALCL). 
MMAE was therefore included in all tests performed on human cells. In line with data from the 
murine SP37A3 dendritic cell line, a dose-dependent upregulation of the surface expression of CD86, 
CD83, CD40, and MHCII (HLA-DR) by human moDCs was observed after over night exposure to 
dolastatin 10 (Figure 7-13, A). Additionally, the potential of the dolastatin analogue MMAE to induce 
upregulation of important costimulatory molecules on human moDCs was confirmed (Figure 7-13, B). 
DC viability did not significantly change as determined by SytoxGreen® staining using dolastatin 10 
or MMAE at the indicated concentrations (data not shown).  
 
To further address the functional activation of human DCs during treatment with dolastatin 10 or 
MMAE, the capability of pretreated monocyte-derived DCs to induce proliferation of allogeneic CD8 
T cells was analyzed in mixed-lymphocyte cultures. A consistent >2-fold increase was observed in T-
cell proliferation following pretreatment of DCs with dolastatin 10 (p<0.0001) or MMAE (p=0.0002). 
Similar results were obtained when human DCs were stimulated using LPS (p<0.0001; Figure 7-13, C).  
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Figure 7-13 Maturation and T cell-stimulatory capacity of human DCs exposed to dolastatin 10 or MMAE. 
(A+B) Expression of CD86, CD83, CD40, and MHCII by (A) dolastatin-treated or (B) MMAE-treated human 
moDC;. graphs show MFI fold change normalized to untreated cells. All data are representative of at least three 
independent experiments. Data are depicted as mean ± SD. (C) moDCs were exposed to dolastatin 10 or MMAE, 
and subsequently used in a MLR with allogeneic CD8+ T cells. T-cell proliferation was measured after 4 days. (D) 
Human tumor biopsies were incubated with dolastatin 10, MMAE, LPS or left untreated for 24-36h. Expression 
of CD86 and MHCII by tumor-resident DCs was assessed by flow cytometry. Graphs summarize all performed 
experiments and show fold change of MFI compared with untreated specimens, which were set as 1. Histograms 
depict analysis of one representative tumor explant; p< 0.001 ***, p< 0.0001 ****. 
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7.2.7 Increased costimulatory capacity of human tumor-resident DCs 
To directly demonstrate maturation of tumor-resident DCs, matched pieces of human tumor 
resections were incubated with dolastatin 10, MMAE, or LPS and, after 24 h, analyzed for the 
expression of CD86 and HLA-DR as indicators of DC maturation. The origin of tumor biopsies is 
depicted in Table 7-1. Single-cell suspensions of treated and control tumor pieces were analyzed by 
flow cytometry. A >2-fold upregulation of CD86 by tumor-infiltrating DCs (CD45+CD11c+CD11b-) 
treated with dolastatin 10 (p<0.0001) or MMAE (p<0.003) was observed (Figure 7-13, D). 
Interestingly, LPS treatment was not able to reverse the immature state of tumor-resident DCs in 
terms of CD86 expression (p=0.062, ns) to the same degree as dolastatins. In contrast, expression of 
HLA-DR was induced to the same extent by all three agents, namely dolastatin 10 (p<0.05), MMAE 
(p<0.03) and LPS (p<0.02). Overall, these data demonstrate that dolastatin 10 and its analogue 
MMAE are able to phenotypically and functionally mature human moDCs. Most important, both 
agents are capable of reversing the immature state of tumor-resident DCs in human tumor explants. 
 
Table 7-1 Human tumor biopsy origin and fold increase expression of CD86 and HLA-DR upon MDA or LPS 
treatment (n/a= not assessed). 
 Dolastatin 10 MMAE LPS 
Tumor CD86 HLA-DR CD86 HLA-DR CD86 HLA-DR 
Non-small cell lung cancer 
(NSCLC) 
1.9 1.4 1.6 1.7 1.1 1.4 
NSCLC 2.3 1.3 2.9 1.2 1.1 1.5 
NSCLC 3.0 3.3 2.5 n/a 1.1 2.1 
NSCLC 1.7 n/a n/a n/a 1 n/a 
NSCLC 2.3 n/a n/a n/a n/a n/a 
Colon cancer 2.6 1.8 1.9 1.5 2 1.5 
Colon cancer 1.8 1.4 1.9 2.3 2.1 2.5 
Colon cancer 2.6 1.3 2 1.8 2 1.4 
Renal cell carcinoma 1.6 1.5 n/a n/a 0.9 1 
 
 
7.2.8 Promotion of DC maturation by MMAE-coupled ADCs 
In order to determine whether systemically administered, tumor targeted MMAE-coupled ADCs 
allow sufficient release of free MMAE in the tumor vicinity to induce maturation of tumor-resident 
DCs, an ADC was used, which specifically binds to a mouse tumor in fully immune-competent 
C57Bl/6 mice. To this end MMAE was conjugated to an antibody against the model antigen Thy1.1 
(anti-Thy1.1-MMAE ADC) and the resulting ADC has been tested in tumor-bearing animals using 
Thy1.1-transfected RMA lymphoma cells. To directly show DC activation, which is reflected by early 
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antigen uptake and migration of tumor-resident DCs to the tumor-draining lymph nodes, fully 
immune-competent mice bearing subcutaneous RMA-Thy1.1 tumors were injected intratumorally 
with FITC-conjugated dextran 24 h prior to systemic administration of the anti-Thy1.1-MMAE ADC or 
PBS/carrier. Single cell suspensions from tumor-draining and non-draining LNs were prepared 48 h 
after injection and analyzed by flow cytometry. In mice treated with vehicle alone, DCs from tumor-
draining LNs showed almost no increased FITC signal. In stark contrast, FITC-dextran-bearing DCs 
could be robustly detected and correlated with high CD86 expression in the tumor-draining LNs of 
mice systemically treated with anti-Thy1.1-MMAE ADC (Figure 7-14, A-B). Consistent with previous 
observations on free dolastatins, treatment with the anti-Thy1.1-MMAE ADC induced DC activation 
restricted to the tumor site, since FITC-Dx-bearing DCs could not be detected in non-tumor-draining 
LNs. 
 
To further substantiate these findings with a clinically relevant ADC, it was explored whether 
brentuximab vedotin (BV) elicits maturation of human moDCs in co-culture with human lymphoma 
cell lines. Brentuximab vedotin was highly potent and selective against the CD30+ tumor cell lines L-
540 (HL) and Karpas-299 (ALCL) with an IC50 of 10 ng/mL and 30 ng/mL, respectively, but more than 
1000-fold less active on the CD30- tumor cell lines Raji and Ramos (both Burkitt NHL) (data not 
shown; [241]). In contrast to co-culture of human moDCs with brentuximab vedotin-treated CD30- 
lymphoma cells (Ramos) or brentuximab vedotin only, a substantial upregulation of the surface 
expression of CD86 by human moDCs was observed after co-culture with brentuximab vedotin-
treated CD30+ L-540 and Karpas-299 lymphoma cells (Figure 7-14, C-D). Notably, DC maturation in 
response to BV-treated CD30+ lymphoma cells was comparable to that induced by free MMAE. 
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Figure 7-14 In vivo DC homing and in vitro maturation of human moDCs by MMAE-coupled ADCs. (A+B) 
C57Bl/6 mice bearing subcutaneous RMA-Thy1.1 tumors of approx. 100 mm3 size were treated as outlined. 
Briefly, anti-Thy1.1-MMAE ADC was administered systemically 24h before intratumoral injection of FITC-
Dextran. On day 2 after ADC treatment, tumor-draining LNs were examined for the presence of FITC+CD86+ 
DCs by flow cytometry. (A) Representative plots depict FITC+ DCs detected in tumor-draining LNs after 
PBS/DMSO or ADC injection. (B) Graph depicts pooled data from two independent experiments. (C+D) CD30+ 
Karpas-299 and L-540 as well as CD30- Ramos cells were incubated with brentuximab vedotin for 3 days. On day 
3 immature moDCs were added and co-cultured for 24 h. (C) CD86 expression by DCs after co-culture with 
brentuximab vedotin-treated L-540 cells (orange). Control DCs were left untreated (black), incubated with L-540 
cells alone (blue) or incubated with free MMAE at 0.1 μM for 24h (red; left panel). DCs were cultured in presence 
of brentuximab vedotin without tumor cells at the indicated concentrations (middle panel) and with L-540 cells 
treated with 3 distinct chemotherapeutics at 100 μM (right panel) to exclude DC maturation induced by tumor 
cell death. (D) CD86 MFI fold change as compared to untreated moDCs; graphs show data from 11 independent 
experiments. 
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7.2.9 Activation of adaptive immunity in brentuximab-treated lymphoma patients 
In collaboration with Dr. Theurich and Prof. von Bergwelt-Baildon from the German Hodgkin Group 
(University Hospital Cologne), initiation of anti-tumor immune responses upon systemic treatment 
with brentuximab vedotin was assessed. To this end, PBMCs from six patients with relapsed Hodgkin 
and CD30+ T-cell lymphoma have been collected before and after brentuximab vedotin 
administration. All patients exhibited marked clinical and metabolic responses using PET-CT scans 
(data not shown). Surprisingly, a significant decrease in the number of CD4+CD25+FoxP3+ Tregs was 
observed when comparing PBMCs before and after brentuximab vedotin administration (Figure 7-15, 
A). While the relative numbers of CD4 and CD8 T cells remained unchanged (data not shown), a 
significant increase of both CD4 and CD8 T cell activation as determined by the expression of CD25, 
could further be documented (Figure 7-15, B). To determine the activation of peripheral DCs and B 
cells, the latter being increasingly recognized as potent antigen-presenting cells and key players in 
anti-tumor immunity, the expression of CD86 on lin-CD11c+CD11blow DCs and CD20+ B cells before 
and after brentuximab treatment was assessed using flow cytometry. As shown in Figure 7-15, C, 
expression of this marker substantially increased after brentuximab vedotin administration. Taken 
together, these results demonstrate that brentuximab vedotin leads to lower frequency of Tregs and 
increases activation of T and B cells in patients with relapsed Hodgkin lymphoma, thereby reflecting 
induction of cellular immunity. 
 
To analyze changes in the degree and type of tumor-infiltrating lymphocytes in response to 
treatment with brentuximab vedotin, skin biopsies were performed on a patient with relapsed CD30+ 
cutaneous T cell Lymphoma before (pre) and after (post) brentuximab vedotin treatment. In addition 
to H&E staining, immunohistochemical reactions were carried out using specific antibodies for CD30+ 
lymphoma cells and CD4+ TH cells as well as CD8
+ CTLs. Compatible with the clinical response upon 
treatment with brentuximab vedotin, a decrease in the number and density of CD30+ lymphoma cells 
could be observed. Notably, a substantial increase in total lymphocytes from pre to post tumor 
specimens was detected. Immunohistochemistry revealed a pronounced increase in both CD4 and 
CD8 lymphocytic infiltrates in the post skin biopsy (Figure 7-15, D). When performing similar analyses 
in a patient with relapsed CD30+ Hodgkin lymphoma, a comparable increase in total lymphocyte 
numbers with a preferential accumulation of T cells could be observed (data not shown). 
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Figure 7-15 Cellular immune responses in Brentuximab vedotin-treated lymphoma patients. (A-C) PBMCs 
from six patients with relapsed CD30+ malignancies (HL n= 5; CD30+ ALCL n=1) were collected before and after 
brentuximab vedotin treatment and analyzed by flow cytometry. (A) Data show the percentage of FoxP3+ Tregs 
(upper panel) and representative dotplots before and after treatment (lower panel). (B) Graphs depict 
percentages of activated CD4+ (upper panel) and CD8+ T cells (lower panel). (C) Flow cytometric analysis of 
CD86 expression is shown in lineage-, CD11c+ CD11blow DCs (upper panel) and CD20+ B cells (lower panel) prior 
and post brentuximab treatment. (D) H&E (upper left) and immunohistochemistry for CD30+ lymphoma cells 
(lower left), CD8+ (upper right) and CD4+ (lower right) reactive lymphocytes in tumor specimens from one 
patient with a CD30+ cutaneous T cell lymphoma obtained before and after brentuximab treatment (10x 
magnification). Tumor immune infiltrates and CD30+ tumor cells were quantified in an area of 10 high power 
fields (400x) and counts are depicted in the right panel.  
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7.3 Molecular mechanism of MDA-induced DC maturation 
7.3.1 Role of pattern recognition receptor signaling in MDA-induced DC maturation  
Previous studies have demonstrated a critical role for pattern recognition receptor (PRR) signaling in 
DC activation [146]. In order to elucidate the role of these receptors in MDA-induced DC maturation, 
BMDCs were generated from mice lacking the genes for Toll-like receptor (TLR) or NOD-like 
receptor (NLR) cytosolic adaptor proteins. Amongst TLR adapter proteins, MyD88 is central because 
it is shared by most TLRs, with the exception of TLR3, while TLR4 may use either MyD88 or TRIF in 
two alternative pathways [242]. To determine whether activation of DCs requires MyD88 during 
exposure to the MDA dolastatin 10, we analyzed its effect on the maturation of BMDCs derived from 
WT and MyD88-/- mice in vitro (Figure 7-16, A) and injected dolastatin 10 into the ears of WT and 
MyD88-/- mice as previously described in Figure 7-6, A (Figure 7-16, B). The TLR9 ligand CpG1668 was 
used as positive control. Unlike CpG, which was not able to up-regulate CD86, CD40, and MHCII in 
MyD88-/- mice, activation of DCs during exposure to dolastatin 10 occurred independently of MyD88 
signaling, both in vitro and in vivo.  
 
To determine the role of TLR3 and TLR4 in MDA-triggered activation of DCs, BMDCs deficient of the 
TLR3 adaptor protein TRIF, and, as TLR4 uses either TRIF or MyD88 as adaptor protein, receptor-
deficient TLR4-/- BMDCs were used. Further PRRs include the NOD-like receptors NOD1 and NOD2, 
which use receptor-interacting protein 2 (RIP2) as adaptor, as well as the NALP3 (NLRP3) containing 
protein complex termed the inflammasome. Consequently, both RIP2-/- and NALP3-/- BMDCs were 
obtained. However, neither IPS-1-/- mice, intended to study the role of the cytosolic RIG-I-like 
helicases (RLRs), nor mice lacking genes for C-type lectin receptor signaling could be obtained from 
external collaborators.  
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Figure 7-16 MyD88-independent immune-stimulatory effect of dolastatin 10. (A) Expression of CD86, MHCII 
and CD40 by BMDCs from WT and MyD88-/- mice exposed to dolastatin 10 (0.1 μM) or CpG1668 (1 μg/mL) for 24 
h compared with untreated BMDCs. Data are expressed as fold change of MFI compared with untreated cells, 
which were set as 1. Each bar represents mean ± SD of duplicate cultures from one representative experiment 
out of three independent experiments. (B) WT or MyD88-/- mice were treated as described in Figure 7-6, A-B. 
Expression of CD86 by skin Langerhans cells was detected by flow cytometry. Data depict mean (two ears per 
data point; data were pooled from three independent experiments) % CD86high cells within the 
CD45+CD11c+MHCII+ population (upper panel) and % MHCIIhigh cells (lower panel) in WT mice (blue) or MyD88-/- 
mice (red). 
 
DC maturation in response to MDA exposure was tested in above mentioned TRIF-/-, TLR4-/-, RIP2-/- 
and NALP3-/- BMDCs and known stimulators of each pathway were included as positive controls: LPS 
(TLRpure®, Invivogen) as a trigger of TLR4; Poly I:C  (high molecular weight, Invivogen) as activator 
of TLR3; muramyl dipeptide (MDP) as activator of NOD2 and nigericin (Nig), an antibiotic, which has 
been shown to serve as trigger for activation of the NALP3 inflammasome [243]. CpG1668 was 
included as potent stimulator of DC maturation independent of any of the pathways tested here. 
Knockout- as well as WT BMDCs were exposed to controls or MDAs (i.e., dolastatin 10 and 
ansamitocin P3) at indicated concentrations for 20 h prior to flow cytometric assessment of DC 
maturation marker expression (Figure 7-17, A-B). As expected, the response to LPS, Poly I:C or MDP 
was abrogated in TLR4-/-, TRIF-/- or RIP2-/- BMDCs, respectively. In contrast, upregulation of CD80, 
CD86, CD40 and MHCII in knockout BMDCs in response to MDA treatment was comparable to that 
induced in WT BMDCs. Thus, phenotypic maturation of BMDCs in response to the MDAs ansamitocin 
P3 and dolastatin 10 was independent of TRIF, TLR4, or RIP2 signaling.  
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Figure 7-17 Upregulation of DC maturation markers and IL-1β expression upon MDA exposure is independent 
of TLR, NLR or NALP3 inflammasome signaling. (A+B) WT, TLR4-/-, TRIF-/- (A), as well as WT and RIP2-/- (B) 
BMDCs were incubated with the indicated chemotherapeutic compounds (0.1 μM) or controls for 24h. 
Expression of CD80, CD86, CD40 and MHCII was assessed by flow cytometry; graphs show fold change of MFI 
compared to mock-treated cells, which were set as 1. Pooled data from two independent experiments are 
shown. (C) Expression of IL-1β in supernatants of WT and NALP3-/- BMDCs upon 24h exposure to ansamitocin P3 
(1 μM), LPS (1 μg/mL), nigericin (10 μM) or combinations thereof as detected by ELISA. Bars represent mean ± 
SD of duplicate cultures from one out of two independent experiments. 
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NALP3-inflammasome activation triggers secretion of large amounts of mature IL-1β [158]. 
Therefore, release of IL-1β was tested in NALP3-/- and WT BMDC cultures. As observed before, 
ansamitocin P3 triggered IL-1β expression in WT BMDCs to similar extent as LPS (Figure 7-17, C). 
Importantly, while the nigericin-triggered increase in IL-1β observed in WT BMDCs was markedly 
reduced in NALP3-/- BMDCs, equal levels of IL-1β were detected in WT and knockout BMDCs in 
response to LPS and ansamitocin P3. Therefore, functional DC activation in terms of IL-1β expression 
is independent of NALP3-inflammasome activation. Taken together, these data indicate that MDA-
induced DC maturation is independent of TLRs, the major NLRs NOD1 and NOD2, and the NALP3-
inflammasome. Due to the structures of the tested MDAs (see Introduction chapter 4.4.1), it seems 
unlikely that the nucleic acid sensing RLRs, or C-type-lectin receptors recognizing sugar-associated 
structures are involved in the observed DC maturation. Rather, it appears that the process of active 
depolymerization of microtubules may be the triggering event to induce signaling pathways that 
ultimately lead to innate immune responses. These may be a result of profound cellular and 
biological changes within a dendritic cell. 
 
7.3.2 Characterization of the MDA-induced cytokine pattern 
Chemotherapeutics with similar impact on immune activation and known underlying signaling 
events were compared to MDAs in order to find out whether similar signaling pathways might be 
triggered by MDAs. In this context, various studies reported activation of tumor-resident DCs and 
murine macrophages by the chemotherapeutic agent 5,6-Dimethylxanthenone-4-acetic acid 
(DMXAA), a vascular-disrupting agent (VDA) [244-246]. Unlike other VDAs, DMXAA does not bind 
microtubules, and although its mechanism of tumor-cell cytotoxicity is largely unknown, it has been 
proposed that DMXAA inhibits various kinases as well as vascular endothelial growth factor receptor 
(VEGFR)-2 [247]. Upon stimulation with DMXAA, macrophages produced large amounts of type I 
IFNs (mainly IFN-β) mediated via the TANK-binding kinase 1 (TBK1)/interferon-regulating factors 
IRF3/IRF7 signaling axis, as well as TNF-α and IL-6. To test whether microtubule-depolymerizing 
agents may display a comparable activation profile, transcriptional induction of IFN-α/-β, TNF-α, and 
further pro-inflammatory cytokines by SP37A3 DCs was determined by real-time quantitative PCR 
(Figure 7-18). Upon MDA-stimulation, mRNA of both type I IFNs or TNF-α was induced only to low 
levels compared to DMXAA. Also, when using microtubule-destabilizing drugs, no induction of IRF7 
or IRF1 mRNA was detected, while mRNA of the IRF3 target gene IP-10 (CXCL-10) was induced only 
weakly (data not shown). In contrast, strong induction of IL-1β and IL-6 mRNA was detected at early 
time points (before 4 h). Interestingly, IL-12p40 as well as IL-23p19, which both belong to the IL-12 
family, displayed slightly delayed kinetics (see also Figure 7-23). Hence, these data indicate that the 
MDA-induced cytokine pattern differs from that observed upon DMXAA, and thus suggest that 
distinct molecular mechanisms may be responsible for stimulation of DCs. In essence, DMXAA 
induced anti-viral type I IFN responses via induction of TBK1 and IRFs, whereas MDAs triggered pro-
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inflammatory responses including early and pronounced induction of IL-1β and IL-6, which are 
generally associated with the activation of NF-κB and AP-1 transcription factor families rather than 
IRFs. 
 
 
Figure 7-18 MDAs promote pro-inflammatory cytokine responses rather than type I IFNs. Expression of type I 
IFN and pro-inflammatory cytokine mRNA by SP37A3 DCs upon 4-24 h exposure to microtubule-destabilizers 
dolastatin 10 and ansamitocin P3, the vascular-disrupting agent DMXAA, or LPS and CpG1668 as control 
substances. Expression values were normalized to expression of S18RNA as reference gene, as well as to the 
expression levels in untreated cells using the ΔΔCT formula as indicated in Methods. One representative 
experiment of two independent experiments is shown.  
7.3.3 Differential activation of c-Jun by MT-binding compounds 
Next, investigations were directed towards signaling pathways that are known to be activated in 
tumor cells upon exposure to microtubule (MT)-binding compounds. In spite of the fact that these 
compounds generally lead to apoptosis in tumor cells and therefore, provoke distinct outcomes to 
those observed in DCs, it is known that disruption of MTs in tumor cells induces signaling effectors 
such as MAPKs, which are equally involved in innate responses [248]. These early signals could then 
diverge at later time points or with additional signaling events. As shown in Figure 7-5, only 
microtubule-destabilizing compounds had the capacity to induce DC maturation. In contrast, 
stabilizing compounds, such as paclitaxel induced only low levels of MHCII, but no expression of 
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cytokines. Accordingly, elucidation of signaling events that are differentially induced by MDAs and 
MSAs will likely give a hint on the pathway(s) responsible for triggering the DC phenotype observed 
upon exposure to MDAs. In this line, paclitaxel was used as control in selected subsequent 
experiments. Particularly, Kolomeychuck et al. demonstrated that in tumor cells both vinblastine 
(VBL; destabilizer) and taxol (stabilizer) induced mRNA as well as protein expression of the 
transcription factor c-Jun and activated the c-Jun N-terminal kinases (JNK), as evidenced by nuclear 
translocation of JNK1 and JNK2 [249]. However, only VBL induced phosphorylation of c-Jun and 
activation of the AP-1 site in the c-Jun promoter region. Therefore, it was investigated whether 
MDA-induced activation of c-Jun occurred in SP37A3 DCs in the same manner as observed for tumor 
cells. As shown by western blotting, ansamitocin P3 induced c-Jun phosphorylation at serine 73 
(Ser73) as well as enhanced expression of total c-Jun protein in SP37A3 DCs. In stark contrast, no 
significant increase of phosphorylated or total c-Jun was observed in paclitaxel treated DCs (Figure 7-
19).  
 
 
 
 
 
 
 
Figure 7-19 Differential induction of c-Jun expression and phosphorylation by ansamitocin P3 and paclitaxel. 
SP37A3 DCs were incubated with ansamitocin P3 (0.1 μM) or paclitaxel (0.1 μM) for the indicated time periods 
before collection of whole cell lysates in RIPA buffer. 10 μg total protein was separated by SDS-PAGE and the 
total amount of specific proteins and their phosphorylated forms were detected using anti-c-Jun, anti-phospho-
c-Jun (Ser73) and anti-β-Actin as loading control. One representative experiment of three independent 
experiments is shown. 
 
7.3.4 Role of RhoA activation in ansamitocin P3-triggered DC maturation 
Consequently, possible upstream regulators of c-Jun were investigated in the context of cytoskeletal 
rearrangement. Indeed, the small GTPase RhoA has been shown to stimulate c-Jun expression 
through Rho-associated protein kinase (ROCK) by activating JNK, which led to the phosphorylation 
and activation of c-Jun and activating transcription factor (ATF)-2 that are bound to the AP-1 site in 
the c-Jun promoter [202]. Interestingly RhoA activation by the MDA vinblastine has previously been 
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shown for tumor cells as well as for DCs [199, 200]. Thus, GTP-bound, i.e., active RhoA from DC 
whole cell lysates was detected using a commercially available kit in ELISA format (G-LISA, 
Cytoskeleton Inc.). Indeed, RhoA activation could be confirmed upon exposure to ansamitocin P3 in 
SP37A3 dendritic cells, with maximum RhoA activation after 30-60 minutes of stimulation (Figure 7-
20, A). Furthermore, pre-treatment of SP37A3 DCs with the pharmacological RhoA inhibitor CCG-
1423 (Selleckchem) resulted in a dose-dependent reduction of phenotypic maturation as reflected by 
expression of the costimulatory receptors CD80, CD86 and CD40, as well as MHCII (Figure 7-20, B). 
Of note, cells were serum starved for 16 h during the assay, which possibly explains the low viability 
of treated and untreated cells. Together, these data indicate that MDAs induce activation of RhoA, 
which is required for complete phenotypic DC maturation. 
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Figure 7-20 Activation of RhoA upon exposure to ansamitocin P3. (A) SP37A3 DCs were incubated with 
ansamitocin P3 (0.1 μM) for the indicated time periods before collection of whole cell lysates. Equal amounts of 
total protein were added to the G-LISA plate in duplicates and processed as outlined in Methods. (B) SP37A3 
DCs were pretreated with the RhoA-inhibitor CCG-1423 for two hours before addition of ansamitocin P3 (0.1 
μM), dolastatin 10 (0.1 μM), or LPS (500 ng/mL) for another 14 h. The assay was conducted in serum-free 
medium; concentrations are indicated. Viability is depicted as percentage of viable cells (viability of untreated 
cells cultured in presence of serum was set to 100%). MFI was assessed by flow cytometry; graphs show fold 
change of MFI compared with untreated cells, which were set as 1. Data are representative of three independent 
experiments with similar results. Mean ± SD of one representative experiment is shown; p < 0.05 *; p< 0.0001 
****. 
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7.3.5 Release of the MT–associated GEF-H1 upon ansamitocin P3 treatment 
Small Rho GTPases have been described as major regulators of cytoskeleton function and are 
themselves carefully regulated by a large amount of activators, such as guanine nucleotide exchange 
factors (GEF), and inhibitors, such as GTPase-activating proteins (GAP) [190]. Amongst the 
activating guanine nucleotide exchange factors, GEF-H1 (also: Arhgef, murine: lfc) is uniquely 
associated with microtubules [193, 194]. Furthermore, Krendel and colleagues provided 
experimental evidence that GEF-H1 is responsible for regulating Rho activity in response to 
microtubule depolymerization, and that microtubule disassembly resulted in the activation of Rho. In 
addition, nocodazole-induced depolymerization of microtubules disrupted the inhibited (i.e., 
phosphorylated) GEF-H1 complex, resulting in potent activation of GEF-H1 [195, 198]. Therefore, 
immunofluorescence was used to determine whether GEF-H1 was expressed in SP37A3 DCs and, 
whether GEF-H1 co-localized with MTs in DCs. As demonstrated in Figure 7-21, A, GEF-H1 (green) 
was found to co-localize with microtubules (α-tubulin, red) in most untreated control DCs. Since 
microtubule structures are highly temperature-sensitive, some residual cytoplasmic GEF-H1 might 
be a result of MT-instability due to the handling of the cells during the collection and staining 
procedure. Importantly, these data demonstrate that ansamitocin P3 treatment induced rapid 
disruption of the MT network in dendritic cells after only 5 to 15 minutes of incubation. MT-disruption 
furthermore led to release of GEF-H1 and cytoplasmic accumulation of both GEF-H1 and α-tubulin 
subunits (Figure 7-21, B). Importantly, GEF-H1 release from MTs has been confirmed using live cell 
imaging of APRE epithelial cells (data not shown, time lapse video file). Since dendritic cells are 
generally difficult to transfect, we used these epithelial cells in order to monitor GEF-H1 localization 
and behavior upon ansamitocin P3 stimulation in real-time (total duration: one hour). 
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Figure 7-21 GEF-H1 co-localized with microtubules and was released upon MT disruption by ansamitocin 
P3. (A+B) SP37A3 DCs were seeded onto polylysine-coated coverslips in serum-free medium and treated with 
ansamitocin P3 (1 μM) for the indicated time periods or left untreated (control). Cells were fixed and stained with 
anti-α-tubulin and anti-lfc (GEF-H1) mAbs followed by anti-rabbit Alexa647 and anti-sheep Alexa488 secondary 
antibodies, respectively. Slides were then mounted with antifade reagent containing DAPI as nuclear stain 
(blue) and were analyzed by confocal microscopy (LSM 710 Rocky, Zeiss). 
 
7.3.6 Role of GEF-H1 in ansamitocin P3-induced MAPK/AP-1 activation  
In light of these data, a collaboration with the laboratory of Prof. Hans-Christian Reinecker at the 
Massachusetts General Hospital, Boston was initiated due to the lab`s long-standing expertise in 
GEF-H1-dependent innate signaling [250-252]. Furthermore, GEF-H1 deficient mice were established 
and maintained in the Reinecker Lab. Consequently, DC maturation upon ansamitocin P3 treatment 
was tested in GEF-H1 deficient (Arhgef-/-) BMDCs. These experiments were intended to elucidate 
whether GEF-H1 was indeed the MT-associated trigger of downstream signaling events leading to c-
Jun phosphorylation and ultimately inducing expression of maturation markers as well as pro-
inflammatory cytokines in response to MDAs. To this end, day 7 Arhgef-/- and WT (both C57Bl/6) 
BMDCs were incubated with ansamitocin P3 for 20 h prior to analysis of maturation marker 
expression by flow cytometry (Figure 7-22, A). Expression of CD80 and CD86 was significantly 
reduced in Arhgef-/- BMDCs upon treatment with ansamitocin P3, dolastatin 10 and also LPS when 
compared to WT BMDCs. Interestingly, Guo et al. have demonstrated that LPS-induced NF-κB 
activation and IL-8 synthesis in endothelial cells is regulated by both a MyD88-dependent as well as 
by a GEF-H1-RhoA-dependent pathway [253]. Thus, these data provide a possible explanation for the 
reduced expression of CD80 and CD86 in LPS-stimulated Arhgef-/- BMDCs. As upregulation of CD40 
by either MDA was only modest, a slight, but non-significant reduction of CD40 expression was 
observed in Arhgef-/- BMDCs. Of note, no upregulation of MHCII was detected because all CD11c-
positive cells expressed high levels of MHCII before treatment and DCs were gated based on a 
CD11chigh, hence MHCIIhigh phenotype.  
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As a next step, it was assessed whether GEF-H1 was required for the previously observed induction of 
c-Jun. Since JNKs (also: stress-activated protein kinases; SAPK/JNK) are the major MAPKs 
responsible for phosphorylation of c-Jun at both the serine residues 63 and 73 [254], activation of 
SAPK/JNK (i.e. their two splicing forms p46 and p54) was determined in Arhgef-/- and WT BMDCs. 
Furthermore, paclitaxel-treated BMDCs were analyzed in order to assess whether the observed 
difference in c-Jun activation by ansamitocin P3 and paclitaxel in SP37A3 DCs  (Figure 7-19) could be 
confirmed. As demonstrated in Figure 7-22, B ansamitocin P3 treatment strongly induced 
phosphorylation of c-Jun at Ser73 as well as at Ser63 in WT BMDCs. In addition, total c-Jun protein 
expression was enhanced by ansamitocin P3 in WT BMDCs. Both phosphorylation of c-Jun as well as 
induction of total protein in response to ansamitocin P3 was significantly reduced in Arhgef-/- BMDCs, 
although not completely abrogated (Figure 7-22, B, left panel). Accordingly, activation of SAPK/JNK 
as determined by phosphorylation at threonine 183 and tyrosine 185 residues, was significantly 
enhanced by ansamitocin in WT BMDCs and reduced in Arhgef-/- BMDCs. Importantly, activation of 
c-Jun as well as SAPK/JNK was detected as early as after one hour of ansamitocin P3 treatment and 
was evident for up to 12 hours, with a peak expression after eight hours. These data are consistent 
with the kinetics observed for induction of pro-inflammatory cytokine mRNA, that was detected 
after four hours of ansamitocin P3 treatment and stayed high for at least 24 hours (Figure 7-18). 
Supporting the hypothesis that only MT-destabilizing agents are able to trigger profound DC 
maturation, neither c-Jun phosphorylation, nor total c-Jun induction or activation of SAPK/JNK was 
detected in paclitaxel-treated WT or Arhgef-/- BMDCs (Figure 7-22, B, right panel).  
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Figure 7-22 Requirement of GEF-H1 for MDA-induced expression of costimulatory molecules and activation 
of JNK/c-Jun. (A) Expression of CD80, CD86, MHCII and CD40 by BMDCs from WT and Arhgef-/- mice exposed to 
ansamitocin P3 (0.1 μM), dolastatin 10 (0.1 μM) or LPS (500 ng/mL) for 20 h. Data are expressed as fold change 
of MFI compared with untreated cells, which were set as 1. Each bar represents mean ± SD of duplicate cultures 
from one representative experiment out of two independent experiments; p< 0.05*; p< 0.01**. (B+C) WT and 
Arhgef-/- BMDCs were incubated with ansamitocin P3 (0.1 μM) or paclitaxel (0.1 μM) for the indicated time 
before collection of whole cell lysates in RIPA buffer. Total proteins were separated by SDS-PAGE and 
transferred to PVDF membranes. The total amount of specific proteins and their phosphorylated forms were 
detected using anti-phospho-c-Jun (Ser73), anti-phospho-c-Jun (Ser63), anti-c-Jun, anti-phospho-SAPK/JNK, 
anti-SAPK/JNK (B) and anti-phospho-p38, anti-p38, anti-phospho-ERK1/2, anti-ERK1/2, anti-phospho-p65 or 
anti-p65 (C). One representative experiment of two independent experiments is shown. 
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Activation of innate immunity, as for example in response to PRR triggering, mostly results in 
induction of multiple pathways involving further MAPKs and subsequent induction of not only AP-1 
but also NF-κB or IRF transcription factor family members (Figure 4-7, Introduction) [146, 148, 149]. 
However, rather low induction of type I IFNs in response to MDAs indicated no or only minor 
activation of IRF dependent pathways. Therefore, it appears that mainly MAPK and AP-1 or NF-κB-
dependent pathways may be responsible for expression of pro-inflammatory cytokines in response 
to MDAs. Thus, phosphorylation of the MAPKs p38 (Thr180/Tyr182) and ERK1/2 (p42/44; 
Thr202/Tyr204), as well as of the NF-κB family member p65 (Ser536) was tested upon ansamitocin 
P3 or paclitaxel treatment in WT and Arhgef-/- BMDCs (Figure 7-22, C). Interestingly, no change in p38 
activation was observed in either sample, while ERK1/2 phosphorylation was detected upon 
ansamitocin P3 as well as paclitaxel treatment after eight to 12 hours of incubation, although only at 
moderate levels. Of note, GEF-H1 deficiency led to reduced p-ERK1/2 in response to ansamitocin P3 
treatment, while paclitaxel induced ERK1/2 phosphorylation was unaffected. Phosphorylation of p65 
was generally moderate and, similar to the ERK activation pattern, appeared to be GEF-H1 
independent in case of paclitaxel (Figure 7-22, C). These data thus indicate a more prominent role for 
AP-1 rather than NF-κB in mediating DC maturation responses upon MDA treatment.  
 
7.3.7 Requirement of GEF-H1 for transcriptional regulation of DC maturation markers and 
pro-inflammatory cytokines  
Induction of CD80 and CD86 mRNA was tested in WT and Arhgef-/- BMDCs in order to determine 
whether increased surface expression of these costimulatory molecules was regulated on the 
transcriptional level as part of a primary response to GEF-H1 and subsequent c-Jun activation. 
Enhanced mRNA levels of both CD80 and CD86 in WT BMDCs in response to ansamitocin P3 indeed 
suggest induction of a transcriptional DC maturation program rather than, or possibly in addition to, 
receptor recycling or relocation (Figure 7-23, A). Interestingly, both CD80 and CD86 mRNA was 
induced early and reached a plateau already after four hours, while expression was sustained beyond 
12 hours of MDA treatment in WT BMDCs. In contrast, Arhgef-/- BMDCs almost completely failed to 
induce CD80 and CD86 mRNA in response to ansamitocin P3. Compatible with previous findings on 
induction of costimulatory molecules by MSAs, paclitaxel was not able to induce upregulation of 
CD80 or CD86 mRNA in either WT or Arhgef-/- BMDCs. In order to understand whether induction of 
pro-inflammatory cytokines was an equally direct result of GEF-H1 activation upon MT disruption, 
mRNA expression patterns were assessed in WT and knockout BMDCs. Indeed, IL-1β, IL-6, IL-12p35, 
IL-12p40 and IL-23p19 expression in Arhgef-/- BMDCs exposed to ansamitocin P3 was found to be 
decreased to almost baseline levels, as observed in untreated WT BMDCs (Figure 7-23, B-C). 
Furthermore, these data confirmed the previously noted distinct kinetics of early induced IL-1β, IL-6 
and IL-12p35 as compared to late responding, but equally high IL-12p40 and IL-23p19 mRNA 
production.  
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Figure 7-23 GEF-H1 is required for transcriptional regulation of maturation markers and pro-inflammatory 
cytokines in DCs. Expression of CD80, CD86 and pro-inflammatory cytokine mRNA by WT and Arhgef-/- BMDCs 
upon 4-12 h exposure to the MDA ansamitocin P3 (0.1 μM) or the MSA paclitaxel (0.1 μM). Expression values 
were normalized to expression of S18RNA as reference gene, as well as to expression in untreated cells using the 
ΔΔCT formula. One representative experiment of two independent experiments is shown.  
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8 Discussion 
8.1 Microtubule-depolymerizing agents promote dendritic cell maturation 
With the aim to characterize immunostimulatory anti-cancer compounds for the use in chemo-
immunotherapy approaches, we screened classical chemotherapeutic agents with proven tumor cell 
cytotoxicity for their DC-stimulatory potential. As a result, we identified microtubule-depolymerizing 
agents as unique and potent inducers of dendritic cell maturation [255, 256]. Compounds of this class 
investigated in the present study include: a) the maytansinoids ansamitocin P3 and its synthetic 
analogue DM1, b) the dolastatins dolastatin 15, dolastatin 10 and the synthetic analogue MMAE, and 
c) the vinca alkaloid vinblastine (VBL). Importantly, all MDAs tested displayed a pronounced capacity 
to phenotypically and functionally mature murine as well as human DCs in a dose-dependent manner 
and to similar extent as LPS. These data indicate that MDA-induced DC maturation possibly reflects 
a class effect common to all microtubule-depolymerizing compounds despite their different 
molecular structures (see Introduction, chapter 4.4.1) [173]. In our settings, neither microtubule-
stabilizing agents (MSAs), nor compounds of other classes, such as for example topoisomerase II 
inhibitors, alkylating agents, HDAC inhibitors or tyrosine kinase inhibitors, displayed significant DC-
promoting features (Figures 7-1 and 7-5). On account of this, our data is partially consistent with a 
functional screen of 54 chemotherapeutic agents that identified not only the microtubule-
depolymerizing agent vinblastine, but also the microtubule-stabilizing taxanes, as well as 
compounds of other classes such as topoisomerase I inhibitors as inducers of DC maturation [118]. 
This discrepancy might originate from a) different DC cell lines used in both studies, b) the nature of 
the reporter construct used by Takashima and colleagues, which detected DC activation based on 
the induction of the IL-1β promoter with high sensitivity, and c) the threshold set by the investigators 
for determination of DC maturation. Furthermore, the authors observed that induction of the IL-1β 
promoter did not correlate with a complete DC maturation (defined as simultaneous expression of 
maturation markers and pro-inflammatory cytokines as well as induction of T cell stimulation), since 
various compounds that had been identified as DC-stimulatory by the reporter failed to induce 
expression of more than one costimulatory molecule or pro-inflammatory cytokines, for instance 
[118, 223]. Consequently, the most prominent compounds were additionally tested in BMDCs. 
Interestingly, only vinblastine was shown to induce the full spectrum of DC maturation in vitro as well 
as in vivo [119]. Furthermore, various studies have reported modulation of DC phenotype upon 
exposure to low, non-cytotoxic concentrations of the MSA paclitaxel and other chemotherapeutics 
[114-117]. Yet, these studies mostly evaluated DC function and phenotypic maturation in the context 
of drug-pretreated tumor cells, or in combination with LPS treatment. Direct effects of paclitaxel and 
other chemotherapeutics on DCs were generally very moderate and thus, are largely consistent with 
our data.  
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Both MDAs and MSAs are used as chemotherapeutics due to their capacity to block mitosis as a 
result of suppression of microtubule dynamics at low (pM) concentrations in tumor cells in vitro. At 
higher concentrations, i.e. 10-100 nM, they actively induce depolymerization or stabilization of MTs, 
respectively [169]. Intriguingly, the latter is the concentration range able to induce potent 
phenotypic DC maturation in case of MDAs. As a logical consequence, it seems that the process of 
active depolymerization of MT structures, in contrast to stabilization, is a prerequisite for activation 
of innate immune responses in dendritic cells. In support of this hypothesis, we observed that drug 
potency in terms of tumor cell cytotoxicity correlated well with potency in terms of DC stimulation 
(i.e., minimal drug-concentration needed to induce expression of cytokines). Yet, the molecular basis 
for the differential induction of cell death in tumor cells as compared to DCs remains to be 
determined. While MT depolymerization induces apoptosis in fast-dividing tumor cells, DC viability 
was only modestly affected and stayed stable up to a concentration of 10 μM. A reason for this might 
be reduced sensitivity to apoptosis induction towards microtubule-targeting agents in non- or less-
dividing cells such as endothelial cells or DCs [257, 258].  
 
8.2 MDAs potentiate anti-tumor immunity and synergize with immunotherapy 
Based on the DC-stimulatory capacity of MDAs and the unique role of DCs in initiating adaptive 
immunity, we set out to characterize the extent and nature of MDA-promoted anti-tumor immune 
responses. Since the expansion of effector T cells upon activation is especially sensitive to the 
toxicity mediated by most chemotherapeutics, we intended to carefully monitor not only DC 
activation, but also initiation of subsequent T cell responses upon exposure to MDAs using tumor-
bearing animals as well as in human in vitro assays. For this purpose, we used dolastatin 10 as 
representative and, besides ansamitocin P3, most potent member of its class. In summary, the 
studies presented in this thesis demonstrate that, first, dolastatins trigger a program of phenotypic 
and functional activation of tumor-resident DCs. Second, these DCs migrate to the tumor-draining 
LNs upon antigen-uptake and maturation, where they encounter and activate tumor-antigen-
specific T cells. Third, CD11c+ DCs and the adaptive immune system are essential for the full 
therapeutic activity of dolastatins. Fourth, when combined with tumor-antigen-specific vaccination 
or checkpoint inhibitor blocking antibodies, dolastatins show synergistic anti-tumor activity and 
promote tumor destruction. And fifth, ADCs coupled to the dolastatin analogue MMAE, such as 
brentuximab vedotin, induce DC homing in murine mouse models, maturation of human DCs in 
lymphoma cell-DC co-cultures, and activation of T as well as B cells in patients, thereby reflecting 
augmentation of tumor-specific immunity (illustrated as Graphical Abstract, chapter 2).  
 
In extension of the data obtained by the initial screen, we demonstrate that dolastatin 10 is capable 
to induce maturation and migration of intratumoral DCs in vivo. Hence, rather “pro-tumorigenic” 
tumor-resident DCs [259, 260] may thereby be reprogrammed into “anti-tumor” DCs capable of 
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promoting functional tumor antigen-specific T cells as a result of increased costimulation and 
production of T cell-licensing cytokines such as IL-12. Activated T cells in turn, may contribute to 
tumor rejection. As depicted by enhanced FITC-Dextran uptake that was restricted to tumor-draining 
LNs, activation of tumor-resident DCs seems to be a local phenomenon, while expansion of antigen-
specific T cells in response to dolastatin injection resulted in a broad systemic response. These data 
led to the hypothesis that dolastatin treatment might function as adjuvant when used in 
combination with tumor antigen-specific vaccination. Indeed, we observed significant treatment 
synergies when combining dolastatin 10 with antigen-specific, adenovirus-based anti-tumor 
vaccination. Thus, these data add to accumulating evidence promoting further clinical evaluation of 
immunostimulatory chemotherapy that acts on both the immune system and the tumor to create a 
microenvironment that allows for better implementation of vaccination approaches [56]. Yet, our 
conclusions are based on improved overall anti-tumor efficacy of the MDA/vaccination combination, 
while the exact characterization of tumor-antigen-specific T cell responses such as the induction of 
memory T cells, has not been addressed in the present study. In this line, previous studies by our lab 
have observed that induction of antigen-specific effector T cells and memory T cells crucially 
depends on the correct dosing, as well as timing of chemotherapeutics with respect to vaccination 
(Fink, Y., unpublished observations). Thus, determination of an optimal schedule for chemo-
immunotherapy regimens is an important issue that should be addressed in follow-up studies.  
 
We furthermore observed that both adaptive and innate immunity are critically required for the 
therapeutic anti-tumor efficacy of dolastatin 10. In particular, utilizing depletion experiments, we 
showed that the anti-tumor effect in vivo was largely dependent on CD11c+ DCs, IFN-γ and CD8 T 
cells. The first studies to report a functional interplay between chemotherapy and the immune 
system have described the dependency of anthracyclines on adaptive immunity for their full 
therapeutic efficacy [261]. These agents are meanwhile known to activate APCs via stimulation of an 
immunogenic tumor cell death (ICD) [94, 99, 262-264]. Thus, ICD triggered by anthracyclines could 
lead to the release of cellular cues, which may elicit an anti-tumor immune response. We cannot 
formally rule out that dying tumor cells upon MDA treatment emit a series of danger signals that 
may elicit the recruitment and activation of antigen-presenting cells such as in ICD. However, in our 
experiments, DC activation by various MDAs has been observed in the absence of tumor cell death. 
Besides, tumor cell death induced by cytotoxic agents such as cisplatin, mafosfamide, and etoposide, 
which presumably is non-immunogenic, was not sufficient to activate DCs (Figure 7-14, C).  
 
Similar to conditions in chronic infections, T cells in the tumor microenvironment frequently display 
restrained effector T cell functions as reflected by incapability to produce cytokines such as IL-2, IFN-
γ and TNF-α, or cytotoxic mediators such as granzyme B and perforin [265, 266]. Besides, tumor-
associated T cells often express an array of inhibitory receptors [267]. Consequently, blockade of 
inhibitory T cell checkpoint receptors aims at overcoming tumor-induced T cell exhaustion, and 
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indeed, therapeutic blockade of CTLA-4 and PD-1/ PD-L1 has demonstrated impressive clinical 
benefits by at least partially reverting T cell dysfunction [268-270]. Based on enhanced specific T cell 
responses upon dolastatin treatment, we explored a functional interplay between MDA treatment 
(i.e., dolastatin 10) and CTLA-4/PD-1 antibodies. The combination was significantly more potent 
against established tumors than dolastatin 10 or antibodies alone. Interestingly, as a result of the 
combination therapy, the frequency and number of intratumoral IFN-γ producing effector CD8 T cells 
increased, while Treg frequency decreased. This led to a substantial increase in the intratumoral ratio 
of Teffs (defined as IFN-γ+ T cells) to Tregs, which is considered to be an indicator of a favorable anti-
tumor immune response [240, 271]. From a mechanistic standpoint, we envision that the anti-tumor 
immune response, which is activated upon dolastatin administration, is subsequently dampened by 
the engagement of inhibitory receptors, such as CTLA-4 and PD-1 on tumor-infiltrating T cells. The 
concomitant application of antagonistic antibodies blocking these inhibitory receptors efficiently 
unleashes as well as sustains the T cell response against the tumor.  
 
Nevertheless, clear limitations of our in vivo studies are the nature of the tumor models used. We 
employed syngeneic tumor models in order to describe the host´s immune system in response to 
tumors. Subcutaneous tumors, however, are generated by injecting tumor cell lines that may have 
originated from a distinct organ, into the flanks of the mice. These tumors lack the heterogeneity of 
tumor cells normally characterizing human tumors. In addition, these tumors grow unnaturally fast, 
which possibly leads to a distinct architecture of the tumor microenvironment as compared to 
human tumors. Tumor formation in humans involves the co-evolution of tumor cells together with 
vascular endothelial, stromal and immune cells, as well as extracellular matrix components [272]. By 
introducing artificial antigens such as OVA into these tumors, we furthermore modulate tumor cell 
immunogenicity and might thereby bias our observations. Hence, accurate modeling of tumor 
complexity and heterogeneity is a difficult task that is best met by the use of genetically engineered 
mouse models (GEMMs). Tumors in these models usually arise within the native tissue and 
incorporate many features of the tumor and the tumormicro-environment [272]. Consequently, the 
lab has meanwhile adopted the K-ras/p53 mutated KP model [273] in order to mimic non-small cell 
lung cancer, as well as models of breast cancer based on targeted expression of oncogenes and 
growth factors under the control of the mouse mammary tumor virus (MMTV) in mammary glands 
[274]. These models will ultimately allow monitoring of anti-tumor immune responses in a more 
physiological setting. 
 
Next, we intended to translate our findings from murine models into the human setting. Accordingly, 
we have confirmed that both dolastatin 10 and its synthetic analogue MMAE are capable to mature 
peripheral, monocyte-derived DCs as well as intra-tumoral DCs obtained from primary resections of 
cancer patients. The latter experiments confirmed previous observations in murine models and 
suggest that dolastatins indeed may convert, at least in part, the immature status of tumor-resident 
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DCs [275, 276], into a rather anti-tumorigenic one. These data are of further clinical relevance, as 
MMAE and the ansamitocin P3 analogue DM1 are both frequently explored as cytotoxic payloads of 
ADCs [277]. With the approval of the MMAE-based brentuximab vedotin (BV) and DM1-bound 
trastuzumab emtansine (T-DM1), the excitement over ADCs is steadily building and this class of 
drugs is readily integrated into the treatment regimen of cancer patients [278-281]. Brentuximab 
vedotin has recently been shown to induce sustained clinical responses in heavily pre-treated 
patients [282]. In addition to direct tumor cytotoxicity, it has been reported that BV interferes with 
the immunosuppressive environment by decreasing the release of cytokines [283]. Moreover, 
Theurich and colleagues have reported a significant and lymphoma-specific increase of CD161+ T 
cells in patients with CD30+ lymphomas previously treated with BV [284, 285]. These data suggest 
that induction of tumor-specific immunity could play a more substantial role for the therapeutic 
efficacy of brentuximab than so far appreciated. According to the effects of free dolastatins, BV 
elicits maturation of human moDCs in co-culture with CD30-expressing lymphoma cells, underlining 
that MMAE can diffuse from tumor cells into the vicinity, resulting in DC activation. In addition, we 
were able to demonstrate that systemic brentuximab vedotin treatment activates cellular immune 
responses in patients with CD30+ lymphomas. In the peripheral blood we observed a consistent 
upregulation of costimulatory markers in both T and B cells after brentuximab vedotin 
administration. The frequency of circulating regulatory T cells was substantially decreased, which 
may further support the induced and/or enhanced anti-lymphoma immune response. Of particular 
note, we found an increase in CD8+ and CD4+ TILs in response to the treatment with brentuximab 
vedotin early after commencement. Our data thus suggest that brentuximab vedotin favorably alters 
the balance between tumor-mediated immune suppression and anti-tumor immunity, which may 
considerably contribute to its therapeutic efficacy.  
 
In accordance with the data presented in this thesis and based on our findings of the DC-stimulatory 
properties of DM1, we demonstrate that T-DM1 induces tumor infiltration of effector T-cells, both in 
patient-derived and murine breast tumors. While primary resistance to immune checkpoint blocking 
antibodies occurred, combining T-DM1 treatment with blockade of the PD-1/CTLA-4 inhibitory 
pathway demonstrated striking synergy and greatly enhanced T-cell responses, including complete 
tumor rejection in a murine breast cancer model derived from a transgenic MMTV-human HER2-
driven murine tumor model (Mueller et al., submitted). Yet, additional studies are required to further 
investigate the specific immune response, in particular the generation of an immunological memory, 
upon treatment with ADCs in patients and to correlate these findings with clinical outcome. 
Consequently, the laboratory initiated a SAKK (Schweizerische Arbeitsgemeinschaft für Klinische 
Krebsforschung) translational research project to elucidate the immunomodulatory capacity of T-
DM1 in patients with HER2-positive breast cancers. Importantly, this study aims at providing an 
accurate immunological definition of the mode of action of antibody-maytansinoid-conjugates. 
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Ultimately, the final picture of all data should guide others and us to initiate early clinical trials 
evaluating the combination of ADCs with immunotherapy for the benefit of the patients. 
 
8.3 Molecular mechanism of MDA-induced DC maturation 
Activation of innate immune cells such as dendritic cells is mostly associated with triggering of 
pattern recognition receptors [146, 242]. Consequently, we have elucidated the role of these 
receptors in MDA-induced DC maturation by using BMDCs from mice lacking the genes for TLR or 
NLR cytosolic adaptor proteins. Interestingly, dolastatin 10 and ansamitocin P3 triggered 
upregulation of CD40, CD80, CD86 and MHCII independently of MyD88, TLR4, TRIF or RIP2. Similar, 
ansamitocin P3-induced secretion of mature IL-1β, which is considered the major response of NALP3 
inflammasome activation [286], was comparable in WT and NALP3-/- BMDCs. Thus, we conclude that 
the tested MDAs exhibit DC-maturing properties by mechanisms other than engagement of TLRs or 
NLRs such as NOD1, NOD2 or the NALP3 inflammasome. Due to the molecular structures of the 
tested MDAs (see Introduction chapter 4.4.1), it seems unlikely that other PRRs such as the nucleic 
acid-sensing RIG-I like receptors (RLRs), or C-type-lectin receptors recognizing sugar-associated 
structures, are involved in the observed DC maturation. In this line, we were able to determine that 
MDA-induced DC maturation requires the ability of the MDA to diffuse through the plasma 
membrane, indicating that no active receptor-mediated uptake of the drug is involved. In particular, 
we observed that the highly polar and thus poorly membrane-permeable MMAE-analogue MMAF 
was not able to trigger phenotypic DC maturation when applied as free agent (data not shown). We 
therefore hypothesize that the tested MDAs mediate their effects by binding to MTs after entering 
the dendritic cell by diffusion. Nevertheless, whether MDAs may bind distinct, yet unknown cell-
surface or intracellular receptors remains unclear. Due to the observed class effect, however, we 
speculate that the process of active depolymerization of microtubules may be the initial event 
triggering innate signaling pathways. These might lead to inflammatory responses as a result of 
profound cellular and biological changes within a dendritic cell; a concept that has previously been 
reported for inflammation in response to endoplasmatic reticulum stress [287].  
 
In fact, microtubule-binding agents can efficiently activate NF-κB and MAPK signaling pathways in 
tumor cells [288-292]. Based on the observation that only destabilizing agents induce functional DC 
maturation, we focused on pathways that were differentially engaged in response to MDAs as 
compared to MSAs. Particularly, Kolomeychuck et al. demonstrated differential activation of the AP-
1 transcription factor family member c-Jun by vinblastine (VBL; destabilizer) and taxol (i.e., 
paclitaxel; stabilizer) in tumor cells [249]. Consistent with these data, Berry and colleagues reported 
a distinct composition of AP-1 heterodimers in response to VBL and taxol, resulting in c-Jun 
phosphorylation and transcriptional activation of AP-1 only by VBL [293]. In line with these 
observations, we demonstrate activation of c-Jun in response to the MDA ansamitocin P3, while the 
Discussion   
 
107 
MSA paclitaxel failed to trigger phosphorylation of c-Jun as well as induction of c-Jun protein in 
SP37A3 DCs. The AP-1 transcription factor (TF) family, together with NF-κB, cAMP response 
element-binding protein (CREB), CCAAT-enhancer-binding proteins (c/EBP), and IRF families of TFs, 
operates downstream of MAPKs and regulates transcription of costimulatory molecules as well as 
expression of pro-inflammatory cytokines in response to PRR engagement [149]. Considering this 
functional property of AP-1, it appears that activation of c-Jun is functionally important for MDA-
induced DC maturation. Accordingly, it seems that the failure of paclitaxel-treatment to induce 
complete DC maturation might be related to its incapability to mediate AP-1 activation in DCs. 
Additionally, the observation that MDAs trigger a rather pro-inflammatory cytokine pattern 
including expression of IL-1β, IL-6, IL-12 and IL-23 and significantly lower levels of TNF-α and type I 
IFNs, suggests involvement of NF-κB and AP-1-dependent pathways rather than IRFs (Figure 4-7, 
Introduction).  
 
Major upstream regulators of c-Jun include the MAPKs JNK (also: SAPK/JNK) and, although to lesser 
extent, p38 [294]. Besides, small GTPases have been implicated as signaling effectors in the context 
of cytoskeletal rearrangement [190]. Indeed, RhoA has been shown to stimulate c-Jun expression 
through ROCK by activating JNK [202]. Interestingly, RhoA activation by vinblastine has previously 
been shown for tumor cells as well as for DCs [199, 200]. Consequently, we determined that MDAs 
trigger activation of RhoA in DCs, which is furthermore required for complete phenotypic maturation 
as demonstrated by decreased expression of DC costimulatory receptors in presence of the 
pharmacological RhoA inhibitor CCG-1423. It has been reported that paclitaxel inhibits RhoA activity 
in primary rat neurons [295]. Yet, the effect of paclitaxel on RhoA activation in dendritic cells remains 
to be determined. This may help to conclude on the specific role of RhoA in mediating the 
differential effects of MDAs and MSAs on DC maturation. Since small GTPases themselves require 
activation by specific upstream regulators, we investigated the role guanine nucleotide exchange 
factors (GEF) in the context of MT disassembly. Of the MT-associated GEFs, to date only GEF-H1 
(also: lfc, arhgef) is known to sense MT depolymerization [194]. Importantly, various studies provide 
experimental evidence that GEF-H1 is responsible for regulating RhoA activity in response to 
microtubule depolymerization (Figure 4-11, Introduction) [195-198]. Accordingly, we here describe 
that first, GEF-H1 is associated to microtubules in resting DCs, and second, after a short exposure to 
ansamitocin P3 microtubules start to disassemble, resulting in release and subsequent accumulation 
of GEF-H1 in the cytoplasmic area. Furthermore, by using GEF-H1 (Arhgef) deficient BMDCs, we 
have determined a major contribution of GEF-H1 to the induction of MDA-mediated functional DC 
maturation. Expression of CD80 and CD86, both on the transcriptional and on the protein level, as 
well as induction of IL-1β, IL-6, IL-12 and IL-23 mRNA in response to ansamitocin P3 requires 
presence of GEF-H1. Our data furthermore demonstrate reduced activation of c-Jun, JNK, p38, 
ERK1/2 and NF-κB (p65) in GEF-H1 deficient BMDCs when compared to WT BMDCs stimulated with 
ansamitocin P3. Importantly, while inducing p38, ERK1/2 and NF-κB (p65) to equal amounts as 
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ansamitocin P3, paclitaxel completely failed to induce phosphorylation of c-Jun and JNK in both WT 
and GEF-H1-/- BMDCs. These data thus confirm a prominent role for the JNK/c-Jun (AP-1) signaling 
axis in mediating the differential effects on DC phenotype and function observed upon exposure to 
MDAs as compared to MSAs. Of note, GEF-H1 deficiency resulted in reduced p-p38, p-ERK1/2 and p-
p65 only in response to ansamitocin P3 treatment, while paclitaxel-induced phosphorylation of p38, 
ERK1/2 and p65 was unaffected in Arhgef-/- BMDCs, suggesting that in contrast to MDAs, MSAs 
trigger MAPK and NF-κB pathways via distinct, GEF-H1-independent mechanisms. Considering that 
MT destabilization is a prerequisite for GEF-H1 release, and presumably activation, it seems plausible 
that paclitaxel-induced stabilization of MTs counteracts GEF activation. Experiments assessing the 
phosphorylation status of GEF-H1 after exposure to ansamitocin P3 and paclitaxel are underway to 
ultimately prove or disprove this assumption.  
 
In light of these data, we propose the following model (Figure 8-1): 
Discussion   
 
109 
 
Figure 8-1 Molecular mechanism of MDA-induced DC maturation. Microtubule-depolymerization leads to 
release and activation of the guanine nucleotide exchange factor GEF-H1, which in turn induces the small 
GTPase RhoA. GTP-bound RhoA might induce downstream JNK phosphorylation either directly via ROCK or via 
the MAPK-family members MEKK1 and MKK4/7. Whether other MAP3Ks, such as TAK1 could possibly be 
involved instead of MEKK1, or if ROCK induces MEKK1 activation, is part of ongoing research. JNK 
phosphorylation subsequently triggers c-Jun that translocates into the nucleus to induce AP-1-dependent gene 
transcription resulting in pro-inflammatory responses in DCs. Dashed lines indicate hypothetical steps that 
might be involved in the proposed MDA-triggered signaling cascade. (GTP, guanosin triphosphate; RhoA, Ras 
homolog gene family, member A; ROCK, RhoA-associated kinase; MAPK, mitogen-activated protein kinase; 
MEKK1, mitogen-activated protein kinase kinase kinase; MKK4/7, mitogen-activated protein kinase kinase 4/7; 
MAP3K, MAP kinase kinase kinase; TAK1, MAP3K7 (MAP kinase kinase kinase 7); JNK, c-Jun N-terminal kinases; 
AP-1, Activator Protein-1). 
 
 
 
As depicted by dashed lines, our model still lacks the connecting link between induction of RhoA and 
phosphorylation of JNK. As indicated earlier, RhoA has been shown to activate JNK via ROCK in 3T3 
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NIH fibroblasts. This study furthermore implicates a role for the MAP2K MKK4, but not for MKK7 
[202]. Both MKK4 and MKK7 are known as major MAP2Ks specific for JNKs (MAP2Ks: mitogen-
activated protein kinase kinases; see Introduction chapter 4.3.2.1) [296]. Marinissen et al. 
furthermore hypothesize that MKK4 is presumably not directly phosphorylated by ROCK but rather 
by additional, yet unknown MAP3Ks (mitogen-activated protein kinase kinase kinases, also: 
JNKKKs). JNK may be regulated by at least 14 MAP3Ks [163, 254], of which we will mainly discuss 
MEKK1 and TAK1 (also MAP kinase kinase kinase 7; MAP3K7) as these have been previously 
associated with microtubule destabilization and/or RhoA activation. For instance, RhoA, but not Rac 
or Cdc42, binds MEKK1 and regulates its kinase activity [191]. Also, microtubule-disrupting drugs, 
including both MDAs and MSAs, have been shown to activate MEKK1 [297, 298]. Importantly a 
recent report on a novel colchicine site–targeted tubulin inhibitor (MT189) determined that this MDA 
causes activation of the MEKK1/TAK1–MKK4–JNK signaling pathway in human cancer cells [296]. 
Accordingly, MT189 enhanced the phosphorylation levels of JNK, p38, MEKK1, TAK1, and MKK4, but 
just marginally changed the level of p-MKK7. The authors found that neither intact nor disrupted 
microtubules were colocalized with p-MEKK1 or p-TAK1, suggesting involvement of unknown 
upstream regulators that are associated with MTs [296]. Hence, in order to provide the complete 
signaling cascade triggered by MDAs in dendritic cells, phosphorylation of MEKK1, TAK1, MKK4 and 
MKK7 remains to be elucidated. Since ROCK kinase activity is triggered upon binding of GTP-bound 
RhoA, its role in MDA-mediated JNK activation is best addressed by using the pharmacological 
inhibitor Y-27632 [299]. Another study supporting our hypothesis demonstrates that the MDA 
vincristine, but not paclitaxel, cisplatin or etoposide, enhanced cellular invasive ability in human 
MKN45 cancer cells via GEF-H1/RhoA/ROCK/myosin light chain (MLC) signaling [300]. Similar to our 
conclusions, the authors state that, although both vincristine and paclitaxel act on microtubules as 
anti-cancer drugs, their data indicated that these drugs influence cellular motility differently 
depending on their effect on RhoA activity [300].  
 
On the other hand, the microtubule-destabilizing agent combretastatin (CA)-4 and its novel 
analogue CA-432 have been shown to impair T cell migration through the Rho/ROCK signaling 
pathway [301]. Combretastatin binds on the colchicine-binding site on β-tubulin (Table 4-1, 
Introduction) [173] and as microtubule-destabilizing agent has demonstrated DC-maturing capacity 
during our initial screen (Figure 7-1). However, we have previously discovered that this agent fails to 
induce IL-1 expression in DCs and thereby induces semi-mature DCs in contrast to the vinca-domain-
binding MDAs (i.e., dolastatins, maytansines, vinca-alkaloids). These results highlight possibly 
distinct outcomes on DC phenotype and function depending not only on MT-stabilization or 
destabilization, but also depending on the specific binding sites on β-tubulin. In addition, crucial cell 
type-specific differences in the outcome of similar signaling pathways are revealed by above-
mentioned studies. Therefore, it remains to be elucidated in more detail, which are the specific 
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effects of vinca-domain-binding MDAs on the migratory potential of T cells to conclude on the best 
possible treatment options in order not to disturb T cell migration into the tumor sites.  
 
Overall, the MT-associated GEF-H1 appears to be crucially required for transduction of major 
signaling events that profoundly affect DC differentiation and ultimately translate into anti-tumor 
immunity. Nevertheless, it has to be considered that most responses were found to be reduced, 
albeit not completely abrogated in Arhgef-/- BMDCs. Thus, GEF-H1 activation seems to be the major 
mechanism, although other factors might be contributing to the observed DC-modulatory effects. 
To address the question of additional direct or indirect mechanisms that may amplify the overall 
immune response induced by MDAs, we will examine samples from ansamitocin P3 treated WT and 
GEF-H1 deficient BMDCs by RNA sequencing. With this approach we expect to receive a broader 
picture on the major pathways modulated by MDAs, as well as on the DC-specific outcomes of the 
profound cellular changes triggered by MDAs. These insights could reveal DC-modulatory effects 
that we might have overlooked so far. On a long run, this analysis will possibly also increase our 
understanding on the pharmacological mechanism of these drugs in innate cells, which might 
support the development of similar compounds as immunostimulants suitable not only in for cancer 
therapy.  
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10.1 Materials 
Chemicals and reagents   Source 
Acetic acid      Merck 
Accutase     PAA 
Agarose      Sigma 
BCA       Pierce 
β-Mercaptoethanol     Sigma 
Bovine serum albumin (BSA)   Sigma 
Brefeldin A     Sigma 
Ciproxin      Bayer 
Collagenase IV    Worthington 
Corynebacterium diphtheriae diphtheria toxin (DT) Millipore 
CpG DNA    Microsynth 
D-Glu-meso-diaminopimelic acid (iE-DAP)  Adipogen 
Disodium hydrogen phosphate (Na2HPO4)  Merck 
Dimethylsulfoxide  (DMSO)    Sigma 
Dithiothreitol (DTT)     Sigma 
DNAse type IV      Sigma 
dNTPs       Roche 
ECL Films   Kodak  
ECL Substrate   Thermo Scientific 
Ethanol, absolute     Sigma 
Ethylenediamine  tetraacetate sodium salt (EDTA) Gibco 
FITC-Dextran     Sigma 
FoxP3-Fix/Perm-Kit     BioLegend  
IC Fixation buffer    eBioscience 
Glycine       Sigma 
GM-CSF, recombinant human   Peprotech 
GM-CSF, recombinant mouse   Peprotech 
Histopaque®1077/ Histopaque®1119  Sigma 
Hyaluronidase      Sigma 
Hydrochloric acid     Sigma 
Interleukin 4 (IL-4), recombinant human  Peprotech 
Isobutanol      Merck 
Isopropanol     Merck 
Laemmli Buffer 2x    Bio-Rad 
LPS, 026:B6 Escherichia coli    Sigma 
Chemicals and reagents   Source 
LPS, TLRpure®     Adipogen 
M-CSF, recombinant mouse   Peprotech  
Methanol      Merck 
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Monensin 1000x     Biolegend 
Muramyl dipeptide (MDP)    Adipogen 
Nigericin sodium salt    Adipogen 
Nitrocellulose Membrane, 0.45 μm   Bio-Rad 
Non-fat dry milk     Sigma 
OCT Compound    Tissue-Tek 
Ovalbumin, SIINFEKL peptide   Peptides & Elephants 
Ovalbumin, SIITFEKL peptide (T4)   Peptides & Elephants 
Ovalbumin, ISQAVHAAHAEINEAGR peptide  Abbiotech 
Ovalbumin (EndoGrade) protein   Hyglos  
Paraformaldehyde     Fluka 
PBS (1x and 10x)     Sigma 
Permeabilzation buffer    BioLegend 
Phorbol-12-myristate13-acetate (PMA)   Sigma 
Poly I:C (High Molecular weight)   Adipogen 
Ponceau S solution     Sigma 
Potassium bicarbonate (KHCO3)    Sigma 
Potassium chloride (KCl)     Sigma 
ProLong® Antifade Reagent Containing DAPI  Life Technologies 
Protease inhibitor     Pierce 
PVDF Membrane, Immun-Blot® 0.2 μm  Bio-Rad  
RedSafeTM Nucleic Acid Stain Solution   Chembio 
Sodium acetate (NaAc)     Fluka 
Sodium azide (NaN3)     Sigma 
Sodium chloride (NaCl)     Merck 
Sodium dodecylsulfate    BDH  
Sodium hydroxide (NaOH)    Aldrich  
TRIS (Tris(hydroxymethyl)-aminomethan  Sigma 
Triton X-100     Sigma  
Trypan blue      Gibco 
Trypsin 0.5%     Gibco 
Tween-20      Fluka 
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Buffers and solutions 
 
TE Buffer (TRIS-EDTA)   
10 mmol  Tris    
1 mmol   EDTA  
1M   HCl adjust pH to 7.5 
add H2O 
 
FACS-buffer    
2% (v/v)   FCS  
2 mmol   EDTA  
0.01% (v/v)  sodium azide sol.  
PBS  
 
ELISA washing buffer    
PBS containing 0.05% Tween-20 
 
10x TBS (TRIS buffered saline) 
80 g   NaCl     Dissolve all dry reagents together  
2 g   KCl     in 800 mL ddH2O 
30 g   TRIS base    adjust pH to 7.4 with 32% HCl 
Add ddH2O to a final volume of 1L 
 
10x SDS running buffer 
30 g   TRIS base    The pH of the buffer should be 8.3 
144 g   Glycine       and no pH adjustment is required. 
10 g  SDS  
Add ddH2O to a final volume of 1L 
 
1x Transfer buffer (nitrocellulose membrane)   
14.4 g  Glycine       
3.02 g  TRIS base      
100 mL   Methanol     
Add ddH2O to a final volume of 1L    
 
1x Transfer buffer (PVDF membrane) 
14.4 g  Glycine 
3.02 g  TRIS base 
200 mL   Methanol 
Add ddH2O to a final volume of 1L 
 
1x Digestion mix  (100 mL) 
Tumor cell growth medium (DMEM + 10% FCS)   50 ml  
Accutase       50 ml  
Collagenase IV (50 mg/ml)      2 ml  
Hyaluronidase (50 mg/ml)      2 ml  
DNAse I; Type IV (2.5 KUnits/ml)     0.4 ml 
 
Cell culture media and supplements 
IMDM  Sigma 
DMEM Sigma 
DMEM w/o phenol red Sigma 
RPMI 1640 Gibco 
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FCS (ES cells tested) PAA 
Sodium Pyruvat 100x Gibco 
Non-essential Amino Acids 100x Gibco 
Penicillin/Streptomycin/L-Glutamine 100x concentrated (P/S/G)  Gibco 
PBS  Gibco 
Trypan blue 0.4 % solution Sigma 
 
 
Freezing medium      
FCS containing 10% DMSO 
 
 
Reaction Kits 
Kit Source 
MACS CD8 MicroBeads (positive selection; human) Miltenyi Biotec GmbH 
MACS CD14 MicroBeads (positive selection; human) Miltenyi Biotec GmbH 
Easysep CD8a+ T Cell Isolation Kit II (positive selection; mouse) Stemcell Technologies 
Easysep Pan T Cell Isolation Kit II (depletion; mouse) Stemcell Technologies 
Mouse IL-1β/ IL-6/ IL-12p40 ELISA eBiosciene/BD 
Human IL-1β/ IL-6/ IL-12p40 ELISA eBioscience/BD 
Direct-zol™ RNA MiniPrep  Zymo Research 
RevertAid First Strand cDNA Synthesis Kit Thermo Scientific 
GoTaq® qPCR Master Mix Promega 
Microtubules/ Tubulin In Vivo Assay Kit Cytoskeleton, Inc. 
G-LISA® RhoA Activation Assay Biochem Kit (Absorbance) Cytoskeleton, Inc. 
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Antibodies and dyes 
Antibody Clone Fluorescent label Source 
 
FACS antibodies  
Anti-mouse CD4 GK1.5 PE-Cy7 BioLegend 
Anti-mouse CD4 RM4-5 V450 BD  
Anti-mouse CD8 53-6.7 BV421 BioLegend 
Anti-mouse CD8 53-6.7 PE-Cy7 BioLegend 
Anti-mouse CD11b M1/70 V450 BD  
Anti-mouse CD11c N418 FITC BioLegend 
Anti-mouse CD40 2/23 PE BioLegend 
Anti-mouse CD80 16-10A1 PE BioLegend 
Anti-mouse CD86 GL1 APC BD  
Anti-mouse/human FoxP3 150D/E4 PE eBioscience 
Anti-mouse I-E I-A M5/114.15.2 Pacific Blue (PB) BioLegend 
Anti-mouse IFN-γ XMG1.2 PE BD  
Anti-mouse IL-6 MP5-20F3 PE eBioscience 
Anti-mouse IL-12p40 C15.6 PE BD  
Anti-mouse IL-1β (pro-form) NJTEN3 PE eBioscience 
Anti-mouse CD16/32  
(FcR block) 
 - BioLegend 
Anti-human CD3 Hit3a APC BioLegend 
Mouse IgG1 Isotype Ctrl MOPC-21 A488 BD 
Anti-human CD3 Hit3a APC-Cy7 BioLegend 
Anti-human CD4 SFCI12T4D11 ECD Beckman Coulter 
Anti-human CD4 SFCI12T4D11 PB Beckman Coulter 
Anti-human CD8 Hit8a PE-Cy7 BioLegend 
Anti-human CD8 RPA-T8 PerCP-Cy5.5 BD 
Anti-human CD11b M1/70 AF700 BD 
Anti-human CD11b ICRF44 PE-Cy7 BD 
Anti-human CD11c 3.9 PE BioLegend 
Anti-human CD14 M5E2 FITC BD 
Anti-human CD16 3G8 PB BD 
Anti-human CD19 J3-119 FITC Beckman Coulter 
Anti-human CD19 HIB19 AF700 BD 
Anti-CD20 2H7 PB BioLegend 
Anti-CD25 M-A251 PE-Cy7 BD 
Anti-human CD40 5C3 APC Biolegend 
Anti-human CD45 HI30 Biotin BD 
Anti-human CD62L HRL1 Biotin BD 
Anti-human CD69 FN50  APC-Cy7 BD 
Anti-human CD80 L307.4 FITC BD 
Anti-human CD83 HB15e APC eBioscience 
Anti-human CD83 HB15e Biotin BioLegend 
  Attachment  Materials 
128 
Anti-human CD86 2331 (FUN-1) PE BD  
Anti-human FoxP3 259D AF488 BD 
Anti-human HLA-DR L243 PB BioLegend 
Anti-human HLA-A2 BB7.2 PE BD 
Anti-human CD16/32  
(FcR block) 
- - BioLegend 
Streptavidin - BV650 Biolegend 
Streptavidin - PE-Cy7 Biolegend 
 
FACS dyes 
   
eFluor670 Proliferation Dye -  Invitrogen 
eFluor450 Proliferation Dye -  Invitrogen 
SytoxGreen® Nucleic Acid Stain - FITC Life Technologies 
LIVE/DEAD® Fixable Dead Cell Stain 
Kits  
 
- Near-IR 
(APC-Cy7) 
Invitrogen 
 
Activating antibodies 
Anti-mouse CD3 17A2 Functional grade 
purified 
eBioscience 
Anti-mouse CD28 37.51 Functional grade  eBioscience 
Anti-human CD3 UCHT1 Functional grade  eBioscience 
Anti-human CD28 CD28.2 Functional grade  eBioscience 
 
Western Blot/ Immunoprecipitation/ Immunofluorescence antibodies 
c-Jun Rabbit mAb 60A8 - Cell Signaling 
Technology (CST) 
Phospho-c-Jun (Ser73)  
XP® Rabbit mAb 
D47G9 - CST 
Phospho-c-Jun (Ser63)  
Rabbit mAb 
54B3 - CST 
SAPK/JNK Rabbit mAb 9252 - CST 
Phospho-SAPK/JNK (Thr183/Tyr185) 
Rabbit mAb 
98F2 - CST 
p38 MAPK XP® Rabbit mAb D13E1 - CST 
Phospo-p38 MAPK (Thr180/Tyr182) 
XP® Rabbit mAb 
D3F9 - CST 
p44/42 (ERK1/2) MAPK  
 
137F5 - CST 
Phospho-p44/42 (ERK1/2) 
(Thr202/Tyr204) MAPK XP® Rabbit 
mAb 
D13.14.4E - CST 
NF-κB p65 XP® Rabbit mAb D14E12 - CST 
Phospho-NF-κB p65 Rabbit mAb 93H1 - CST 
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β-Actin Rabbit mAb 13E5 - CST 
lfc (GEF-H1; ARHGEF)  Polyclonal sheep - Exalpha Biologicals, 
Inc. 
Phospho-lfc (GEF-H1) (Ser885)  Polyclonal rabbit - Abcam 
 
 
Cytotoxic Compounds 
Drug Mechanism Source 
Ansamitocin P3 Microtubule Assembly Inhibitor/ 
Destabilizer 
National Cancer Institute (NCI) 
BIBF 1120 Angiokinase Inhibitor LC Laboratories 
Celecoxib Cyclooxygenase-2 Inhibitor Spitalpharmazie 
Combretastatin-A4-Phosphate Microtubule Destabilizer, Vascular-
disrupting Agent 
Cayman Chemical 
D-64131 Tubulin Formation Inhibitor Santa Cruz Biotechnology 
DM1 Microtubule Assembly Inhibitor/ 
Destabilizer 
Concortis 
DMXAA Vascular-disrupting Agent Sigma 
Docetaxel Mitosis-blocking; Tubuli-stabilizing LC Laboratories 
Dolastatin 15 Microtubule Assembly Inhibitor/ 
Destabilizer 
NCI 
Dolastatin 10 Microtubule Assembly Inhibitor/ 
Destabilizer 
NCI 
Enalapril Angiotensin-converting Enzyme Merck  
Epothilone A Mitosis-blocking; Tubuli-stabilizing Santa Cruz Biotechnology 
Gemcitabine DNA-replication Blocker LC Laboratories 
l-NMMA Nitric Oxide Synthase (NOS) Inhibitor Cayman Chemical 
MMAE (monomethyl-
auristatinE) 
Microtubule Assembly Inhibitor/ 
Destabilizer 
Seattle Genetics 
Naproxen Cyclooxygenase (COX) Inhibitor Cayman Chemical 
Paclitaxel Mitosis-blocking; Tubuli-stabilizing Cayman Chemical 
Patupilone (Epothilone B) Mitosis-blocking; Tubuli-stabilizing LC Laboratories 
SAHA HDAC Inhibitor Cayman Chemical 
Sunitinib Receptor Tyrosinkinase Inhibitor Pfizer Inc. 
Vinblastine Microtubule Assembly Inhibitor NCI 
Vincristine Microtubule Assembly Inhibitor NCI 
Vindesine Microtubule Assembly Inhibitor NCI 
Vinflunine Microtubule Assembly Inhibitor NCI 
Vinorelbine Microtubule Assembly Inhibitor NCI 
Antibody-drug conjugates and therapeutic antibodies  
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Antibody-drug 
conjugate 
Species Antigen Cytotoxic 
payload 
Source 
Brentuximab Vedotin 
(Adcetris®) 
Human (approved) CD30 MMAE Seattle Genetics/ 
Takeda 
Anti-Thy1.1 
MMAE 
Mouse 
(experimental) 
Thy1.1 MMAE Seattle Genetics 
 
 
Adenovirus (vaccination) 
Virus (Vaccination)  Species Protein expressed Source 
Ad5TRFOva; Adenovirus 
type 5 (replication 
deficient) 
Mouse (experimental) Chicken ovalbumin (OVA) University of Iowa Gene 
Transfer Vector Core 
 
  
Therapeutic Antibody  Species Clone Source 
α-PD-1 (blocking) Mouse (experimental) RMP1-14 BioXCell 
α-CTLA-4 (blocking) Mouse (experimental) 9D9 BioXCell 
α-CD4 (depleting)  Mouse (experimental) GK1.5 BioXCell 
α-CD8 (depleting) Mouse (experimental) 53–6.72 BioXCell 
α-IFN-γ  (neutralizing) Mouse (experimental) XMG1.2 BioXCell 
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10.2 Mammalian cell lines 
Cell line  Species Origin  Cell Type Source 
SP37A3 Mouse; B6 Spleen Dendritic Cell Merck  
E.G7 Mouse; B6 Lymphoma cell line 
EL-4 
T cell Lymphoma ATCC 
3LL-Thy1.1-OVA  Lung carcinoma cell 
line 3LL 
Carcinoma Douglas T Fearon Cancer 
Research UK 
Cambridge Institute 
MC38 Mouse; B6 Colon  Adeno Carcinoma Mark Smyth, Peter 
MacCallum 
Cancer Centre, 
Melbourne 
RMA-Thy1.1 Mouse; B6 T cell lymphoma cell 
line EL-4 
T cell lymphoma Angelo 
Corti, San Raffaele 
Scientific Institute, Milan 
Karpas-299 Human T cell Anaplastic Large 
Cell lymphoma 
Jürg Schwaller, 
Department 
Biomedicine, Basel 
L-540 Human T cell  Hodgkin 
Lymphoma 
Jürg Schwaller, 
Department 
Biomedicine, Basel 
Ramos Human B cell Burkitts 
Lymphoma 
Jürg Schwaller, 
Department 
Biomedicine, Basel 
  Acknowledgement 
132 
11 Acknowledgement 
At this place I would like to express my sincere gratitude to all the people that have accompanied me 
during the last years at the Department of Biomedicine. There surely have been times in which I was 
not so sure anymore whether I do the right thing here. But irrespective of all ups and downs I realize 
again and again and I am undoubtedly sure now that research is exactly what I want to do.  
 
And therefore, I first of all want to thank my supervisor Alfred Zippelius, who was the one proposing 
to me to start a PhD when I have not even thought about it before. He gave me the confidence to 
choose this path for myself and I have never regretted this decision. I am especially thankful not only 
for the opportunity to work on this exciting project, but more importantly for his constant support 
and for having an open door and an open ear at all times. I am absolutely appreciating that he always 
gave me the freedom to take my own decisions and I want to express a special thanks for the trust he 
has put in my work and myself. I have been encouraged to visit other labs as well as scientific 
conferences in order to expand my knowledge and experience, for which I am honestly very grateful. 
 
I want to address a special thanks to Daniela Finke and Jean Pieters who have agreed to supervise me 
as members of my PhD committee and greatly supported the project (and myself) with helpful 
discussions. Also, I want to thank Jean and his former PhD student Vincent Tchang for providing OT-
II mice in times of need. 
 
I want to thank Ed Palmer for being the chairman of my PhD defense, and more importantly for all 
the helpful discussions, for all kinds of OVA peptides, mice, and especially for inviting us to be part of 
his labmeeting at the very beginning of my PhD. I always enjoyed these meetings and learned a lot. 
At this point I also want to thank Simona Rossi and her lab for many discussions and their help 
whenever needed.  
 
I want to thank Giulio Spagnoli, Giandomenica Iezzi and Elisabetta Padovan and all their lab 
members for their constant support and for setting up the Immuno-Oncology JC with us. 
 
A special thanks goes to Daniel Speiser and Petra Baumgärtner at the Ludwig Institute for Cancer 
Research in Lausanne, who hosted me for two weeks, showed me how to handle human T cell clones 
and answered all of my questions with great patience. I am also absolutely grateful to both Freddy 
and Hans-Christian Reinecker for giving me the unique opportunity to visit the Massachusetts 
General Hospital in Boston. A very special thanks goes to Christian and his lab members Yun, 
Guoxing, Shan, Pankaj and Tatsushi, who helped me to get the most out of four weeks, and thanks 
to them the project on the molecular mechanism of DC maturation evolved up to the current state!  
 
Acknowledgement   
133 
I want to thank Sebastian Theurich and Michael von Bergwelt-Baildon for our fruitful collaboration 
on brentuximab and Alexander Dalpke for taking the time to discuss my project and giving valuable 
advice by sharing his expertise on DC signaling. 
 
I am absolutely happy I had the chance to learn from and work with all the great people in our group! 
I learned a lot from Philipp, who supervised me and developed the project with me from the very 
beginning on; thank you for all your support! Also, without Greg I probably would not even have 
made it through the Master Thesis ;o) I want to especially thank Sébastien for his (not only) scientific 
support, the great help with the DC immunofluorescence and the hint on GEF-H1! I am thankful that 
Yvonne and Béa accompanied me from the beginning on, and especially Béa helped me with the first 
experiments and still works with me on the last ones. Thanks to Norbert for his invaluable technical 
advice and patience, to Mélanie for showing me how to handle the mice and for the nice company in 
the mouse house, to Narasimha for being the great person he is and for discussing with me whenever 
I needed scientific advice or simply clear my head.  
 
The biggest thank you is for Petra, who shared so much time and so many conversations with me, is 
always there for me and helped me through the greatest troubles!! 
I am also absolutely grateful for the critical reviews of this thesis. Daniela, Franziska, Jens, Sébastien, 
Philipp and Christiane, I am aware it takes some time and thank you for that!   
I think I am lucky to be working in this group as we generally had a lot of fun and I made some true 
friends. Thanks also to Matthias, Michal, Reto and Vincent for the good times and endless coffees we 
had together.  
 
GRACIAS para TODO, Seba. I would not have made it, at least not so smoothly, without the endless 
support of my family. Only because of them I am now standing here. 
 
